var title_f15_27_15792="Cutaneous aspergillosis";
var content_f15_27_15792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspergillus fumigatus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cutaneous lesions due to disseminated Aspergillus infection in a patient who has undergone liver transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean-Fran&ccedil;ois Dufour, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15792=[""].join("\n");
var outline_f15_27_15792=null;
var title_f15_27_15793="Uncomplicated crown fracture";
var content_f15_27_15793=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Uncomplicated crown fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 330px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFKAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5/C1IinIFSwQmRwAOtW2tNpA71yWb1PtI00mXtLj2sARXQW4yVyOKyNOiPy4HIro7WIFQWq4kzWpctY0cYJwPStHyoXjwuMis6IfNjGBWjaTogC4G7p0reLujGVPW6Iv7PXIwcGrdva7APMXMfqKvIwOAzAA+grQi8gwhFDNk4z1AqloTK9iC0s7Wf5kYBv7vU1FeWSEgbCOeeOKvW8MiXH7kEkdwP6VO8YMpNzuJ+nBpOzM1Czuc5daZGBtVCc9MCun8Cax/YN2hu7N72zWJ4VikYHyg5BYqDxzjke9QmcowCorDtxzU0ULO5Y/KT2FJKzM61PnjyyRlfEnQPDV6tvfeH7aSymmLCW0GNiAHh/bPoDXmF94c2Mdqn8K9yl0uJosMc+9YUtmvnsm1SB0B71EqUW77DwtaVOPKnex4rc6HOn3F3Vlz27xMRIpUj1r3S40hHyAoBJyeOlc5q/h5ZVYCIcdwKzlQdro7qeLTdpHk5jIqzDf3EIALb1HZua2NV0G4tZDsQkelY8sDocOpB96wvKL1O1QUtYs0bbVIGzvZ4X+mRXVaPeW7wrHdwQXsSnduHJH05rz8pQgaNsxsVPqDitI17aMyqUOdWZ6S9lazuXtZ1Qc/u2Bx+B5P51Se0MTEEsvqA1ctaazdwY37JgP74wfzFbNv4jt5B+/R42/76FVzwZzfV6kdtTQMkyhlD5Vjzkc8dPpTkmlUg8YFJb3FrOwWKeNmPTDCtGGAFGAGSD1FCTZMvd3RHFcIVxIm4eoOCKfEyMdqk5HPNTxW6lgrAc+1E9mqOGRsfVTg/lVcrMeZDkyqSFdr4XJDnB69vU1Gs8aZ3rJG2OhBOaXyjsaRYiyg5zHIG/MGkW6jUHzA+T3Yc49OaLBv5k8KiTOHA4JwT1qrJMhbbuxg1MtzDJjeeB0zUU0tuXzhQD1x607eYKPdDgY2A+YD3NMn2KgPmLSB4nUbcD6NUnlowzgHB60WbFZIrI8RBLTLgc0O/nJ+5DFV7kYqXMScMFI96Y0kQXANLl7i63SIPNuPLICrtPHJqu1w+CpjwR1wc1OJkUsAuc1BLImemPfNK3Zj66opTySt8qptX3pyCTaCdmRTJp8EgYwPas6e8cjHQCo2NVFyVki7PfsgKvGCR3BqoNRCqRswx74rPaZmJJPWoTIA3PH0oVzZUUlaxee7G8Mi8j19aaLtwS3y7s/SqEk2MDBNRtLggY496qw/ZI0HvZHYtxk8nioGmIOWc5+tUnnAzzULTZPHWgh8kS89yo5Ayfeqk1yzHk/gKrszMeTSYpXMpVOyBmLGm7adilxRcz5W9xhHFNIqXFGKLidMhxSYqUikK07mbgREU3kdKkIppFMxlEVZf71TpLjHORVUigEr0pkqbW5rQXGO9aEF6ehPFc6r59qlSQjHNBspp7nWwXYPersU27pXI29zjrWpb3fTBpBKC6HRJJg8HmrUVx/tViJOHHXH41aikwBTTMpQNqNg3zhsEd6KzFkfsTiincz5DMjsEjAIHap5YVaNQAM1biGcbhUX3rnZnik3oe9FN7k+nWhB+UDjqTWusOxeSKWzVY1GFzxU8gBOc4FJaCu5Mi2Ac5JzViArjAHJpCqFRg5pIwEkVhkc01I0UbmraQTFcZxj1rTsLgRkrMMEdOOtVbOQuAuPm9c9aushiUgIGJ7ZrdMwnrozWG6eMlcKmOG75qCSIqv+tBJHOO9VbH7nzbup6cVowqrElAp2+pFDVzna5XYqRMIXAlYhR6VcVkRwyrJtI5FF35flhz8xxnBqtHPghSxYnooqhW5tbGi0p2R+STj0aqYti02935PGAO1WIo5CN5bBHOKtrJhMfJu9xUGb91e6UBblTuH3vQ1HIqM21lwT1qw4c5ywHtVaVgeFJ3H2q1LQjkbZRvNJtzuOBz0HWsW98MWlwjN5Y+prqIyHO2TIx04p0sWE4yPYdKr3WtUNSnB6M8n1LwhtYmMFR+lc9d6HcQE/KTXuE0anO5ecc7hWfc6dDKPnRcVhPDxex3UsbNfFqeJ/YJACSDn0xTPsr/3T+VevtoUDuAI+KlXw3bqcPGK53hn3OpY6K3R4y1uynPIPrVm21G/tP9VO+PQnNetT+E7Yrkx5FUz4Gs7jhQUPbBpLD1I/Cx/XaEl7yOKtPF08ahbmFXbIy4ODjFbtj4m06fl5JYZOxZNy/jjn9KTUPAMqE+TJn2Nc9eeFb+2J/d5x3FO9WO6JdLDVfhdjtVvraSDbiKXJ+WRGAz+BqpIYhGQ3mdemegrhXgvLXIYOB9Klh1K6QAM25fQ0/bdxLApaxZ0rqiklJFBPtihQG4mb92OeOp+lZEOqfL+8jY/TBpJNRifIYsqntikpJh7Bl92Mbfc2qegNC3SAYY4I6jHWs77XBtVPP2heMYxSPcW+4ZlU8Z65ofkN0U9zSN0vGcYPfHWmy30ajJasd7qE5G8kdlGTVeS4tzjk8ei9aOYawy6mnLqSA5U7v5VUlvpZSfJjLAckis+W4Qn5FYj34qBpWP3QF7cVPOu5oqEexZe6eTuTVeW46hmFQMGYcscVGYzSUxONtkPNxjpmomnY9gKQqaTbT5jGSkI0jt3phyepp+2jbT5jJ029yPbRtqXaaXYfSi4KiRbaNtTCJj0FWYdPnkxhDg96Fdj9iluUQtOCZ7V1Gn+GpJQGfn2rUi8NKnJj5rRUZsxlWpQ0ucMYmx0NRlfavQJNGRFwUFY19owByoxQ6UkEK0J6HLbaQrW42kMFyCaoS2joTxxU2Y+WL2M9hUZFW5IyOoqFloMJ0yEikxUhWjbinc53TGYpwOOvSikphy2JBj+D8qnhmK1UGR0qRXB+919aaY0zWhuDwQa1Le5BABPPpXM72X6eoq3bXOD8350MvR7nWRSjpmism1uwTyc5opXaIdM6Z4wiZHWqsK5uQT0NaLgGL5qqwx5PAwRUy7HsU9L3Nq1YeWU4zjrUyp5iZqtaYYDPWrtvH8+3Pymq3QkrDViwMHihotjA8MBVt4ip9QOlOwSg45qb2KTJ7GVFweMnjFbKqGjBdufaudtkKMSR+dbsTj7Pzjp1Hat4SujGrHsOKiPnBZT2z3ojnEf3QPpiiCRQ4LtuA98E1NFCj7pCSGIzjHGapMzdrakkciTMu1BnPQircdsg3GNlyeTkdKynBhnymFbGasRXW9lA+U96CZQfTYdcGeNxwT7A9aVJ23KHXaR6UlzG8qjbI6YOflxk/nTGU7Qf4qV+4lFWLvmeYvUsfU9qZ8yZfAx61UtiVzu5XpV8TbUwRn6Cn5kuNtCpcO3mxkKSCew6VZaRGj5P1qJ+OSOAexpi4742nqM0XE4JgTuyo5A6ml8oEggYxz060iFd2M8+1WoQMZY89s0+YHGwQQhgcrk/Sp4bZSclce1PjBCkg4NTxNk98ntWcpGbT6DTZFiNpwKi+yiN88Z9OlaUbMoOSM0yUGRfTFLnM1e9mZF0gYgbDu55oNmkiDcoNXHiO/HO7txUchCEbiQfUVpGfc1cdLIxL3QYJlJMSkehFc/J4TtGmZREFB6V3SkcjqvrSeUpUE4z2xRJRluioVJw0ucJN4DiZMxHg+tZN14G2kgMc16uGEcYBHAqC4ijlKSAfNWXs4di4Ymqup48/g28V/3UhHPrUDeEb2F2YMm49dwBzXrzgAHKjArJnQF+ORT9jTN44mszzQ+EbtiXaRVJ6hRgfpTovBkjcs4969MMQCYHU/rToLUZyBUOjC5f1mrbc8+TwQAv3s0kvgzaBycV6S0aocdPam+UASOoo9lT7EfWKvc8x/4RWNThgaa3haI5OOleh3lqrAsnbqKz2hI4FXGEF0IlWqNXucDN4bQHABqo2gAHoeK7+eMZyRVOaIA5GMd609lAhVanc4pPD4LZycVMvhxGbocV1ccWW6AelWxbfd6U1Sj2E6s+5yUfhyNedtWIvDqHpDXYQWZHzEgj0pZJEjVsLz2p+zijP2lR9TmE0S3gIOwZzyMVdi01f4UGO1XlRppf8a0ba1ZW2jAwM9apW6IU79WQ2FqsSruTGamniVQSpU47VbkOFC4wQKpM+xicA1XNYx9lzO5n3GCcFQPas64tgw4A5rRuSJCSDzTAilPm6etZuV9DZUuXUzfsS45FZWoWChTjAro5RtHXP0rLvF35z0rNtWBRadziNRtwjDFVEs3cZxXSyWgkl5HApZYFRKmMb6s2qSSVjlJrcx/e4qswq/qMoaUhegqltJqJWvoQ1oQkUmKlx60mKRnyEWKKkIppFFyHEEcr9Kkz3WosUAkU0yS5BPtNFVlOT70VRakz1DbgDinRL81RyORKM9KsKQMYFYvc9ixahRlYEdK0Yhjt8w5qvZJvxmr6IS24Dj2q4kOXQngy8ZLKDmnJDzn2qa2wq7SOtTugGMdKpxMubWxneWFbBz1q2rbVXBGR2pZIiwxyKUR7U6c9qcdi27gzfvAvCjqfersT7lCAkqe4NZzZ3ZKmp7aXHGPpTuTKOhfMe3d/e/vZqnLD8weP8cVdRg64Ioxk4UfhRdERbQsBZ1bJyRTZH2H6Uw5Q5VTg9cCp1jyMgH3Joc0OyRECHQnOD7VZQL5Z4OMfjUJh2jg8etML7jz0HbPWncTjfYtFT5eQmfaojjGSMY7Ux7kqDwfYU+A7xk+lHMTyNasSMhWyc+1WokLEYOR29qRIGfqOKv28JUY7VN7kSaRLDFwBjmrKQHIPSpLcKgHGTVvKsvFJM5JSdyEwLwRkmgxoo9TUy4z7VNtiKg4GaRF2jMMZPzAc1UuoQwzjmtcx8nHSqksZ5BxTWhtGWpjqNh74HapWICBgp4PQd6dLGVckVAH2SfXqKrmN+W+okrh8nPFMZmER+bOO1MmRlf5eB6VXlkdUyBSLVO9rEU9zg7FGT3qpI/XI59KarbpN7dfSpoF3NyOfTFLnOj2aih9um4Dj6+1aMMagDCk1Ja2p2524Bq9FbEDkUNnPOSKMsAYAgc1EbU454NbSW43cinS26g479cUGXtLaHNXERGexNY1zGY+1dbdW+9cdKx7yyYAkDI60rm8Gmc5cKSpIPQVnSZPJ4ravICoOBWPdDKcdqtTNVAmiAIHFX4OUC4wazbNwVA71qRuByfStYyMJwtoSuFRduTmqkqBjk/nVglJfunOahmOzgcim5ExjYfFtjXJwSKY87F9xOAemKiA3E46+lHl5jOOooUh+z7j/ALS7nhs465qrcTNznA/rShggywyfaopBvTJqXJtFxpqLISm5CwpYySOV4FS26Kc76mWNeQOtQl1HJpaEMrJt7VlyoCCT3rVeDqcYrPuo2HTp2pNmOmyMt1CHoM1h6zd+WhVTya2r6Ty0ZmrkrhGu7kkHim7vRBGOvMygiGR8mrQtHk6DirUNoQ4UdR1q/PJHbQjOM4oULLUmU3e0TBmtjH1FVmStdYJr05AwlPfSXC+9Q4t6lpxWj3MIrTSK0pbKRDjaaqvEQcEVFrFOF9iqRTSKnZCKYVouYSpkXSinlaKdyORnqVwmWyKWLqM9KmlXHWooztcZ6VnLc9ZPQ2rNTwV6VrWkBZCR171naeAVGK37FOCpHetqa6nJUnYhSLDZFTvHtiwetWFjHm+1TOqsOmauWpn7TUoJuHUZqYoCM4xU5RQnSoJZMjAHFOOhalzbFZ1HbpSIF38CnMB0J61ZgiVSD1NRJGvNZE0ScAY+tWkhB5HWo0JzwMVYX2pGEpMmhhQpk1IbZSBxSwr8oO7n0qTcMZzzQY8zuVZbde4zjvVGa3BI2itN2yM1AGUAsaRtCbRmy2jBwevtWnZWuMFxQmWjVnGM8iraEKoJPNFhTqNqw5wvRRU8aDaM1WUjPJqxHIo+lCMWnYsxpxjpU4AAqsr8daRn96ZnZsuKm4YTkntTkhYsAAS3tzVWNyDxwatwXMkbgqxBGOfoaRMrrYfJbzQk+ajIQMkMCKrSqDx3rUl1eZ7RbcuAN24fz/8Ar1RcxyE7iEbBOfX2pkQlL7SM2VByCKz7y0yN6Hmtdhnn1qtMMcHvSZ1wm1sZ9pIjwyRzBfNQfIzHjHcY71VeNpYyAvI9KsywjzFKjOeMVLYl4JuSBwVJI46dKaZvdLVHNSxMk+0d63LLTRH5REiyFlDtt52Z7H3qncRkXAz0rbsAogxtA55bn+VTbU0rTfKrFlQqLgAkD1qYOCgXCileNVTeGznocYzULuNvuPaqOHcVTg5OKbuGeP1pGy5zjHsKj2kDNBVkMueTVORN4IYcVPOT1qs86jjPNKxrGLtoZ95ZIwytc5qOnHJZBg+ldUzrIT3qpdqM+tDR0Qm0cLseKTuOavwzoUw5yTWhe2YkJKjBrGaNo347GiMnE2aU9TSiC44P41IYiV4zk1FaOGHI5rWtoTIMgYzV3uYTfLuZfkkdV/EUbQoIByTW6bIhcnrWbdW2GyRimk0ZqqpOxkOjBiG6DnmlRBsyBweeKmu1LhlXAzwc+nelBHAAoRbZVChWqdDt+tNkXHQcmpkiJKk5pdTOclYY6sUORWbejapJ7VsuOOtYOsSbVYd6ctEYJ3djkNbnaVmjT1qvZRCNCT1q7NBuyx6k1FImyMClT01ZtNq3KiMHY7P2qKG3N7c7nzsFSuNq49a19IhUKMitEruxi5ciui3aWCogCippLZQORVuV0iiByK5/U9ehgJAO5vQVUpJHPFOWpLdW0ffrWHeW8YY5xVK812WYnZ8orMlu5XJ3OTWEmmdEG47suTxpzgiqjp6VD5jHvQJGrM2U0OKe1FKsnrRQV7rPT5XJHTn0p0cLPyB0qWSMCbmtC1VdvTrUtXdmbSqcq0LeloNq57Vu27FWXaNwJwecYHrWTZgIMDvWrB0rSOhx1HzMthDkn3qUDC5qJDuFSnaVxzu/TFVcyK87c9arM3TNTzI2DxwOc1RkbGTnNPmsddNXRYXaXBHPoKuwISCccms62f5sk1s22CgqOa4qt4irH0zT8Y6dKlUrt6imkZxigxUrixO+cA8HrUhzjmkQbBxThk4HegL6ldyxyF549aaoJ49akkkCHAUYGeccmogXkkwnBx64pXRqtiRQqKACc5PHpTySRwagh3Akn8Qe9WQpx6Ubiegi5xzTlZx0HFOVcCp0jbbjFGxLkLGxxyalUbhmnJASOnFSrA3TFS5GLmggAz8x474rXt7S1lkVZbpIFCF2YjsPT1PSsvyWHQYFTW8rwNuAUkHI3LnB9aFJGNS8l7rOguvDUypHJbSLKDjjuM96zJ9Lu0L4hchPvYFWtM8Qz2axxOqPAp6YwQPQfzrobHX7O5DbyYSo5L9PwNarll1OKVTEUt1dHBurKxDA/iKikwVxwCT3ruNS0GK/LXFpMMvk8/MpPsa5K9tHt5Ckq4YHBoaaOujiI1dtzImQxydSCPmBFNnlWOCNclifmOfU1ZeNRkEbuc5Jx3qrJHulBCjOMDip2O6LTtcqzJ5jKQOPU9K0LMgJlwwB+7g8VV8v5tpyB0NWkQx8HLDHGen1p26lTd42LAbKBe1NKZBGKI278ZpS5yaVzDVBgLmmO2QaR2981GXwTjNJyKSIpRn6VUkjU5yKtyMzZAFQFTnpxSUjRNorLEFfgYFFxGsg5FTPjHpTRyfmPB7VotRtvcyriBkBwMisW5twWLfnXYSIpXGOKy7u1Uq23g0NGlOqYNrEFbggj0roLB0GFc7TjIJ6GsQIUc4ODV2KTeig4wPX1pxCtFyRtyHIIBBqvcRIU+YVDFOC2X60+eUNGa0OLkaZkXVltYsnK9azH+V623cKCO1Yl2QHP6VkzphJvRixKZHFbEdvheRVHSlVmGe9dEYwI+laQV1c5cRVs7HPXq+WDXKanmSQjnFdbqzAZHeubni+Zs0rXKpysrmI8YzjFULn74Fbc0YUtWJc8SGnsjWLuQP80iiti1ZYo/TArDhbfcZ9Km1S88i1OD8x4FLmsrhKN7Iq+INbdmMMLdOprmXcsxLHJNLIxZiT1NRE1k3czbtohxamlqQ0lBDkOBp4OaipymkyoyJRRSCikbpnss8f7lH71LbnKjrUbP8Auip7VLbdcVUtxt6amnbcnPpWjCfSsyNwAMVehPIPtSMmaluOOanO0A8ZNVIHwcVaTlSaEyLalS+YCM8nkYNZEj7jx0Faeo9PpWUOmKJM7qFlG5PASGrUgkb7tZMJYMDjJ9K6XSrGS6VXYAD6YrB3Wwq84wV5DYlZhxmnMrrzziumtNIUR4IzUsmjnDbM4PbFO0jzvrtO9jlopMnDHFT8biFbK+tT6lpskPzBce/rWejFcg1Sn3OqLjUXNEdJ80nPahYySOKepXj1IzU0RUqCvIPeq3G3YEhAHNO20juB1NIjhjRzJGepPGmT8orasbIy4G2otHsmmcMV+Wu0sbNUUBVAGKWrPOxWJUNEZtpoob7wGK0ItEhB5z+Va0SBR0qYDirjSueXLEzfUyDokB6019AtmXGSD9K2cUuKpUA9vNdTkr3w3Iq7oCH9h1rCurSa3JDqRivSear3drFcoRKgbjFRKm47HTSx0lpPU8+stUubFz5TkA9V7Grs2q/2hgXAUMM4IFT6zoLQgyRDcvtXNTI0T8g5FKM3sz0qapVvejuXb+3+zlSxBRuQVOao2jq17GWyo3jkdRz2/l+NI0pkUKzcU+zjMEqzgrlGBGfXNaLU6ErRs9ya/tTBOy479Mcj6iqZkOcelTXk7PdSTSyGRnOSx6tVCSTJ+WnJ2Lpp2VywZPQ80+NWc1DbRM7iuq0fRHmw0gIUdqwbbM61aNJamNBZtNxsLe2M1cGjzN/yzIz612kOnxwphEHFWVtwB0p8p5kse+hwSaJPjLKAO1QzaRIoOQK9ENupGDVaazUg8cY4p8hmsfK55fc2TJwRWe6DcQRxXoeo2KMh+UVyWpWbRcgcGqWh6NDFqpozIdsDGarSjIqy5UcVXkZR3rTc7YmLdoQ5IFJBlTkj8asz4d8jpUDfL1pLQ6N1YeWJxjAoaU7cNUfOM9qRhu65qkzFpEM0uKy70hs1flQcg1n3SYzipY0kibSrny2XJ74Nda0oeJAO4rzxHaKYZrrtNuxJCoJ6VcHfQ4sXT1UkVtUiPm+1ZE0Wcmuh1EhxkViXI2IcVpHQxjNtJGFqHyqa5i+bDNzXRak/HvXM3vzE81lOWp30Y6EFk+CSetUNXmMsu0dBV2IbUJHas9oHlkZsHFQ72N7K7ZmsKjbpVu4iMbYNVnHFScs4kDNg0A5pJOtItUcF3ckFOWmjpT1FSdMB4opQKKR0I9hm+VsnoaljbkEVHP8AMn0psUg4A7Vci1qjSifLVqwN8oFY8DZ6da0IXwvNSkTJGlG+KuQzDHNZIlJxinpMOctyKGrE8tyS+m3EjtWcrjOKW4lDscGqiuck+tRJnZTjZG7pUf2mdUC/WvR9JtFWNFA4rjvCFoSBIw5bp9K9J06IKF46Uoe9qzwMzxHvcq6Fm2tvlHFXVthnJFTW8QznAz61O0YPHb2rU8T2jMy6sIp4mWQAg9K4fXtJNo+VU7T3r0ry8riqeq6clxaMjLzjg1Eo82p2YXFulLyPKORkVJE247QQDjPNXb+0MEzKw5BqmVAxUxPoYzU1dEw055WtN7lFuWKg43EDIGcD+XtV5tLittcltbedp4Y8Aswx83ce/NVvtRMaqwBEY+XA981p+Hl82eSVuvQVTijCtUnGLk2dTpkAWNVUYFbsS7VFUbFNoHAxWivFXFHzdSfMx4p4PFMFOHeuiKsSh1FFFUMKaetOpp60mgI5Yw4Ncj4k0oBDPEPqAOldlVO+iDxMCOCMYrmnC2p0Yes6cro8pk+VsHrmnrOOAcHHarms2v2e6dccZrJbAbpSiz6OElUimOnkBzjrSW6F3GO9Rj5j0rpfCmmi7u13geWnzNn0pS1YVqqpQbZr+GdFDKs9whK9VHrXXCNAMBQMe1EY2xKuMADGB2p1axgkfNVq0qsuZgaSlNJWjSMgpGpaaxqWiWzPu4g65A4I7iuZ1O3BDDHFdhMMrisPUY8qeAayNqNXlZ5nrEDRMSOBmsckjGeprstdgL275UhsZx6GuJLEZ3ZwO9XBX0Pp8JV9pAkC5qKWM7TUyEkcjimysNm3P1pvQ6Lu5VVgOKV2XPWkVGkkwi1cj0uVxnGBWdzOpOMdZMy5ivNUZxuziuin0chDuJzXPXkTW0m1uh6U031IhWhPSLMy9jIGR2q5pkx8rIPSq1448s5qHTpDh/Sqi7SNJrmidPv8yL8KzNQbcgWrEcmIuD2rOupMv7Vbdjz3HUwtVyHIrm5VLyEV0+qYJyK58riQ/Wsn8R2Up+6VhEwUr3q0sSpCAOtP2HOaJeEqmOUrnOaoMzECs5xWhfHM7VSkrO5co6FKQc0ijmnv1oAqjzXH3hRUiimqOamRc1LOqmhUGTRVq2hJYcUUWNr2PS3uCBiQEVUabbIpQ8GuhuNP+Xlax7ux2HMY6c4qZxktwpYmnIs204HU1oRz5Xd2rngz4yB8w6ioHvXzgMeO1JStudMYKex1n2sBetV5Ltgcg4NZNhLJOwVATk11FlpLOAWGTQ5OexnUqU6HxGWLhm5IwB1IqRJEZlyevat+TSFCcqfwqnYaI0mqwBl+QNk/QVLjOO5ksdSkmeieGLfZbxFhj5RXa2a4xXPaUm0ADiujtOgrWKsrHyeJqc8mzVg4WphUEX3RUqcKACT7mqOO5IOtOYKykYqMVMgXbzWkY3NIs4/xVpy7RMg56EYripl2tg9a9avYldGV1VgQRg15prtm0EzgjA7EdawceVnt5fiLrkZlyOMHAxmup8Lx4twcck5rj/m+UEknpXe6BDi1j5IIx0o3ZvmE+WnY6a1GAKtiqltwOasB8SBcds1pE+cctSUGnr1qOnKea6EUmSUtNBpw5pmiYU00rdKYTSYmxw5qC5HyGpwRg1BL901lUWgXscd4ntw671xuUcj29a5Bh82Oa9G1OESIwOMEdPWuEuIfKmcYxg4rDY9rA17x5WQ28Jdxgc16N4dtUt9PjTZiVjlm/pXMeHrHzZ97j5VrubNMAe1VGN2c+PxHM+RFs/dpPrSnpTDXS1qea2ONFNzSmgLgaYx9acTTG5FS0S2Rycqaybxeua1JgxjbYQGxwTWddjg96xFGWpymrp8rDHFefToyzyKOzGvSNVQFWIGM8/WvPtSDC8cDPPNOLtI+gy2puisrApjHI4pYbZ5pAEGc1JbWrP8ALg811ug6TsAdl57ZqpanZicTGjFsh0vRERQ0i5fH5VoNZiMYArditdq4xzTZ4Pk6dKcUkfN1cVKcrtnLXcAKZC++DXF+JbfapbHvXpFzEBkEVyPiW3D274HOKJLQ6MJXamjzK9f5SBS6eMdPSq1037zZ1OcGr1koUdKmOsrn0snaBpA7Y81mXzkc1dZvl5rMv5VGQKqRyJXZmXcm5TmspCS5PbNW7g5JqCIfOAKzjqza3LEtxxAJuPWqt2Qqmr0h2xgVl3R3ZxV1HbQmkuZ3Zz1yC0zGqM5xWpcKE3E1jzHc5rFG9aVo2RCRk04D0pQpqRVqjkjARVq5bRFiOKSCEsRxWxZWvTIoSubfCh9pb4A4orUihAAoqrGfNc9ZMG4dKzL6yHJArejHHTiq12F2kV2TimjxKdRpnFXVsY2yBg1jXiRIxaUhTXUaqwjR2bgCvMPEOoNdXJVMhFP5151RWdke1hq0kro9G8JQK8gZGDA969Hs7ZVQcV5f8KmD2Jyfm345r1m24AFdOHirHl5jVlKdxXhGOlS6fbL5pfA4p7Yx71a09Pkz71rUWh5qm7GxYLjmt227dayLIYxxWvB1rlaMZsvxdOanU1Xi5AxU60zEkFTx/dNQCpk/1ZreJpDcgm5rlfElqJlPTKjiuresXVUO0k1lNamtCo4zujzeSPbcqpH8WK9C0qPZCgx2zXG6hCG1GAA4zIo+vNdvaMNo2nIHFZU46u53Y6rzxiasS4AqcVBASVGamFao8lbjlORkHinU0UtaotDs09WxUdLTuWmOdqbmjNJUtg2GabIflNKetRSn5azkxXKNzyRkZ/CuK1qL/iZhMcsa7G6YYwelczrCltZhbaCAuc496yqJtaHdhJuMjoNCthHBgDtk1v24xis3TRiH8K04f6VvBHLOXNO5I1RE09yaYTzVslsBTjTQaM0CA01qU01qTZLYxuhrOuuBx3rQkI2mqN0Bt5rISZzupjO4GuK1K2JvyMdq7rUVz1HNcrqS/wDEwgx9xlOR7g//AF6Gj0cJW5GTaLpmSpIyOuMda7O0tPLQcc1Q0NFWJWI9hXQxAFelWkcmJxEpy1IfKGKilQcjHWrhWqs/rTOPm1OcvlGWIPHTFctrgzG30rqdRyryEtkE5HtXJ6y4MTVMnod1DdHkzxj7fNns5q2H2gYqteNtv58Dq1CknOaqHwn1N7pXJpZmxgVmXQPOav8ACjJrPuZNxIHSlJWWok+xnTdKjgHzVbdAYyTVZMDJrFOzuW9VYllYvwKrTKiocnk055QFJqi7s5J7e9S5Xdyo2SMfVHO4gVmBea09STDVTjTcaaFJczGpGWNXbezZu1WrOzL44res7IccVUY3IlNRM+0ssY4rUgtttaMVpgdKnFvg9K3UTLm5iokXFFX1h9KKTiNXOp0rW4biEfOA2KnuruJF3PIOa88tY5EOVJH0q4sc9wQGZiKz+sStZrU55YOKd0yfXrv7WTFB909TXPSaJGy5I5rq7fT9qjjmny2Xy9KydKU3zM0VSMFyxKvgqNdOmaNTwTnFepW8oMSt0J5ry6NWtrhZADgHmu40rUEmtFUMDj3roorl0ZxYuHP7yOnL7kUjp0rUtRtVRXLLqVvGoEk8ajPdhXUWbbiPQDNa1Hc8twcUbVr90Vp2/JrLtjWlankVi4mEi+jBVGSAScD61Yjzjk81WWp42FK2piyYVNj93n1qAHirH/LGtolU+pCazNVwUfI7Vp9TXPeLL+DTdKu7y6bbFBG0jn0AGaiZVPWRwE+orL460vSkwztvnl/2VCnH5n+VejwYU4AwBxxXz18J9Uk1n4lHUbkfvJ0mcL/dGBgD6DivoCElpM+5rGjqmzsxi5XGPkatvke4POfT2qyKqwEYFWR+laI4RwpxpvXrSk1SZSAGlzzSUUrlC5oByKb2o9weMUuYBTVadsD3qctgGs67uEjBzUuSKjFsrXTjNc7qyl9YtSOdqnJ9MkVz3jLx7Hp149rZBZplHzEYIU+hPrVHwFrFzrV3dSXZXMbLtx6HOf5Vn7WMnyo76dGVOPOz2DT+Ih9K0ouFJFZlkR5Y57VpxnEea6InAviEY5pppSc9KaabYmxaQ0maTHzE549PWpbFcM9elIT60E1GzcVNyWEp4qjO3HFWZT71SnPahAkZN/0Nc/fRhjGw+8r46eorfv8AOBg8d+OtYN7NHBbzTSnEcY3MfQVdtDem2jo7KSNnJhj8qM4ITOccDNbVsTtAOAfasLSl+RSOnWt+2A/GtLHJVeo+QjFU5zwa0JkIGSMVm3TBR1pNGa0djmdXfa7iuN1iT9230rqdZkzI4ri9Yb5DWEz1cKtUed3zbdSl96Uuo70/UoC96WB61JFYkjmtKak46HuSrxikUZ5iwwAcVnSTAk+tbl1abFOOuK5a4kKSsMc5qKkWn7xpQrKa0JpZvlxVZ2Z8AdKbktgmrMMXQmsbcxpKpYr3K7UUA0gjO2n3R3TAelOkdY4iTUpXY29DC1T72Kiso9zimX0u+U46VY03G8VaNEtDotPtxgcVv2luDjiszT1yBW/ZrjHFdETlle5PFbjHSle3wKvwJntUrQ57Vd7BEyBD7UVp+RyeKKLmyMeGwLYAWtqx0s4Hy1pabbKTkituKJVAwKcYRWp5latLZGPHpwReRzVa6tMA8V0chVV7Vl3jrzittDGCnJnNzoqQujKD74rmrrzImIjdlB9Diuk1WYKGFc8QZi3rXNV10PSo0nFczKKBpGwzMfXJr2rwhq63thbOzDzVURSj0IHX8a8ustMdhuYVq2MlzpU3nWxwf4lPRh6Gs405JXMcSo1VynttvJ8oOa1LWXpzXF+HNftdVtwYmxOg/eRE/Mp9fce9dLbSBsYPTnFaJpng1Kbi7M3fMyM5qWJ8ZrMjm456VMkvP+FDRz8pqRyZ71aDkJtGKyopeTUeqa1ZaVZPdajcx28C8F5DjJ9AO59hRewoxk3aJqOwUEtXhPx28UxXUR0GykDDIa6Knpjon1zyfoKTxx8V5ryOSz8OK9vC3DXbjEjD/YH8P1PP0ryK5lLbixJJ5JJySa469ZPSJ72XZbKL9pVXyOo+CxSDxrbqef3EoH1xX0VbSZP49K+Yvh1eLZ+MNOlfhGkMRP8AvAr/ADIr6SgYZGD71rhtYsxzWny1U/I6G2fpzxV1Tnisa0m4rQjl6c5rRnktFyjNRb8jnj6U1pQB1oAnoJ96gSXPQ5FNml2jNTcpJlgkY5qNnwOPyqk1z71m61rVvpOnTXt7II4Yh+LHsB6k0noaQptuxZ8Q63Z6NYPc306wxLxk9SfQDufavEfFvxAvtWaSDT99naHgkH9449z/AAj2H51heKvEN74i1Jrm7YrGuRDCD8sS+3v6msbaTXJOblse3h8IqavLcQnJ5ru/hTLt1O8izjdGrgZ9CR/WuHWPiuh8DXBs/E9kS2ElJhb/AIEOP1xRSVpJl143g0fRWnk+Stam75FFYFlKVjUE9q0RcZUDPQV6FrHzrvcu5BpCarLPzSNMSMggZqRFnP4UpNUUlI4Zyx9TUxcFcnoKljsOeTBqNnycVBPKFPWoI5tzMewppBYsStkH1qnKx2gsAGxzzmm/aGPLLtz2zmq08w7nrTSGkVLxuDzXLeKXUeG9Z3dDaSf+gmuguZM5Oa4/x3cCDwpqhJALx+WP+BED+tU9Is6KMbySL3wk8R/2voSW075vbTEcmerL/C35cfUV6dZygOo718ieHtau9A1WO+sWw6cMh+7IvdTX0Z4S8V2PiHTlubOTDqcSRMfmjb0P+PenRnzKxGPwrpy547HoN1tFuWZu3U1zV9KMn2pbq+lkhCbtwBzWdcy/u+T0Fa2ONvnlc5/WJAZGwa47WG+Vs10mpS5kP1rl9WbO6ueSPUwy1RzEgzOCavwKMdKpOR5wq8v7uPJrsofCa4i/NYp6kQsbH0FcLMN87t6mur16422zAdWrlkBP1rkxD5pWO7Cx5YXYsUeWFXAAqk02FMUty2yPHrUpcsTVPmkZ0rgOznpWLqWobiVQ1NrNzsjKqetc5uLNkmskjeU+XQshtxya0dOfEgrKjNaFlxIKOp0U3dHbaY2QK6SzHArltKbgV1ViRgVvF6GEo6mxbjgVbVciq1v0FX4xVNiSIvKFFW1UHFFItEWnyBAMmtA3XHFZyR4xT2YqpIGSB0HerSsYPDpu4+WcnPNUbiUkcVI7kqCRg4zg9qpvJufFVeyNY00tjNvoi3JGaoWdvm/UdjW7d/d6VnwIVuQ46VlLe5rZuDR0UNqI4xx2rO1MKikngVeOofuwMc4rA1aZ5g2M4rSdVW0PPo4aUpXkcvf6pNa3qy2czwyxnKuhwRXofgL4jfaXW1150jkJwlyBtU+zen16V5dqkDK27FZ0ExjkHYV5MqsoSue3Vy6lXpWtr3Pru3uRLErxMHU8gqcg/jUN7rNppXlnUrmG2SU4UysFya+cNK1y+sY3FleTwBxgiOQrUN9f3N7P5t3cS3EmMb5XLHHpk1o8Xpc8FZO1Kzeh7z4g+I+j6XbMLKdNQuj91IDlR/vN0H614x4i8QX+vXpudRmLkcIgPyxj0Uf1rE8z3ppfNc9TEuWh34bL4UNVqyR3wKqyHc2M80sj/wD1qsafatK4OKzhJzdkepGkoq7LFhC67Xj4cYKn0I6V9C+HdTXUtLt7qMjMijcP7rfxD868t0Dw3c30Lm2iZyiM+0DJIAyas+GdfHhzUWiuSzafMcvjny2/vAfzFeql7JJs8PHUlik1DdHskE+0jNaMdyAB2rCtporq3Se2lSWNxlXQ5B/GrkCswI9P1rTmUtUfOSg1ozaScsOtV7m42kLmqMM7AkHNPkJdsjj3pXsJRL1vc/LkdKfcTbk61mI8axGVpkWIDJZmAA/E1har478NachWTUkupRx5VoPNP5jgfnWcpxWrZtCjOTtFXNrUtSg02xlvL2QR20Qyx7n2HqTXh3ivxFeeI77zZyY7ZCfJgB4jHqfVvU0/xf4puPE14CA0NhEf3Fvnp/tN6sf0rGjTOBWE6nPotj2MNhfZLmluRrHmpkhq1FBmrsFqTjinGFzWc7GesB9KUI8TrJGcOrBlPoRyK3orDPUUk1jhTxW6o6GDqp6Hr3h6+TV9HtruEjEiZYf3WHUfga0ULKpDE5rwmw8Q6n4baU6dMBGx3PFIu5CfXHY/Stax+LWpuMXWnWMuO6FkJ/nTlVUdGcMsBUd3BXR6+bgqSc8U1bnd9R3rzq2+Kdq/F3pEi+8Uob+eK1bX4h+HZP8AWfa4Cf78OR+hNL2sO5jLC1Y7xOtFydx61cjuMpXN2vivw1cKWXWLZD2WQMhP5itFdb0HyDI2s6d5a8k/aF4/Wm5xZn7KS3RPd3Qztz1rJ1LXLDSBjUL6G3Z+QjP8xH061zniPx7okFrcppkz3d1tZYisZChuzFjjgda8ZnkkleSWaR5JW5Z3OWY+pNQ6qWiOyjg3NXlofQOneJtK1Pix1CCR/wC5vAb8jzVuWUmvluZ/35z1HSus8OeOdS0sCG5kku7XptdvmT6E/wAjSjXXU2qZc0rwZ7NNKVAXduI7kda86+K2ogWtrp6H5pG85x7DgfqT+VSy/ELT/JZkt7p5scIwUDPuc155q2oT6pqEt3dNmWQ9B0UdgPYVUqnNoisPhXGV5IzpeKsaRrV1oV7FfWUhSRDyB0de6n1FV5R2rL1aTYoUVKfK7ne6amuVn1Fo2ux6jYQ3EbAiVA6n1Bqe4usqQDXhPwx8UvbN/Ztw4MfLRZ6g9xXqE2powG1hyPWulVbo8KrgnTnaxJcy7nYnoK5rVJcljWjcXa7SMjJrktf1eC1RhuVpDwFB5rOUlY68NRdyqbhftJ+YcGrUt0HA5GK4Ge5lLtKrkEnNEWuyRja4yR3q4V+VWOqWEcnzI2tcuN8oQHgVRhX2rKa+aWYu3etC2u49oyeayUk5XZu6birI0furuPAFY97cl5SB0FWri48yMhKyX4JonO+iNKVK2rMvU1LNk1mYxW1eYZcVmtHz0qLlypX1Io60bH74qkFxWjp65cUbmkFy7nVaYflFdRYNwK5bT+MV01geBWkdAaOgtjkCtCIg1l2xwK0IGA+p61VyLF+Kimwtzk/lRTCxFuG3PamE+lTRQ5FS/ZwOTVJsbaRlT72yAOKz3zG3NdDLGpHSsq/gJ+7SlsaU5p6FZXEvynrUggwOtZ4YwyfMK0Y5d68VCkaSg1sPWFcY9aZcWilSab5u09akFwWyMA1SaMXCS1RzGq2QYNgVyN5bskhGOM16RNF5jNkYPpVC70XzbdpQBxwR3rnrUefVHZQxHstJHC28pjJD556VaEgI61avdNdG4GRVSOBt2Oa8upCUTtcadRcyHA8daWpktzxV61sGkI+U1nGlOTsQ4xjqzPgtzKwJHFdh4d01XIDDa3UE9KXRdI8y7ijYKqswUs/Cj6mu10QQaZr0MgjWSCOQMoIOMV6uFw/Jqzz8ZidHGJ634K8P2mm6FEm2GaWdMyyKAc5HK5HYdK+fPH1n5OtXq+V5WJX2oP4Rk4FfRm3TbtYjp15bwOZfMiMJ27iCCwZcjdXjnxRs2bVJ53ljmDOU8xFChiOp2j8s98V11VeLR4WWVGq7cup5joviDUdEuSdPu5IcnLJ1Rvqp4Nd7p3xanhiC32lxSyj+OGQoCPoc/wA68x1SHZISvUVSSfcu1uGFeHKpUpNpM+lr5fRxC53E9sj+LNh5Tl7C5VwMhflOT6ZzWLq3xc1CVXj0qyt7VTwJJSZHHvjgD9a8uLH6VFJJkbVPHrQ8TUlpc5YZTQi78po3+s3t3bR2txeXE1uhJWN5CVBJz0qtbviQZPFVNwA5/WpoWBIpXO72MYqyR0tmMqBWnbRZ7VQ0gbkHeuisoMkcV2UtTxsQ+VsktbfJHFbVpYjAOKdZ2uACQfyrctrfC9K9CmjyatQpR2gA6VBd248tsCt7ycCmW6W6XStdgtEoJ2gZDHHAPtnrWtzKMup5pq8J+bjOfWucMflOeMD+Veq6npqGxkk8lWQkqDn7przrU4VWYqpJ781yYmNtT3MK1KNihk54pQWqUR8CnCPiuNMuSSItzU0tjtzVgx0x46q5lZFdj61DKcRmrDJxVa8+WA/SqTsVGN2Y7HLsT3PWlBphBFOWsVI6507EynNSquahSriqPKyOtdFN3OaasV5Vx+FczrD7rnA6CuomPyk1hXNkZCz461q9djWhFX1MiORkYFSQR0IrTh1W7B4uZh/wM1QmgaM4IqLJU1B0SoJm6NTvJOGupiPTeaaWLHLEk1mQS881fhYHvTTOWdLlLQj3qRWTfwtFLyDg9637Vc4qa+s1mtmyOQK25LxuYwqcsrM5RHq3CCcUwWxDcg1qWNsMDIzWSjdnVJxSCLlMVn3DFXINdKlmCOlZ+paacblFU6bQqcotmGy76ie3OeBWjDbc4PWr8dmCOlSkb6I5027YziprEFJOcdeK32sht6VWWwJmG0cmtIoyqNbmjY8gV0mn9BVW00GdbcSIpOBnpVmyypwetayg0c0Kqnsblv0q7G2Ko2v3RVxalo2RajeiokzRU3NFFF8XKotRyXgY9eKyvPPU8VDLc84quYFQubSzqajd0cmshLghafHPkcnmjmuP2FhbuDe/AGPWo0Ux5HanPcYYc1VuLjLYWoa1uaRi9h07ZOBVcuyjIzT45AxBIzipCqseOKl3K20Y2J2OM5NX4ZD5TIRwRUccIIytN3bXq1K25zzSlsQTWayHpmqx0xAclK1A+elSqQx5otFiU5RMmLTkDZC1pW9qqEcCrSqPSl2kHIFUrLYTm5blu1JjdHRijodwI6g10+nXemzWt2NXhlnuZSrRyocFTzXJK+0UpvBHg5z/AEqudHNUo+0NrUzLG7RrPHKOCHU8EY45NYF88kqjz2d1AwMnpWjb6gFSUII2MibDuUNge3ofeq8irLGQau9xQXJujhtVtN4eQdOwrkr1JI5c4NekX0BTfgBh6EVzrWH2m8jjuJFijdwGlIyEHrgda83EYe7uj28NiVFe9scujs454ApC+DwRitPVLJLdmSGQSA9wCKy1tnLdCSa4XTcXZnYpRkroTBIqa2c5xip4bKYnhT9MVqaboVzdTokEZZmNUqU5bIyqVIJO7Nbw0C/FdzpltnHFc3pWmy2F15UoG5DtOOld7pdv8qnFd1GDWjPmsfJXuupcs7fAHFasUOAOKLWIY6VbCgCu1M8OWrK0iYHSs2dWeQpECznoBzWrcttQms7T7jytSimU/NG24DOCfYe9NPU6KEHuWPFNnZi3tV02aIiSFUkXON7cknPbrzXlWtQ4uGPUjjPrXoWsXrkyIkkrpyCwULnPb6dOK5XUrZXYfOHAHJAPB71NSHMrHq4O9NanMRwZHTrUv2c+lalpbBycVcFhkdK440WOtVUXY54we1RPCa6NrE88VVlsyO1U6TRgqqZz8kWBWXqC4XArpp7cjtT9O8Ptf21xeOMW8JCFj03EVCpOTsjqp1Ix95nn0ikHgcUqrwOK6G404ByAOKqSWJTkCpdCSR6DqRkjOjHSrBHFOSLB6U9kCkAcmlC6OeSuyER72welWDZqU+UU+KFvStK3hOzBXrXfSjpqTKPLqcve2AcHjmudvLYxOQRXpFxaqqnIrmNVtQ5wKzqwsdNCrfRnJ4KnirFtMUIzUlxblD04qOJCXHFYX6HTKKaOg06TcAa1WIMRHrWXpsQCitqOIbRxXZTvy2PIq00pXRmNbBkPFS2kW3g1pPEojwBRb2+R0ppWZMtiSGP5elNuIwUIIq2kZXjFRXCnFOb0CnuYL2+JcgVchi4FWPJB5PWpI021io2OlyuRGDI6VHHGIp0fHQg1fbAXNVshnwK1huRNXR6RZ3duIY/soDArlQP5GuLvFMV/KQhVS5IFamgL8hRTye2eop2twGOJVcfMTkfSu2UOaNzy8P8Au6jiQWj5xWilY9q23Fa0BziuRxsetFlpBRTo/pRWbRqjDaTCYxVQv8xJq4ACuDiqlwNppSR1Ra2GmU9AafGzdarx/e6VcjUgZIoihydgc7VLEE4GeBmq8p3EY71aYkISap9STV2JRMgHAXHvmrEYBUA9apLnNTwPjlqkmSdiwJWib5elNkfceKrT3GBjafqKWCTcc5qGkyeVrUuQAgVbCEDNUfPVMZOAfSr1vIJACTmp2MZp7k0bHGMVKpp8Ua4yOaUxkN04p3OfmQjqMdetUbiNg2UGauyHnJqvJIVGVbDCh2ZpBszjJJG/BxVuG6boetVZmABPeqzSYGQcNQpWNnBTNOaQOOazp4Ffnoaj+0HFMefcpI61XOnuJU2tijc2IZuTTYLCMHnrU77zz2qaIAuCOKjli3exq3JK1y1b2SFeOvrWvpafZZ0kCZK1nwkjbitW1k7EVqmuhx1IyejNOdhd3ZnZFRm6hRgV0mirCY2SaXYwHyZHB9ee1cwkgBFatnOhwHP5Unvc4q1JyjY7B7aNFXE6spAPGQRViMWaqTI8shBxhMDdWLpjSSyGO2vYIyw/5bPtHHTrWydOvJVb7Zq2nxIxDMRKDz+QoT8jzZUuV2bMfV3VFxGeGJwCckfWsAuVfL4GORnvW/rE2kWcckVtPLe3RIPnEYQeoHr9a5ieYSMSKaPQw1P3dicI9xAVJARmyWPbHSs7WGjt2EUEwk4+cqDtU+gJ68VOJsLgtxVO5KycYqmzqhFp67DdLQGUjqDW4IAR0rG0wGOYY6V0UeCODxSiceMXvXKhtxuPy8Y6+tVLi2GOlbLLVWdeDiqZxxuczeW3oK1NKu/7K8IavApiEt26LskU7iozkr24okmaFZgiRsWXlmGSoz1FU9b1T7dZWNnD5iwW0fzByDukJO5hxwD6VKSR3wpymkmtLnNiIueaJLXK9M1bJWIZPJqFrsYxT06ndZvYyZNP3OSOnpSCwC44rW8xScjrUm5GUdKShHcfNJFGCy2gEjirQhxjAqQOF4zVW8vRGpCmrclFE2lJlW9O6RUHc1k3tkFlYAgirUUxeUt37VM8RxnrUfGXZwOXnsdx5FQLpu1uldRJGrIBt5p8FnvI4rL2auU67SMS0tyhAxWnwpArTt7FUlBkXIFRajCvmloxgVsvdRi5qbKErcYq1ZdOaqMOKswHCjFQnqOcdC65AGaqTMGz0oklwDVQy5ahyuOFPqSIhPbinxx5fBojyRnNKWKnIq9C1F3Eu12DAPBqC1jLSA1MzGQ4NX7K3HBxV01rcc1aNi3poCzruO0Y49q07oR/ZnVmBY9BnJzVExYWliiOa6ebocLpXdyqV2npVy0fIFPkgyOKhjUo/NTJHVT1NeHmio7Ujt65orBo3RgyPtGf0qs8wZuannIzjFVZUx0FY3OyKRNByauqcjJ6Cq9lH8hJp875G0CqiRLV2IbiUkkDpUQBYA9KnCZGT1pWww47UNlIRFBGTUcxJbC9KmGdpFKYwibj1qdxbFJxgHJpUfaQB3FV55Mn0z2piNz81Zt2NeS6LTvuYEnC1agm8s5U8elZ7gkZpVV2IwcYqXqS4Jo6W2usKGPSrkN7GQd3WuYWcKmGbp2ppuzuwCQD60XOWWGUjpJpVflSKqOj/eGSPWsM37A4U49yetPl1OclEYHBH8NJsaw8o7GxNDmHfuXPoO1Y0koD4z9aVrjYyq7lGb7wz0FVrtLbyHkSfEm4BU9fem9UXThZ2ZYLIxwr1GVINMswgs5JG3+cjDbxlSp6/jV/T3tZplE77FzzjtTWpUvduQ/wc9KdE3OT0q9LFFFKwcKV6qynIIpgSGSI7WAYHoaHdEJpjEbAHrVqC4IPNUhlDhqeOxA5pXe4+RM20uSNnOdxxx9KuR3QCjPFYkTEDmpklxnNPmM3RTNqO+w+M9KVr7GfXtmsYtuAK8VDK7EEgkkfrS5hrDxZstdFgcmq7XOB96sdrlgmckVUa8ZmxnrUuoaRwyOhS6BYjPOKnR93UVziSFXUmte3uUKcn6GqhO+5nUo2WhqwkBgTWraykKMmuaS5yeKtx3pXArRTOKrh3JHRGYYPeoJpwgy3zD0rH/tA54NV7m7JBG7mq50YRwmpLqVy0ytGAiRs27AHP0zWYxVBxUU02TkmqNzdgZFS5o74UGlYLucc81nSyelMlmLMTnrTODkk8elTe50qHKTxyt61KsrZ61TRiKk3hRzRcTiTSTsFPNZ0jNM9PkcuxAqza256gc0r3E0oK4WkOOSKvpGSAAM1LDanA44rQgtScYBzW0XY4qs1uZDwAPgCrlnDt6itRNNZnyRU4tFjGByaqzOSdaLVisbUPEz8AisTUkAU10Ez7VI6VzeoPl2FRMdC7ZjPndUkUmOM1DK2GNRpJ8/Ws1oehy8xZc5Jqvty/FPLUsQyauJSVkTocDFSYzUGcGrkK7gKoa0GQx5cGtq1jwBVa2h56VpQrgCtYaGdTUfsyKWNOakApyDmrbMuUCvFVpo+c1f21HKmRVxlcIKzK9qxBxRQlv8A6Sku9wVBXaD8pzjqPXiihq50owZW+amRBpGA7VYS2eVskYFXxFFbxZGNwriUWbuaWxVb91HgdaiiHzfN1pJZt8me1AYF+DVXsNLQkk6hVHFIq/OOKnSPONvJqwtuVG5ql6i5khiw7V3tj6Vm6hdYBUVYvLvau0HmseQNLJk9KTl0RrTp/akNT95+dWo7Yq4Ljj0ot7fJ54Aqy5bO1fu1C7sqcuiIJNo4UHHvTJG2AkHB9KlOQ4BFEqrJlQMdyab8iU7FLDMdzDA9aSSNmUEDNTSZLiNOV71chtlO09MUKFxudjNgtm3hiMgdqe0MkjfL8qj+7W55caxlu/pSQWxcnYCM1SpXM3W6swjakEY5NVbpCHA7+ldR9mCAjbkjqaoTWBlkLFSAKv2Wmgo1tdTMguJbeRHVVZR1VhkH60szxzSb4ofLbncFOV/CtWLS3mA+U47VIdHZGypIz6UvZt6CdaCfmY3muikljiqz6hJAPvHDHn3q7qURt8IASM9KzjaGVwSOAaylC2htT5Xq9i/aallwW4+tbsTpMUMXU/w1ylzE0a5A+lGn6hJDcx4YgqetQm46Mbp86vE7pUOzleaTYNp45qWyvop4DJPKBJxgBalSUSIflwSappdDi52t0UDlSOAVpGjzk5wDU1xjcyqPfNV5HbYQ2Q3T2NRY3jK+xWvGEUB71ifaMNuJ49Ku3oIYk554JzWNOQ0wApM6qSVjVW4ZpYynIxg1pQ9B2FYlr8tyo7YraguFQDeuR6CrS0M56bFiOXnrVpJwOh/Gs4EFix4B6D0qUkcYqdTGSTLUk/GQapzXRJ5NQTynBqhPIcdaTbLhTRYubo5wp5rPlmJPWo5nxyTiqclyoY80jVQ7Ftpe3enKzHr0qhFcJnJIqUXiswVTzVJilB9i28uwUxXaRhTdu/k9amtAokAIpu5nZWNGwsvNwSOK6S005cdMVV01kiiDED6Vu2s8Z2gY5raEdNTycTVnfQj+w7UB21bs4lyBjmrAYEEA0qjkMK2SSPNlUclZkhCqCO1Z924Q8Dg1akkXnmsm9kJU4olKxNKF2Ub6Uc81zeoP82exrSv5SeM1i3j7lx3rnlK569CnYz5jljUCkhqlk61ASA1Sdli4gzViBarQtxU6NhsCqi7MhoWQYar1qeBVJjuPvVm2JBFWVbQ2rbtWjEoNZdqc1oROF5JwK1jIxlEsKAykjI7c0+NeaYGzU8I5ouTayJQnGT+dNeMYzVkoWjIXbk/3hkUroMYAwKpMhbmesZDk5JB7elFWdnNFa3OhGDdyrACARWVNd7s81HqDvK+2PcTS2mkXM+C/yrXIrs6VGMI3bGKfMOF6mr9nprkh3YqtXrXT0tQMJuYdzU0m4jlsAUNLqZuo3pEFEcQwvUd6q3lyXQqtMluFBKqCTT7WzlnO4javvQtQUVH3mYskbSyYAJNXI7ExoGcgH0NajRw2ysAPmrMurrc20cj1qGkjZTlPYhnJDZU9O1LC4ZgCPrUcu5UyADmnQKxw3IHrUa3CTViy6pI2F4x3qtc4j6N09KushCghcAjrVSRQ7gHj3rRxM4Ms2VuhUM3ernyD5UXmoIDnasf41KW8tgM8muhbGUtWMWLDHd0zWha7REWBHHrVMZBUNzk9BV9LcspyuQB0pxj2M6ktNR6i34L84GeKLm1draKdUIt5HKIfUjrVcIAhY8KOOKuvcpFpyWhtEFw7eYJSDvC9h6c09bGEk73R6fZfD3T7TSg2oXM5dELymIDA4zxkE1wFzpM9xYXV7Zwv9hgbb5r4HfgH36dK6ews9eufDgu1u5E0/aQytMQSg6kD0rkNY1yKGBrW3dnUtkjnB/D1p2sebhnVcn713c5K7tjNcYIzjtUIsd02zGFHYVpRzEAsoO4nPSnwuvmZZTluelQ4Jnsuo0jJvrAbcKMgDmufW2/f/KOAa9CIR1PAwRj61z8tkqysEBAJ6VlUpX1NKGIaumQaY2GAcEgGt4SYIKAhaxIoDHc7BkZ9q6i8WOCyhRlQXK/e288f41jGLVxVpLmVupSIJYlqbMoIGOtSJyOearXDgZ9qAjroZGpvj5QeayWTDrxlia1ZQJXZj0qjMpEy44xUW6nfCVtCW3iZp1UdfatAxNBLsOTnoD1FM0mF5HaVjjHT3rXSMY8xseYTzkdBWyjdGFSpZ2KSnOEIwKklARRg80s0ixt8pHPaqdxLxnIqHZEq7IrqTy17c1j3t0IzjOTT9QmMknB+UVgX0hZwASSKxk7uyO2jTvuSXV87HGc1ReZnzk1JDbyS9AfrV6HTDwXzjPNNQbOhyhApWkbynHJWr8cHlTHJwOtasGnLApYAhak+yl0EhHXjFaxpWOeWIUnpsQQElRk8VYt42Dh+oqKKMqSD2NXoXUDYTirsjnn5FhLxgdmelaNndsUUk9DXPTKTIdpxz1q5YMyrgnOaV3cyqUYuJ2kF38n3uT0qyLwbevNc1Ax4OatLPgg+nWtOY8qphlc0prj0qncz5Q01pAVzWfcSdcdKhsUKSMy+kO488VnNJlsdatXx5OKy8/PxWN9T0qcNB1ypHIqnID1FaGd8eByaqSqQcVTLiNtpCQQetXIm71nAFJvY1cU4AoQ3EuoRmrUXGKoRnkVfhGcCrTFY07RuKvoazLbIrSt/mAq0RJFhSasQvzUDLkYzinxLt9+c1RFrmvDyBTyCc5UgA4Hv71XtmPANXl5WqMWrMqFOCM49xRT5Fbew3HBHHHT8aKpM2jsc/BEqP9zir6sqqCUxSRQHILsAB61ZgEDFgTvI6VmpWM566mdNIznEamk+yPNjJwvetVPLjjPAUV0Onaj4ah03a9hcXGobuQzELj65x+lTcUqjpq8YtnFQ2scT8qCT3NRy3Mm1lhXmukubiDzJPKtkjRuADziufmwknC8E0jWM+bVoyJIJpGJkbg0iWkSZ3nn3rURSx6Y+tMuoQVGF3GjlXQ09q9mZbhF2gDcT69Kt2lwIY2QqrA84x0pfsj5BYjB7USQrEflIH1pxVtyJyUtCKYyzMGYEL046VGYl3H+I9BTp7k8RISKltrZkKyEblNaaDV0rsS0jMe4DirDW5fGOB3NXEgSUqeVarcQgUlGYMe5NUmtjGpUe63M1LHeQyBhjpU7xvuWIStz1zV9JUwfJGQOtJY2M+p6lFDbRsZ5DtUE8H8aG10MvaPeWyKcVjdaq7QWMbySIR8kakl/Uj6Yr0vQPh5Db273Wu3bs5jBAjbAjGO5Iq/BoVt4PRb6KA30gAAaSUIYzg52jHOfzrhta1nXPElxJumltoCdqW8ZITj19T9adzzpVp4l2pu0e4njnxHPNL/Z1vcKdOtsJDHGMbsDALHuf0rk7W2wDJJyzckmr9zolxE4W4R4nZdwLqQSPxqtKk8Ue1uUHBI600ztpwhCChTZDOqo+Fwd3HFTmMxw5yAfpRE8LxlVGT39acIXZQVY8cYPNDBytoQqzAggZNSRW7SMXZBiug0fwjq99AtzDYs9uw+V8qN34E1XmsbmzuHhuYJImRsFWHIpXMvbRcrJnO3dg5YkKfX2qvErK+GBwK6iU7jtyAnv1NUpEhyQFzUOnfU3jidLMoZyMAGqV0of5RkHvWnMoRflH5VngfP8ANzmspRtodNKXVFB49uFqtNBvYEcYrWMeGPtUckJEfTqalRubKpYis0aJM9V9KeZyWwDxViJMJgfjVee18o+YpyvcVTi1sJTUnqQSDPQZBqnd5WM4HFXi33R2qvekNGeMVHIaKdjnLlXOcNxUVtZmRuACTWgtv5k2O1dHp2nRJGC2AfWiFK7NamJ5FYoWGklIgzAc1ansthUqvGa1VdIwB6VBqF0HYBAAtdCgktDj9pOUtTPmUJGfMIAqqJgRtTmn3KvNJ85496ZGixQnpSbbN42S1K/QnnnvUasNxJpSvmMx6elMjUchuOaz1OjQcJBnI5UdasWzneGHAqkYyC20kg1PAVxj7pFStwklY047koxFSCcsSSay1l+cnt61KDhwQal36GMqaNWO5wmDVe5l4zmqby7CeeDUUkoK4zmhsx9kr3GXEgPNZNzKRJgVZuZAD1qpMAwyOorPc6acUi9aAHHNPu4e4qtYyDbjvWnEhkjORk1ojKa5WYlwvKsDgirMJ3ximahCY2PpSWTYjOallpe6W4jzWjb8gd6y4zlq0bQ1cSGa0HOK0ITjAFZluxwN2B9K0ITnFaoyZfjIOM1OkYAAAAFQQ1ZjcbguDnr0pkFqBcVbTpVaGrG7ApXM5bjZRiimSPk0U0zWOxjIxYAHJNRMxhkZs4z6UvS6XHpTNQ/1S/WosCetu5ZE4MQOcmnxeYBuQde9VrIDyxx2q2T+7FNakTfK7IdJeeQMyLvx2zVKTUEl4VQm7pkU2+46VnpyoJ5pGlOmnqzRidUUliGNRfbBuKrjAqJ+FOPSqcQG48Vduhagndsvte7uMA1AWaSTDthfpVCbh+OOe1ToeaLhyKOxoQxxLnK7/fHSr6SplUA2qOmazYCdx5qZidnU0XsYyV2aqBQh2tgnvSpCs3yR4VsZJzWdbk7hyavwfdP1qlqYSvHqPtLd4rjYASuOeOK1LSBo7lJoCUkRgVPoaW34VccfSti0UG2kJAJz1qkrHLVqtjNb1PU51heS4cyxnOTgFT7elRWWvXdtJ58bq07HJ3KDlvU1U1JiVfJJ4qPAzDx/DR1Mo04uGqLd7PdX0fm3kplLHcSTznpWLCrR3gZ4o3AOSknRhV644Q44qjMT6mmXBcqsjFubdob15UXC56dhVu3lVcs2Ae4pk5OV5POc0yUD7O3A6U2rG7fOrM2LPxBd2hU2lzNEF+6qyHA98dKfqur3mq3Bubt97kAZUBRgfSuYtuHTHrWq5Oxue1JO5nKhCLukRzuHG1RnHfNQxRksVJIJ7UWP3W+tXYAPOXimxrS6KskBUYwTVVIlM7KQOK0rr/XH6VkEkF8E/ernludVLWJKbYFtwyAKjmRwcFcjNabf8e34VXbkR55+UVpGJHtG2U1Qb1ypGabcwh5Dsfj3q4/X8Kr/APLc00WpPcqzWyRxBupP6VkXUhZsY4reu/8AVmsaUDPSlJaGsJN6sr26Bpc44Fax3bVCrVW3Aw3ArQgAES4AHNOK6EzlqV5A7nbVZLd3c84ArVb/AFdVo+jU2hxqO2hBPCEjHOTWbcsPKKryau3hPlnk9Kqxj5PwrOT1OiGiuUFlw+Bx2olTf0bp3qK4Hzmnj/VD61mjpWmpNbnchHcVHIhDbj0qzbgb/wAKa/3vxqmtCea0iJCNvINHmY4pz/eNQT/eFZN2L3JT8wIzUQO089ant/vfhUN/xLxStoZ3u7GdefM5PamxYaMinT9DUdr3qEjb7IWZYSkH8K6C1cKnJ5rDi/1laVr0q46GVVXLd3bCaInqTWNHGYyytXRQ/wCrNZF7/rTTkjGEnqiCLhq07M5xVBOtXbb7wpot6o1oxxV+3OQKz4qvwVojJmjBkVdgAcBgeKoxdV+oq/D978KDGTJl+UcnPvQ0h6UxqY1AJCs/NFRnqaKEbJH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient has fractures of the maxillary central incisors; only the enamel and dentin are involved.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McTigue, DJ. Managing traumatic injuries in the young permanent dentition. In: Pediatric Dentistry: Infancy through adolescence, 4th ed, WB Saunders, Philadelphia 2005. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15793=[""].join("\n");
var outline_f15_27_15793=null;
var title_f15_27_15794="Aplasia cutis congenita";
var content_f15_27_15794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Aplasia cutis congenita",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15794=[""].join("\n");
var outline_f15_27_15794=null;
var title_f15_27_15795="Macrocystic type1 CPAM";
var content_f15_27_15795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Macrocystic Type I CPAM at 26 weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 478px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHeAfcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5cs7WS7m8uHG/Gea1YfDN5JIE862Vv9piP6VQ0c4vAdzKcdV69RX0F8E/hXoPjXwTrGveJtZ1e1Nheyws1rLEqLEkMchY7o2Ofnbv2HFAHjkvgTUkC4ubB89lkY4/8dqMeCr/AHlWurFSOxduf/Ha+hvhb8NPh58R9NvL3QNb8ZwCzmEUsN3JapIMrlWwsbDaecc/wnivniDV70GKWSQyNtDE/hQBUbwxfrKYy0OR33HH8qV/DF4ihjNbEH0Zv8K3o9cV5hNIgKngg9q2pdc0w26sREGHGQOKAOHHhe+PO6AD3Y/4Uh8MXox+8t+enzH/AArtZdTsbmJNkzecRgj+H2xVeRzNGEI3HsKAOO/4R28y2XhG3rkn/ChfD140xjVocgZzk4/lXZr82xZopRGv3sfw1FJE2TJFOCqthtw5oA5E+Hr0BifKG33PP6VX/si44+eP06n/AArtrach3hOAOobuaEnjWR2eMKrrgFhxn1oA5mPwlqLorgwBW6Esf8KsReCdUkcKslrk9Mu3+FdfDfW39nC3Vh5wbcWXnip4b93mXyIncL27/WgDkX+HurrEZPNsyoOOHb/4mpl+G2sNFHILmw2ucfffj6/JXomhLf3d0ogDFXbDZHCn3rudG03Ujc3NkkULOi7gXI5P0oA+fLn4favBM0Sy2kzL1MTOR+qiq114K1O2hWWR7YqTg4Zsj68V9B3Gla+4kC29v5hUn5V7VzU2iakImP2fzk+85PQGgDyKTwRqaIHEto6kZBV2/wDiaZ/wheqCRUJtwT/tn/CvSHhlWGQtCditkKh6VFYSW+Zw07pI+Au4cA/WgDzZ/CepJdNbkRb16nJxj16UR+FL95GTzLdSOuWb/CvTNTP+io7SAXH3fl4NZdwk6kSABgF5YGgDh5/C15Am55rXpnAZs/8AoNQ/8I5fYBzFjGep/wAK7kTT3dwomQIqrgEnk1nzzXMbT7VBIGMkdKAOY/4Rm+/dfND+86fMf8Ke3ha9VCzTWowcYLnP8q2hd3TxpvUqV5GO9RyWt1cpk/IT155NAHOXmj3Fq4V2jcn+4Sf6VVktmj3ZdCV6gZ/wrpJ7U2ZDSTttVc9e9Zj3kRm3Ph1+99T70AZkcDSKSpGAM5NXNO0e51BgtqUY/j/hVmTVIpIXjESIGGOByK6DwpJHaQq8k0kabcrsHf3oA5oaHcea8bywIyddxP8AhVY6fIE3PJEnsxOf5V1upwSy3v2jnnngcH61XvBCl07XaB2dOCBwKAOQdNpxuUn2zW34S8MXXijUZbKwuLSOWOEzEzsyrgFRjhTz8wrLvRGJCsZzg9a7T4MPs8V3HOM2jD/x9KALP/Cotc5H2/SB9ZZP/iKcnwe15wSt/pH/AH+k/wDiK9qTRdJh8A6d4l1/VfFLy6jq02mxWulCzwHFzNHGB5sYwMRjJLnk/lMfCmi3ng3xrqOk6z4wtNU8Nw3ImtNQ+xfLNHEzgExxsrLxztb8qAPDT8IdeBwL3ST9Jn/+IoX4QeIGOFutMJ/66v8A/EV2K3F1FMT5jYNW7bWLyG4B3nbQBw6/BnxK77Em01m9BK//AMRTLr4M+LbcZ8i2l/65yE/+y16vpGoavcXomtw7oOTgV2+i+NDZXQTUoRtBwSaAPla/+HviSxBNxp8gA9AT/SufudLvbZiJraVSPVTX6NaPqPh/X7cBFgYnscVFqnw58OanlpbKPnuAKAPzkFrNjLIyj/aGKlisHlHEkQ+pP+Ffc+t/AvQrxCLZRGT7VwGq/s5SI5NnMGHagD5XOnyh9u6PP1P+FPbTJ1Gd0Z+hP+Fe0+JPgjrungmCJnA/u1w974Q1ywJE1nKMeqmgDiZrGWJNzbce1VsHFdHfQXceEkt39+KzJrSc/wDLB/yoAq29rJPnZjA7mp/7Mn/2PzP+FbukQiO3AZMN71beIKjMKAOTlspY2CnaSfQ1DLE0Rw1XLueQXDZ6A8U+zC3UmJP1oAzKK0p7ACfavApJNMk/5ZfNQBnUVcu9PntUV5VO0/pVOgAooooAKWkooA1NM0aTUMCG6tFJ7OzA/wAq6S1+GurXS5ivdMP1lf8A+Irio5HicNGxVh3BrqfD3i67sZ1WdyU6Z9KAMLXdLn0XVZ9PumjeaHbuMZJU5UNxkDsaKt+ML1dR8RXd0pyJAn6Io/pRQBlW8vlMxIzkYr6i+BOh6z4r/Zz8UaJ4dubS2u9Q1h4ZJrlmCrCYbfzMbVJJK5XHueRXy0mNw3dKdJsPMYKj0JoA++/Anwy1DwP8QpdS0rVFu/D93pkVndRXWxJxLCAsTKsUaoVCALzzySc18HwzIsKfMQR781SOCBgYPejI24xznrQBr2ym52vvKrnkHFJdhEldGGUboAehrMilKcZO30Bq3pcCzM7S9BjndgigDasFb7TEo2BAB14rZjtjO73HmKjqcBcn86owWkW0NIplUj5Tnp+NaUsX2FU8uIsCARg7iaAH3M8qWLozuJHIGT0x61luwYOkb7iPyNLqmpy3MJjmV1Zfu4GMfhUNqXYeXsJkkxtA70ASxEyjYzBHUZGK1bCOJbhFuipjxjBqSx0O5m4/drkYbceV+tdRB4esWtrdJGUzA4fmgDNsobaQJ9ltd8hO1uOo9a6nSPC3m30flMkWcN8xx+FLpVyllep9nsiYowUWQDAJq9Z61bIkq3sSx3AkyH6gUAamneG9Rtrib7KPKV2yr8YatGbQ9VkcS/bQZYx8zRdQPeuXvvFeoTr5VldwgQ9MHk/hUll4p1HTbLf54eefIfI+6PUUAdM9jr0dms6XGwyZXzDxuHpVb+xNVlQQC9MYILEnFYknje/mtPLuJEcQDKKw71lw+P389pbzq3DAcUAWrrTLmJkS1AnEhKsfcVh3NhNGGX7GCFyWJHStD/hK5xewiFYhvPDlux71Tu/Edyk8sU06mMn5gBxigDGu7K2aCNlnYDkncehrNbzdpUTlo1GQgHBroc2Fwx8jiBiC4k6j3rM1i3ETt9jlVwThR0FAGHv3MWlR1kAyu08E1as54lCmVVlAOWGeTUW+WBSjxk7jyW6VUnlKzkQQBVYffHFAGhqFmtzm7h2CPP8AqwT8tZeqloQsvmADGMr3q7CxeIp53JHKqKkjsracLGY2yv3sjgUAcTNcS+diRndSc/Njis6RjJKSxC59uld14h0KG23FHDgqGxjpXDTRMrthTgH0oAYjbXzgGr+m3apKfPkZYlU4UetZtLQB0cV3K8BQXRRpORu5OKkjDPY4Lu02TgkdaxbKRN2JTlm4B9K1HuJTLGkQKCMcP6e9AEWpaZb2toH87zJn5weorX+FLmPxLKR/z7N/6Elc9eQyZaWWVZCeQSeTXQfCgBvEsoPe2b/0NKAPp/TPB1/44+Bfh2x0wae8ltr1xfSRX7ssUsaXlzuQkI/XdjlSOta03gu/8LeAPive3Y06xtNU0y4kttH0x2e1swltIpKkonLk5OFUcd+3mlz4Z0Q6e882l6e875Zna3QsxPcnGc1yc+iaWx2JpliDnqLdP8KALFuHnXOOaty2Z+zFlHzCrFratGAoHJra0+zLqVcUAbHwmuY0WaGZQWz1NdT4g8O2upRSMihZCOormNBgTTJ2kxhSOau3nikoStuCw6UAcjaNfeHNScrKyqD68Gu30r4o3NtEFbc31rAvYTqiedKME1lX40vTbbfcTJkds80Aeq6X8TppWBlT5T6iuqt/HVqwUyKBn0r5Z1Dx1p9tDtt2BI6c1z0vxMd22q5x7GgD7Yh8VaRccSSoB/tYNOuP+Edv0IlNm4P0r4TvvHV7IfkmcZ96pL4y1dXyt3KB/vGgD7Q1jwP4Rug0jR24J54xXJ33gjwmFKhYM9sGvmPUPiBrf2bat5Kf+BVgp401sSh2vJG9txoA948W+BNNhzJYuo9hXmOuaY1mfLFZMfxD1MkCaR2T3NDeK472cfaCR7mgDKu9PaV/u81UFpJay5ANdE+sWazDLDFV5L61u58Iwx0oAzeT8x61atLpIGDS9M1algjJG0iq2p2O6D5OtAHZQQWOr6eFO0k1Rn8ExmP5EHNclpl3dafIpViFHavSfDXiOK4C+cQGHrQB55q3hWWzJ2kg+hrm54JIJCkikGvdtajh1GMtEBkdxXKT+G11FWjCjf2oA5LwzoB1OCWdvup0rNi0qe4vpbeBclM16hFolxoXh6ZVQhiDjisD4XMsXiCRtQGFOfvCgDgJY3hkaORSrqcEGmV2fxRs7eHxA89ljypeTt6ZrjKACiiigAooooAKKKkhG6QDAOTjmgC5p9rLcypmMmLuQK6aLw+mGdZAuRwp703RInS1k2OoA46c1vW0ksdkZBF82CobOTQAmmWMUd1DZ58sOO/SpNUshYXm4zjenCgZINUFubkzr9rwc/dLcGpm1e1gk3OWkkxgK4zQBFb6Sb5wbycgO3DjoK6a1l03S0gSSKI3MZwH659654zTavNHDZLtL9l4FW7SxtILW5F9LK10pwoHWgDRZ/ts73MQZCrZck8EVcsbYzqlzBMFYvgBjxXNSyvDblIrlfKkOGXPNOvGhtrWJoLqXJ+9g8CgD1Oz0fxElo0dm1nJETvOTXN+INK1WO5O+3R7luWEfIxXHx+JLyzssxXs/Lbdqua0bPxZqNvOrRzyM2OVcZJFAEUoaAsNStHjnXmPbkbqrT31xdIDwFQ4AOQRWtd+Jhqt9aLqW1Y4DnI4J9qx9WktbueWS2chmbKrmgDKkuf35Adg3ck8U+Qy3VkXZxIgO0qowafDYX0shTyQHI4Gzk1aggeyhCzkJMrZMbDgigClYRzRsDCu4YwN5PFdPBZrDGJb1opMpkqDXHa1r4e58u1j8sHrjjH0rCl1C6eYossjjsM9frQB3N8sSgNGj4PXac1Am5YvlkLKvzbT1rF0m/urcLNKeSduw8jFdqUjuoIJ40VWxtbA4oAxhqMNxGIZISCeRk8VWtmSTzVcHCHPsorodQ0S0g2MUld2XKsi9/SudubP7IbhZ/MUHn5T296AIzGzbpbJwyMec8EVrWl5IzQxbsDA3HjFYhVIkXaJSJBwc4rW0O1iaJzI6wFQTlj1NAHZpb2Oq27NeTA3iDbHtGFP1rn/ABn4CmitlngkJaRckRjimaReNdRSqJF3g4XA6/jXYaBq/wBoni07U5yMjywVG4rQB86XELwTPFKpWRDgg1HXqnxY8BS6VeG7sBJPFJ8xJHOK8sIIOD1oAVDtcH0Oa6WyuoJoDHEo3ydS3auYqxZ3Bt5d3UUAbk2kSyWryDDFDw3rV34XHHiGY+lsx/8AHkqml/PLHttwWQA57AVe+FURl8Q3Cj/n1Y/+PpQB6tLfXNwixKTt6VLa2u2VS9WLYRWse58Ej1qhNqe64+TGKANoEJKGxxWjYzhnyo4FYEd0JMZOPrXQ6Pb7kGP4qANYqLuDavBNRT2djpenvcXkirgE89az/FOu2vhvTi+9TMRwM14D4x8dX+su8YlYR+xoA7nxh8R44IZINPPsCOteR6prl9qUjNcTvtP8INZrOzHLEk+5p9vC8z4QE0AR8k9yacAUkAbgg1tWWnnzBuXmpG0OWW63AHb9KAMadmLADNI3nkch8ewrudN8NeaN7r071u2OgwSuIvLGfpQB5TFBPM21EdvwpssEkT7XQg17t/wjVvZ2rP5a7sccVe+H3w2Hia/ea4jxAp64oA+fY7S4kGUhkI9lNBtZwf8AUv8AlX3nofwl0SCPy3gjJxjkVzPjD4SafbXIltoQEJ5AFAHxc8bocOrL9RikVipypIPqK+vda+CVpqWkF7eMLLj0rxbWvg9rNrNIkFu7YPBAzQB5pBf3ETAhy3sa04da34Eox707W/COr6Mpa9tXRR3IIrn6AOuhaG6i+Uqarq0lmzMhrnoZpIW3RsVNdJpNxDfQ+XKQJe9AG54c8SBSY5j14rrdNmMT/a15TrxXl1/pz2zGSPgV3Xg7UYp9JNtKfnA70AelWGqWWtWZjfaTjBU1z2veEIhFJPp42N14rGtwbCcSRMRk9BXpVpIX0gSv1ZKAPBdX0u4dJEmUt7muImiaGRkcEEV77qcKbmaRBtJrifFPhhL2D7RYj94OcUAeaUVLcQvbzPFKMOpwRRQBFRRRQAqjJA9a6TQtNdWd3TcMcehpNG00SovUgnOcV19nps5VI45Y2xyFxjigBbKw8223W8I3H7wQ9Kvaha+Xax4mAdRygGaZDFew5ljt5RGpw5i5AqhJNcz3JFu7HecMdnNAEEkZjjM0sZcH7rU3T9MfWLyTyysUarks4rqNP8OvDB52oM0kAPygHGa0tU1HRzbxW1tbmKSPgFT1+tAGPZLHpcEUVrDF53OZc1j6xJdF98u0Nn76DIq/IYUmMc0bISckA9RTrJrcLcRT5j3fc3nqKAOduZoElVWdXfbkHHU+9c9ca9JiWMKMk4LCux1DSovL3l45Uc8MvDLXL6roMf2kCycEEZOTmgDJa5QLlQWP16VftNUcxh2kJkHyhfQVXhsDCC7sGTpgVpaVo9tcXKkzrACM/MaAOt8PBIwJrqISb/u5Ga6u3j0+azlmewRFXo/Q5rh9FVFvDG0sjhTtBTkVvtLKEMMEgcKcMCTxQBtQ+QIjLbgtx8+/+lef+L9UBzbrFhQeZAK6S3SR7gQSs+w9ShOK4jx3F9jvmjt5i8R6hqAOdvG2OgYhmPJb2qBpxuyiBT2PeoSTn3pKALUV7OgAMp256V2mg36Xtqlm1x5CK27zM8iuSjfTxZqXjYzjqATzVdrkqx+zr5S+mc0AeqT6pc2aLELk3cX8EhHNF/d6X5CRBjJcSruJJ6GvOk8QXS2P2fCkg5DntWa93O8gkMjbh3HFAHW3rwiQKJCWXpk9KiN/KcIdrAeveuZWZpJN0oaQjk+tS2NzKsjKjogcY+YZoA6i51AwxJIjbAOy+tNsdcmafO75j0YHGK5z7TcIrpkEnjdtrbttFU2v2u2uQ4RdzjHegD0zRvEMur2S6feSLHIflWV/mwK82+IHh2PRdRPkXK3G/wCZsDGKf4f1Ga11HzJkBGcKCcV2PiSGHUbFjMqgMM78ZY+1AHjlFWtQtja3BQg46jNVaAN+1ubZdPYquyUjAFavwpl8nxDct62jD/x9K5rTJo0l/fjcoB2j3rT8DytDq0rr/wA8CD/30tAHqeo3buu0Go9MhZ3y1ZK3xkatrS58LkCgC3lvtKxICTWvrviaPw/paruHmkce1Jp0UMdvJe3OAqDNePeMtb/tjWJQrfu0PA7UAV/FHiKfWZ2eeRtmeOa5RyCxI6VJctmQjsKn0qye+u0iUcZ5NADtO02a9OVBCetd3oHh2OJUDjk9c1ZsdNFuI40UAKK0XleGZVUUAMm0mKKdcAYq7HbRKAFAz3qG5kdgCetLbOUXc5oA1oWht4tpwMiktHjhn84HpWDd3BkY4NMjvSE8vPJoA6qfVxdkRL9K94+F8cVjoSFFG5hmvlp7k2ciP719BfCzWft2nRRqeQKAPS7i6kjIdGxUwuxfx4lGSPWqc4LR4qtbSiNz2oA2IL9bYmLHy1aim04jfOsYJ9RXOmQGcEmsrxE8jFFg3YPpQA74raBpmt+HZkt4o2lYfKVHevk/xR8JdV020kvFhbYckYFfXumwKlvH9ofcOpBrS1ibTL+zFoyI2RgjFAH5x3VpNauVnjZSDjmoUZkYMhKkdxX2p44+CthrGnSS2cYSXbkYr5H8Y+G7vw1q8tndRsu04BIoAv6LqC6hF9muCPM9+9Wp1bT5MxnHuK4yGV4ZFeM4ZTkGu1spk1W0Qn746igC9puoS3F1CJm+TIr2aG5S4063jtyCMAcV4bqEEtlDviBwO4ro/h34ndLjybls54ANAHceI4kaARL9/Fc3ZpNaOVlUlDXT3sL3G65xx1pmkSW980kE+AwGBmgDwbxuFHim+8sALlCAP9xaKk8fw/Z/GGoxZyFZR/44tFAHPVbsoQ00ZlRmRjjAFVkUuwUdTXbWFoxhgjdAGAGSOhoA6HwrYRA4jOYgM7GHStWF5YLmUwqDAD26ir3h2wge1dbphlBwycE1iXpMckn9nMyHODuPFAHTaR5uqyrYwXItPPPO5cA10NvpWl+F4JhO8U+o56gZFeWvrV1bokc8sfPR1PKms/VdV1BrlSJvbdnO4UAdp4m8YKU+yx24XJySjAA1xrao4m2yoMbhtZTnH1rG/eXV0QZcueuatrE0Z2hPMGecUAdVqUcMdrHczOpuGGQBzXLa1rUlztVWXKjaFIrobCzunI+QPHt6P2pn/CEXWoSlrfAY88jFAHO22m6ncxGfDJEFydp61v6F4bnuLczXfmrDg7WUZOa6rSfhx4nEANtC5jZeTnIxXQQ6Ze6PYiJ7tUlj+/G60AcFb+DbY4do7qVj6qcV0mm/C9LvSJLiFWQ7+rHFay+LZJT5amKPyhg4H3q5/wAeeNdQtNN+y2Es0cEg3HAGCfrQAX3h+x0dI0tZMXH8XPGfrWfeapDp8UZS2XzTw7E5DfhXlkuuX89yTPcOc/7R4rpLGe2msszu5uF5CsetAG+uv3M0v+jxLFkY4Pb6Vh+LdCvTbrczyqUbkepqa3DFxMsLIwHB7V1NhBJdxRvqGBboOMjvQB4tLC8J/eq4PbIxS4knwqIM+wr17UdA1DVoUmhsoBb7yit3Nc+/hJrOctdq4OfmCDigDgvsU3Py8jtmpZpEltQrArJHxyK9Ps/DcWnQxane2rtaM3BbuK5zx7f6Pe6i7aZa+VAMYAUD60AcLRVieSJnPlx7VqvQAtSRQSSAFEZhnGQKfa2dxdEi3iZ8dcV02jWt3aweWYVOezUAVrS2y0aoOPQ9zXV6foV6s8cbECKbBIB6is28s/IuYxJtQkA5U55rvvAWnWcjNc6vdzokWNhI+WgDh/HmmpavGNNjdSo/eOBxTfDeqGa3W1leVmUdxXWeLri3lvriPTpUkTryOMVx9hONPvso8WW4IbtQBV8W2SyQNMkTF1/i6ACuLr1bUxJe2MkcQSQ4yW6AV5dco0c7o2NwPOKAI63/AAW6rqcwb+KAgfXctc/Wv4XBOqrj+6f5igDv4oVSMua6HwzCty2ysdoS1uAtbvhYfZMu+QBQBB8Q746bpps4XwWHNeHlyJ2YHkk12nxF1o3mruFOVHFcjZwec5LdKAK5zJJgDJJrvfBemm3/AHkg+Y1haHpBkvQ55VT0r0XT7YxlcjAoAsRpiYMelS/ZxJcBiOKmvZIYIhkgGoYdStkhyzigCvqWBKoUdKpzSg4QcE0l/qEDlmRxVG3uUlJkDZA96ALFxbmOAsKxxMyz5xwK1Hv1njaNSDiseWUJIQw4oAtyzi4+8eld78KvFa6Xf+Ux+UnFebIwdHMZrS8EwCTUXaQ96APsHTtXh1CAMjjJFRXjeW24NXkOj6vPYY2MSg7V0tnrc+pMqAGgDuoJEkTduGR70i3Nsu4yuvHrXMn7RCDuyAaw9VjuXHyM2D1oA7Ga+8+QiN/k6cd6s21kz/vgenNcfpyXK26qMk112l3rQWojkzuIoA6PQtZKOYbjlBxXk/x58BReJ7Z7ywiBnUZ+Uda7r+PI4LV0mhxRNG0Vxhgw70AfnPqWly6bcywXSlXQ454qfw5dm3uCuflNe6/tL+CBZ6kb+zixG5ycDvXzsjNBNkZDKcUAe2+Cbe18RO9pKBvIwM1xnjTR7jwd4hGVYRbsqfUVF4J159K1m0uUYhSwzX0Z8YvCEHi74bR6tYKGuYoxICoySMUAcj4G1q313TI0BBfGDVTxLpsmnXYltSefSvL/AIW6pJpurSQOxXHY9jXr2iagmu6m9vPjgcZoA8C8cu8nim+eT752Z/74WitD4r2ws/iBq0C9EMf6xIaKAMHQ4EuNQjSTO3rxXqugW9qZo4GcuX+UDHNea+Ebdp9W+Q4MaF8/Qj/GvYtIsknuLa5ieJZExlh0zQBp3mkf2ZG4Z2MbD5G6EGuA1nVmjilR8hmOAcYr0rxzfNHaxRzw7onGNyHv6149rEXkndJKZIWPftQBWuZ4ooMyR4mPIJ6EViyXkxmWNWLJnPI6VJeTLLcCINmLoCe1LbRGAmSWQOnpQBqW02GXzI9qMMM4NasF5DCPLGZBnO72rml8yQnylcxjn5emK3bC23243TeUR/Cw60AdNbajHGouAGMajnb2qxqXjuJAjabGCqrh+2TXHF3TKw6gkYzgo4rn9ZmMMhWIp8x5ZDwaAPevDvx7lsbJLZHVmxtG8Y21bvvGUXi20ETmNbtm58sZ3V8w1b02/uLG5jlgldCpzw2KAPoa20q3juJLd5Cm4dGXB+lSDwXpmtA2q3Eztu+ZD91a5fwl4mk1GWM6rMXjxgNtGa7O81VIpkS0nFohAJlwMtQByGs/BqaO6xbNG+fujfg4+lULTwO8EphvJTbzRnhGbOa9SgkttQgR5b0iQNgTBiCa5jxZZWul3byM8t6jjPmB8kUAZuhLp2mTSLqbRmEggkDJzS6lqlpJdpBZeZcRAZwVwBXA6pOk0rSRSPHzwGNV7PWJbS5DyS7vQrQB6WJZ7SIYO6JhuAB+7+FNu9ahis8uQCy/M7GqGhvBeyRifUUELj5sdvzqLU9LsZ7yQbXlso+hB60AVtT1JdRtIrf+0Wa2U/LGhrDvbHS7Yl5N7KeNrDoau3NjpTSbdNjeGUH7zngUreHZ9Wu4oTco80g+72oA8+vLVXvNsCgKx+XmthfCapDHJLeKSwyVTnFdTH4SXRdQBvrqCV06IOlS6glqGtzbyBGY8oozQBR0LQEtYZJWlaKMpjLGooUXzjGtx8pOAw64qxrevSCIafDs2nAdwM1Z0XTZG2hlbaRw+3NAHdeGLTwrBpypdTNc6gTkBxmsnxp4jFtA9jBbiNWPynHJH0qhY6berc+VDGQzH/Wkcipr/wAKyy2clzeX0Zx0Zm5oA8/1K6eVAYpWinYYIzVbTwIniWRgZc5LNU2r2ghm+aQMoOMr3qDdbRxRBkkDlvvHsKAO6uHgn01REQzL1wMA15/4niRXLtGqSHgAcV3Ie1ezhVX3HA4jHNYWv2DusjpFsUDjfyaAOArf8FhTq7l+giJ/UVhyKUdlPUGrekXRtLwPnG4bf1H+FAHrVtIixjJzmuuurGO08LSXe4bivFedaQZryaCNQTkium+I+rtZaDFYRHDMOaAPHNcJlu3kHOSan0y2f7KzAc9afCglOG696vi6itUCEgUAbXg5RGXabgds1o6z4ntdP3IjBnx2rkLrWhBbMsDfO3TFczLI0rl3YsxOSTQBtal4kvLxzhtq9qzm1K6ZNpmbHtVOigC19uuPLKea2DUttqU8CldxINUKKAOi8P6iRdkStw3rW5fxrLhkPWuCUlSCDgitaDV3SJFckkdaAOtttPeC1LHJzUlhK1o+9Mg1Y0TU4by1VXYZxT7yFM/uyKAOz0a/a4t03Dk16P4TaC1iEkmMkZ5rznwZCksaKw5Fd20GyAbCcAUAdXe3sdxGBAM1WigYp8wJqDTYglj5uckCtTSbhLlCGwCOKAIoJoraVQ4HNariKQo4wBTH0ZLr5lbkelULyN7ZDEGPFAG7OgKI0Rzj0qa0vgHBB5WsbSrvy7R0lbnHFGkxSSXEpP3aAOh8UeH7bxV4dnjmUM2w4NfCPxE8PvoOuTwsMAOQK+9NFlni8yEZKMK+U/2mrRLfWwygBmOTQB5HpBD27DOGVs19e/s56+mv+Fp9FvGDmNSoDelfG2mS+XdKCflbg17b+zdrx03x6kTNiKb5cdqAOc+J3h3/AIQ74j3CopWGRyy/Q1teE74WmvW0+cK5H5V6J+1/4dMtpaazbJyOGYV4Xpd+W0+2lB+dCBkUAV/jWQ3xN1ll6HyT/wCQY6Ky/iJcm88X3k7cs6Q5/CFB/SigBfABxrrZbbmEjJGR1XrXsnhyFIHbKiQNztT+leNeA4kl1mRZJPLHknDe+5a9q0iK6sbeOUeW0a8iRSP1oAj8Y6hAdP8AIe2MbJ0bHSvItYkklYRCQmPOSDXf+P8AUZDKvlP+7k+8AMivNNandACgXFAGVexmG4MaSBlOOc1JbNL5gjbbIp42HmqOdz5Y9TWrZhECEqQw7jrQBvafHHbRMA7xE9V7CtGGRTGSyhiBwwFVIMtEJIG8zIwdwrU0+QGEQThY5G6EdKAOf1yWOSIyLGinGCCK5JsbjjivTdc0V0sjviSQt93aetcRdaUVJAV43/usKAMipbdAZlDg7T1rS03Q7i7uFQgIpONxrsB4cOmGPzlSTkY285oAf4LsTHIrsrvbngY7GvTNP0O3WB5prY3i4zjzcbPwqp4fjsrCKG6G2QtjMPQ1rX97bzrLcW7m0YDDKx60AVFtt6EQwFAvQ1I39mrp9xCzZd0IYHrmudPie7gjeBJVeENntxWUutQXF1KwZlkPVsUAcxr9pGhMEqssRJICjmsCG0lQtsQrDnhivSu3uG2O1yczKf7w5NYd/ezndsBAbgKVoAbaaokESW00DSqP+Wit0/Ctpta3RRxKTFE/HB6/WuKSMJdB5JCCDnavQ1oW0MV/dxrcZC542mgC7qupYxBB5iuDyw7/AI0mn300Vypsp5Y5/wCJ2PNXbvQ5YYvOmlUMDhFBByKrR28CJiVHMjHIYdaANvUEeNle5keVmUHJ+Y1Jb6c90gZYmAIwrKf51XsobuObNvC0mVx83zCuq06e6tIljlU7+pUpgCgCt4c8Cs92rXAMoyCVX0r1y2i8M6FpbuIVSVFOd/XOO1ef3Wu3lra77d44yOrLXG6/ry3u4XLCQgcHcQKANvxD44QmWTT1VM/KRUXhW9XWrhIZLePdIcZZa823L5x3lEUc4Uk1o+HNSjW+YvcMhToScUAeh+N/Bos0E4MUmR9xeCtcJaaRDcXb/aDhUUkbjjmvT9M8V2UelvbxRi4eReXbJP61zd9pV3Pi5WGOKFuFyetAGLpJjst5htZHl/hc9KXUWleFmvJFDN/CK3ILM211Cl2jPHjhAev5Vz/iUx/a5AqiJOcDqaAPO9ZYtqEnTjgYFQWcLz3MccYJYmtHWbdgBIdoHv1NX/h3am88RrGF3YjJx+IoA9X8EWMENqJ58KyL1Nee/EjWDe604Q5ReBXZeOZJdFt44oCR5g5xXleryK5DN95jQAaajyOWPQ1X1kFZgCasi6S2jXb1rNvrj7RNu7UAVyc9aSiigAooooAKKKKACiiigC1Z3stq37s8elegeEX/ALRtyztk5rzWup+H96YNYSBj+7koA9ZsZxp8QKcECi58deVGYWPz9KydZvI7SQBmwG7Vx+rWhmm8+Ikr1oA9BtviUbaLyZGBDVpnx75NoHt2+dq8C1ISSXKhM8cVp6fdSrLEkhOB60Ae5aZ8Vbu1ysoJzxWlD4+a9O+UYzXlbQxyxowqxE+xlRaAPVIfFaPcKHOFJr0Xw9q9q8SneuCPWvna8VljQoTnFPs9bv7VlVXYCgD6oh16ys0Zmdc49a+S/wBonVP7U8QM6coOBXQz69dTKvmSNj61wHj6VLtlJOT60AecgkEEdRXeeDLt9L1azvU4IYHNcRcxeW/HQ12ukBDolvKx+YUAfXHxEh/4Sz4RvLt3kQhx+Ar4z0O6VLt7OQYAYgZ+tfcnwoiTVfhXDA/zCSJk5+lfD3jDT20jx7fWi8GO4IH50AUPGRB8R3W3kbYx/wCQ1oqr4gLNq85f72Fz/wB8iigC94LkMWrSMqI5MJADHHcV6dDrBityrx+SpHzA/drxWOR423RsVb1FaMeq3MkflS3DBTxzQB3OpX1myuftEcbAdM5Brhb5refe6PIxHNSZRRsnc4OcMBmsxjsZljfKnv60AMrVsollCsshOOo6EVnQsquNybx6Vt2MkMyqI4TFjofWgDfgJ8mJEJb1AHJq20PllH2spB/i5rBS5aCZjHN8x4we1aUc91K0ZM25TxgigDrNK1BYAHuI45EJxgitibSrDWJEaWSK2c8rgVy+lWSTTbGZy39ztV+/VYNsdvL5Ljgqx5oAtTeEZFuRHFPGSp6HvV250cW5iWedYpc9XGRisdPEd/BGkACyFeFfH86rXdxqd8rG4lVAwyPagDqNa8PSWtkt8L5Z4ycBkFcVcT3rB08xXiz909TWDe6rfWMDQvPKy7ugbg1nLrTbWErMrds9aALVzqEcN0VSNwScEA8VtabfQru894oeMg4yT7VwDzk3BkDNknNammN9tfynVsMfvL2oA7aHWLWVGSVwU7FVxVSdHumLOrGMfd4xmn6L4eV7/wAhMSKo3HPSuj/sWZwHiQvtOArEAUAcaukNcRvhDHH3INWtG0mWOOXZAZFH8YbBFd5D4SuTEJL+5SEP0ROR+NZMemywXssMUnyjoyZ+agDF+wsV3mQ706K7ZP40mm2tzd3RjZAfTB61YuxdvLMjy7SnYDmr3hG+Gk6ml1cYuIwPmXHSgD0rwVb6doOmia/A87dkqV4P41f8QeItGubSVZI4d0owjLg7a8w8QeLJtVuzBZIqwnovWueu0kkfPkt5q9SzYAoA1b/UrbTpLgXG4owO0kV5xrWprcSsYmynQA1NruozGVkZVwODg5zXP8l8sDz2xQBct7oRgFgyj270wSRyzlnJ5PFAuTHBsiKZJ5+Xmomt58gmGTnkfKaAOy8NarI1zHaoN6jjA4/WvTLZMInmKcLkojNnmvDNFnNpqCM4kBz0HGTXt3hq5mvrBpltcug5kJ4FAFSW/WO+33Uh88HGAOgrnvFzxjUVcEGNl79a09bw96ZJFRpOy5HP5Vzevh/LD+SVmPdzkD6UActqzRzyuVzgdyeK7r9nOyS+8dXSSKGCafI4z6+ZGP6159e2zAsWYdMk16Z+zAM/EC+/7Bkn/oyKgBPjFqqReIvsfZOK8x1Zg0i7eldv8YoPN8cTntu5rj54kW4jMn3aAMxkfG5gcVHXU6hDENP3RgE4rmGUg8igBtFXoLQS2TS5wRVGgAooooAKKKKACiiigArT8PSNFq0Lr/Ce1ZlXNNnEE4Ldz1oA7LxKbi7CScnHpTdKmkktzDKDxxWvpN3b3ESiQqeO9aU2nW4QPbgc+lAHJW9igvx5i5BNbN7oMe9JIxwfStOPSvlEhHHrW/YWq3CBT2FAGBFZbI0GTVmTTtirJV3WPLsyFLAEVQ/tuBY9kjc0AacEHnxrntVfUfJiAGBkVBFrEaRMQRXPanrKyyMM8mgDTu7xJISsZw1cV4jaURljyM1ft7hvMyx+WoNdmjnh2DGaAOQlcybc9q3NOv8AOmrAD8ynpWPeBU2qtLp7FLlT270Afcf7MOri98HPZk/PAwOPavmT42WosvjJfqRhWmDfnXtX7JFyZJtQQH5QnSvKf2k1U/GW4Cd2X+lAHl/ikAa9dAdPl/8AQRRUnjBPL8RXS+0f/oC0UAYtFFFAEqzyKmwMSvoabGpllCgjLGiONpGwuM+9TrazBvlAB+tAF+TSJLdUMyHDdHXkVbuoPLjTYwQAdV70lp/a8UOQnnxDorc1pHVrd40gvLHypiMFgc0AZcEeFVphnPIYjOa3rCcNHtdgpHQ44FQnTbW4iUQzOHHY9BWzolnBHi2ueXYffHSgCPT9Ze2vAXLyY4DKOK0UmW4mkupR5y5ycjmsbULWSxvWitvmT1PStOJBHZu2PLl29CeDQBkapqyxzKYlJAP8Jqhf6/PKylQB/smsrWLsCYhlG7PJFY807SsM8AdMUAdhZoNUfdLsU471manYpACJSjEdxWAksifcdl+hqzeXQmhj+Ylu+aAKpADkc49q2tHaMPGmXjJ6npWHVuzkaIl2VmB4BPSgD0axla0mPkTFYj1bOc12Gl6lZeX5SOXY8lt1ea6JrVjHHHHJGZH788Cu302exul8y1ZUlA+6O9AG9rHiC5W3W2tLEPEB/rexP1rj9Qv9QiuQPlhLHPyHJFdfDrOoOscVzsNvH0XAxXE+ONSmhu2uhGFyMA44AoAibWIrPzHnuonnI539a5y+8Rx7THAeG+9gVzF5O1zcNK5JLetQUAdCmpxRHzLaZkk7DHepLnxHNNAEcSM4+83TNc1Vp5YzbIiowOeWPSgCa2j+3XxZiFTOTk1JqdtDFOVhnDKPSkiltorLaSWc8kCs5juYkDGe1AHTeGEsYJY5r6NHUfjXY6v4h0f7JttlhDBcZHUV5VHM8YIVuD2pHkZxhjkUAXL27L3pkhYnnI9q9B8D397cwfZopnVcZcMcCvMASCCOtdBoF55Tguck9t1AHomrRxQuSFiQjrKDkk1hanNJPEEUh8DhiajM6XBVkLlzwAegqprFndWwDBT83c0AYN1aMiyF5Fcn1PSvU/2R7b7V8SNST00mVv8AyLD/AI15vLYusDySOoBHbrXpn7IFwLb4m6gxON2kyqP+/wBD/hQBl/Haxex8ZSMQQrNXnOqRvJEjrzXv/wC0rYJNcC5jA3+teEfMtn8w6UAS6arNY7ZcnjvWXqIQHamM1NFqO2Eis4s0s27r3oAs2tz5FuyN0NUmPzEj1okYs1NoAKKKKACiiigAooooAKKKciMxwoJoA19N+0PEBEWz7Gu28NyzwhVu2O33rlfDYlifeV+UV0F7dPLCxhBDAUAdHqOu2iSLbrIN1RT+IRpkRdGByK8juZZHuWd2O/J59Ks291PcyLDK5dT60AbGqeJp767JycE9aqXE0zgEMc1kbPLutp7NWyXGAKAFXVmgj8tmJNUTemS4HPBPWks7X7dqqxE4Vm5PtXcy/De6lRbiyDOgGTgUAcublolyTWbc3bOSc10fiDQbq1smLQsCnXiuOJJGKAB2LMSaltSRJx6VFxt96v6cqCKRm+8eBQB9P/seQSomq3TKTGFxmvI/ijctr/xnvinO2fb+VfTX7OOjDRPhU97Ku2S5V5Tn+6BXyvoUy3vxH1S9kI2+c75/E0Acx46Xb4qvV9PLH/kNaKPHbiXxZfuvQlf/AEBaKAMCiiigCaKdo8YwR6EVbW7JYeaqFB6Gs6lFAHp3hDVIBGscsiGM9io/nVi+0iyvbx/IdUuGOVPUV55ZQxsgdXeM9Dg1qQv9ilVjJ5yn35FAF+9sprK68p3BI6lGyDVuwUxuFR5GYjnNUwrSnzVjZk64Jrb0RQlwrEfKeuO1ADpIp4yBO/yN03VNPpdzexr9mDMvrnpV7W2jaEbWLf7LDFQ6NHcJOssczRhedh6GgDiNb8N36XDFIXb8Kz/+Ec1Hyg/lcdx6V7q+syrbIslrby84yq81XvB5dl5v2eNPM5JIoA8Nl0W4ij3tt46g8VmOCGIIx7V6Nr98GU7fId+ny8CuEuo5i7N5QVT6HNAFKr1vegRCKdd6DgY7VWiQls88elX7S4sUlVriE5U8gDrQBvWcenXOmxpawH7RnJJ4q5BaXEe3bIImHTBqax8QeG1VFkgkRvVQRXRN4g8MmwCRy55/jHIoAy01C6wsE7fKOrBuaxPGEatBGRdO+f4Ca6Ge98PsN1hcYcjkH1rjPEKKxDQymVienpQBgTxeUQNwOe3cVEBnpkmtK1sQ7ZnG0+gPWtZbWUxCJLNVBP38UAczHtEg8wEqDyBT9vmyFYt2zsD2q9qdr9hk2MI5M9xwaqR3ckSkR4UH0FACzWr26bplIDfdNVqsXV7PdKizOWCDgVWoAKKKKACpIpCjA5x745qOigDp9MvXiZJUXeo6Bj3rsNYN/LoK3VzFGGYcewrg9HtjcNCDKqDOdvc12uqSyLpscY2BVHVjzQBws0xjj3SSO0hPK54Fdp8ANVTSfHhmkbaslq8Wfq6H+lef3cu6VwCp56irXhyWSHU0eI4bH9RQB9YfE/Rf7b0B7qL5iq7uO4r5qmQK0kLjkHBr6g+HerpqnhQWlwQ77dpz6V4b8UfDcmh6tLMqEQucg0AeZX1r5bts6VXtGEchLjjFbZQTJk8/Wq17Zgwgx4zQBlMm93ZPu9aiq7LZyxW2/Bx3qlQAUUUUAFFFFABRRSgE9BmgBVUuwVQST2ru/C2gI1oXuFG5qr+ENDHkte3S8Y+UGum0pvMuCkR+UelAEUlvbWMZjIAq5pdlBNC5AHINZniW3Z5lVCc1JZyy2FqBJkAjvQB53rUJg1W4jxgbzitDw5pFxcSmYoQqjjiuwXT7a/3SsFaQnOa6bw3ZwwwMjgCgDx3VrGa2vGLIcE5zUc8x2LjrXsXiPw6l5aSPEgyBkEd68rl08w3DxSDkHHNAC6BFNcThoFJcGvqf4SRtHooj1FR5jdNwr5r8Nzrpd8JSuUBzivX/AA/4+hFzBkhI0IzQB7V4y8CaY/hC9upI0DeUWzj2r4Q1CFY9SuIk+6shA+ma+oPiv8abd/DLaVp77pJE2sR6V8szuzzNIx5Y7s0ANMbeZsAya2/CWkT6z4o0/TLdS7yyquB9abpcSvatPIMtyAa+g/2UfApn1ifxLfR/uYM+VuHf1oA9y+IV5b+BfhDdRxsE8i0FtGM9WIx/jXxB4bBRLi7XO6Ziea9U/al+Ib+I/EMfhzSpCbO0bD7T9968/wBLtCqQWwHPGfrQBxfiMltZuC3U7f8A0EUVb8bw+R4nvIh/CI//AEWtFAGFRRRQAUUUUAaGmyrtaJ92G746Vradp0hYstxHJ6Ketc6hc8IT+dbeh6jbxyLHqMZZem7vQB0StdRbUmtSE7Op4rRj1JrMYWzbp94UwPBdRBLG6by/7rUSRzwpt2mQ464oAh1G+N3aboiwcHkN2qnbTXjKV+1oPQbqbHHI0rLPK0YI7ikh0iC5Z2kukR16YOM0ATL4jksSCXLOv3hmk1X4gz3VmLdF+Ue1cnqNov2qQRSByvBy3Ws0jBwaALN1ey3EhYnbn0qDzHxjc2PTNMpxZiACTgdKADcexIz6UnGOnNJVzS9n2xPMUMvfNAFQAnoDipY7eSXiOORj3wua9P0nWNGsIDG9itw+3gqtQr4hlst8trpwWNu2ygDzuO0l3gMsin/dxWja2E5cAE4rpLjWk1JlMlqIMdflwTUCyM0pe0RgF9aAHaXYOXJlRV2jILdTVl4nkZ3kneNBwBjFNgubiS4ALbJAepHFaE11KUZbyZyo5xEvWgDhdct0jnLGUs7dM1kHrW9qohmuC8UEmwHrIcGsSZCrZ27VPSgCOiiigAooooAKVRkgDvSUo60AdloNrbwW6vIylsde9WdXuEktiEtn8sD5pGOc1iaEkhQ45btnpTtZvbpYTFNPCV6bE5NAHPysrOSi7R6VY064+y3PmY7Y/WqlOT7wz60Ae4/DXxDJZTxyMxEbYBFemfEvTYvEXhHzbcB5Au4EdSK+d7TVPKtIkh4IHava/hV4kjurIWV64z0G7+VAHh1tZSC4a3dSGBxg1Fqdu9owEgwor1z4j+HY7DVjqFioMEnLbR0NeceKG+2WxCL8+KAItI+z3sJibByMYrP1DwtILki3ztbp7Vk2Ms2myhmyPau50TW0utu7GaAOPu/C99bkZGQfas+40q7g5aIkeor21VivrYDAJqKXQ1MBLKOfWgDw0wSgZMbAfSpYLG4mj3xpla9cvNAt/srAqNxqlpelJCrIV4NAHnthoV3dShSu1e5rp9N8OqsqpszjrXWWenMk4VU6n0rqdP0IqQ7L155oA5LU7V7bStkQwcdqo+Eomh8ySbrz1rs7+2XzzGy/KPWuf1RPsmfLHymgDKa4E+s4fpmp/GzxQ2KiMYOO1Y8iut6kozjNdFqulNqOmrKOcDmgDjfCl9N52187c969EiWRoA8I4rE0bRoo7YkgbxXXaAU8gwuPm96ALljdxxWDCYDOMc15T4miWS9kliHGa9Vv9PURkA4zXB6/ZpBP5ZOd1AHHpIskZRuGrMv7t4DsibBrorvTlgXzPWuW1SLM+U57UAUHdpGLOxZj1JpCSQAe1BGDigAk4HWgDu/Cmhy6vHZWdspaSZhkCvrPXdTs/hf8IhbRuqXbQ7FxwSxHWvGPgPDBpsMmsahtWOBMqW7V5/8AGDx9eeO/EjJCzfYYm8uGMfxe9AGT4Zhe91a51O+y7MxbJ5ySetdhpPlm+8w1Y8HeGJX0pVZCDtzTjZf2feGN+DmgDzX4guH8X6gw6Hy//Ra0Uzx3j/hK77HT5P8A0BaKAMGkrY8MJBLfyR3QBjaIjkZ5yKfqWlxrcuLdsD0PAoAxKWrbWbKh3jBA7d6jhgDsVZirdhjrQAyGJ5WxGORW1p2krJzO+4H36VRt4JoifLZAfQ9TWlpsx80GdGGOy0AaS6PLYbZtPm564PNb2maxLEUa4HzjrkVc8PWdrqj+W8rJnoKs61okWlGQh/MjxigDP1m/sL1dyAiUjBIXArkZtNme4zv46grmtu0b94VVvl/ustddoMOxQTaRSOemKAPJLnSLgyMV5J9eM1HDoGqTnENlM/8AuivaJordLtXu9KQEHOScV6X4Q8ZeD9Jt1GpaVDv6FkAagD5MuNA1W2GZrGZB7iqP2afOPKfP0r7U13x58NbyBt+lmT/aWHbivL/EWpeDLlHk0nT8PnhsdPwoA8R0rTIpVP2lZAfXsK1zo1hDCXWUb/8AaNa93DDK0jWwVVPbpXL3NjK07He6r6DpQBoWt4ICqCFMA4ynOa6htT086fscMHOMDFcZaWkkbiRn+UfwmrdxKhbAhcCgCw0cgl3RorqeQCaq+VcyTESSLGnotXlQtED5GQB3NZF084lBhjwue/NAG3bRW0YBlmYt/tVBcTjznSKdh/IVBEt3NAm9cKO9Nupbh1MJgAUcbkHNAFS+vbSJGimzJKe61zk0hkYnt2HpV65hj8wKuNx6g9aoSpscr6UAMooooAKKKKACiiigCZZpkTCuwT0BxUROTmkooAXHHWhfvCilX7woA6Wz8qK0VnYbq6fRbkxxrLA20j0NedRtJcOqAnFdLazS2UAB70Ae9+CdVtNetWs9QdTIBjDd68/8d6ZaaTrkkcJBiPIrzdfEF7p18JbSQqa2lvrnWYzLdOWc9zQBQ1aGO4kzGOlVdNc2k/cCte302RdzEEj3qrPChDHHIoA6vRtT27Tu4rso7w3UKBORXhU2pz28hWM4x613PgbxZGR5V2QGHrQB6F9haRBnvUS6SVmU4AGas6Tq9vdTgK4K1o6pOiEeVgtQBPaabBHtYgbhWjFIryFQMYrM01pJBl84q/KBDA8icnFAGTqtuPOZxXFeIJP4Qua6v7Q907LzVHU9JVossPmoA5q308XUCtt5FdJoMZaA27jtUug2eH8vHFaE9uLCUsOM0AZ9tpOy4b+6TUtxaC0lVo+tSx3u6UYNSCYXF0qyEYFAEFyJ5yu3OAK888TSuuqESEjb2r1C/wBWsrDIZlBArw3x5ra3erObY/Ke4oANV1TzB5QPSuYuJmWY5ppuMncSS1QOxkck96AGk5Oa3tC0wSOj3AwpORU2kaGWtvtE456gVLcTsFMUIORxxQB0mu+IHj0P+yNNON4w209atfDvwOyzx32oj/dU1U8C+H3luPtd+DsU5APevUYLxUKRIAO1AHbaVp0MVoPLUYx2ryX4k3cVvrAEbAN3r1eS+TTNAeeVgAFz1r581KaTXNckmY5G44oA4fxTIZdduXPfZ/6AKKb4lTy9cul9Co/8dFFACaBIIr1nYZAQ/hyK1r5POCyJMvTNZGhPGl1J533TGR+orQlNup3JOgHpmgBbWVVQpNFu9xWlFY2NxHlWKyelZEPyy+YoX1+91rbs0S7XLJsb+8p6UAXdO0i3llVLmSPFWr7wnJCrT6flgvdRkGoGsRbqJGlWTHo3IrQsdcvrGFtk4MB6r1xQBiQR6hHICxaNlPbg10ljfecgS4ZmY8EMM1qWBGuRblaIOeNxHOadJplzpk/7zyJU/vJwfyoArRaG0z7tOmSQHrHjB/Wuj8O6XdQ3S+bHLHIOQpXIP5VitfmKcGK2k3/3gMGvQ/CXicaYqXN0iSMuDtlOaAO/0DS7LV7dbW9gslJXBLKQx/OuT+IfwYulgM/haJZJCcmPPH4ZrduvifpV8UU2KRkdZFHSum0T4jaK1tHCb3zJR0BTnH50AfJl7pl/pF60Wv2EkbKcEqpxWRqz2kjb7ImIY7cZr7dvl0LxTA0VxHGJHGA7gV414r+FmnkyJZW/myZ+Vwdo/KgD52N3MAVLgKB1FZlzfTSS7I5Dj1CmvStZ+H+o6XIxmtQU9h2rjtShubZmjt7V09SVoAzJ7q8t41P7piD1A5qOS+nlAklEhI7Bas2rm3cPNGruf7y5xVye7Z5VK+WSf4FGKACz1SGWIi5jdTjA4xmmXIDkG2Tap9TVqaaFCpvIY0yOCGqOGayaQ7pW2+p6UAUHnlgYKkxOf4aR552PGSw6k8Vdmu7SCTdb4Zh3xk0TTQ3g3KRnvnigDCu2iZGDxhZf71YjjDkZB9xXTXFrhjnDR/TNZlzah32wRKB69KAMqlxxntV77CIgWuJEA7BTnNR3E8TR+WiHA6EHAoAqUUUUAFFFFABRRRQAU5e+fShFLthRk02gC1bSLFIrVu3F0ksChcZrmKntpTG4JPAoAku2AkG5eav2erGGPAGMVRuCLhwRgGoQoQkMRQB3mg6qt3A0TdTRqNg0UTMo4NcxoVylvJwe9d9Yyx3VuBKRigDg57Nbh9pBV/WqF3ZzWcgKFvqOtd9qekxoRLFisqWMOQHXOKAMjTdcu9OCsWb8a7fTPFZmiV5mya5HXtPBtg8I5HPFc7BcyQkbWOB2oA9+t/FEcdhkEbjWppWuJe2jB2Bz714PHrbGEITjFaGn+JGtYztc/gaAPabG4t0vcbhya0ddmt0jUq4zXg9r4rme7yGYVcuvE9xPMqtIdv1oA9e0m9gR97MoxTNRv47pnYNwK8juvELqu2OQ9OxqO18TS7Gj3cn3oA9B/tGKF2JcYqlea/FBG0iuN2OOa831LVpmO0MctWZeXU6qoZjzQBqa54guLm4clzgn1rBdGlV5ScmkdWmKlRknrW1pOnvPtjI69aAMK3heeUJGpLGuu0/w9HDCJp8b/Q1eXTINPXIA3Dk1karrEhcRRA+nFAEmp6y1rB5Cc9q2vA+ki8/0u5XKjkA0zSvDKanbLPOMNjPNdVoipZxG2GAooA2NM2G5ES4VBUniO4h0mMTK43DkCuX1DU2s7v8ActzmoXgvNdkUHcynuegoAbrHi+91tY7JNwjPGB3rMcvpUyrICHPau60Xw5ZaGftN0VZgM5btXJ660eqa400P+rHFAHnviYltbuWPU7T/AOOiineKf+Q9dY6DaP8Ax0UUAUrBS8xAbadvWn3FrOhySCPUGl0u3e5mdIzhghPX3FSXKXMOUkUunrigCp58mAN3SrtleuHHHA6jNZ5AzjkfWrCWrOA0Dhv0oA6aG/t1QMY3Y+oNbVreIyjbGQpHQiuSsjdQrtkChfpmtqztJ7jBjkYZ/umgDpdMePzWLNsOPlKnFbenahbmYLcznjs1clAlxZNtuGQqe7D+tW5ChT5olK/30agDuG1Vrc7rWSFk6YZc1lXWsMJt9xbiQZz8h4rDtZcJsicke4zVSe4njdl2Lg/56UAW7/WIzdLJAsluQeB1Bq1b+I7wMrQzQof723BNcvJKHkBkiYEHg5xWmGa9gSNFSORfUYzQB2tj4p1JNqxzEuf4s10mh+PLm3lEepyyunXnFeUW8d9D8nG4dMNU73dy7KsygkDHT+tAHvn/AAmUOox+XBZo/GA0h4NOs7TQr9nh1K2hSSQYIVa8HtPEVxZXCrFHnaehaupg8TXNxIkz7IWXH3TQB6HqPwy8PXLbdPhczt3Y8A1l/wDChb2eX940UanoV5qlYeMpPvGRXl6/NLtz+FdHZ/FC9hlVJY3RsfKUORQBRm/ZzZlAfUN59MVm3v7PNvaAefebN3T0rrl+Ll9ys4YJ2ZY8GsrWfirP5BEltLNG38cgxigDlLv4KpZxb5L1ZIB2QZP6Vk3PgHQ7WM7gRt65yK23+K7sPJsoQpxzmuJ8SeIZr+4kMk5BbsGwBQAalpOmpA0Vo6oP7zGuJ1K3EcuxX8xQeduMUuo6kuxlJJwfXrWDLqEtw22IYx/DnFAEepRQJKW2tg9gazgwSTIUEDs1bVnol5qBz5bJ+FaVv4VEPzXr4A9KAOYbzro5VRgdhgCoHXacEjNdFqCWVgCLWQFvcZrnpTucnIOeeBigBlFFFABS0lTW0ZklAzjmgCS2jPLDcTjtTbRPMaQYzhCf1FdFY2WY32AdDktWb4YhE97MrdBCT+ooApwWTTZ29KrSIUkKHqDXVwots7A/hVLVNPDRtOnWgDn+QeDSsSeTSDggmpZWRlG3rQAyLO8bc561rf23NFEI4iQR1NZ1pIkZYv1PSoWOWOKANyHxJdDCycp3rtbS1hvdOE6MC2MmvLlUnJ7CtXS9aurQrEj/ALpuCKAOkeUbmgbkdKwdR0nyXMnY8111vpv2i3WZclyM1TvoZJG8pkOBQBw1woR8CogM9elWtTj8u9kX0NMe3cRqwXPrQBHE2xtw6ip/Oby2bv2NVirAcgipmQi0UkdTQAkDEy5YmnRz+XNu6imW8Ukj/Ipx61rW+jb4izkg0AZ5le4nDIvStEWUl7H0wQOK1NI0uGJGMhH40XeoRWTkRYNAEOiaasDMbjH41o2l7Db3DsuOKwJ9QnueIlIzVm20udoN5zk0AWbnUpLu6YAErUmlacs1+plGRmt/w94fVrUs4+Y1qJoclsDKF+Uc0AaUU0dpaBVA4Fc1fXsomLRZ5PatJgZ/kzWxpui28kW6QjjmgDlbW0e7dXm455r0nTTZ2OlKY9u7HPrXn/iq/j0+Tyrfg1BpGqyzR4lclTQBe8T6rPfuYkJWMHpWLaA2xyx5q1q0scIDqRk+9ZTXZkBJoA5TxKwbW7kjuV/9BFFQ6u27UZiec4/kKKALvhTZ/aT+Zjb5R5P1FdRK0JcBWi/EVw1lN5EjPjOF/qKstqjdVQZ96AOtl0uG7GG8oZHBArA1DQZrRy0ZLxf7NMtfEEkSBXTP0q9D4nhVcPDKfXp/jQBQtbd9vyvJnurGrdj9oinwsxj57U+XXdMkbcbW4D+o2/41C2t2JORbzZ9SR/jQB1cMspQLvWQkdahjfy5MXCOmehHIrmRr0A+7HKB7Y/xq3Z+KLaJgJ7eaRR2yP8aAOvttq4LN8vrjFVtU2GH91KrEd8ciq1r460NIis+m3bHtgjH86ytV8V6fcZ+yWtxEPcL/AI0AQ3bygZ87cB1BotLxQoKby3cdKxpNVRnzsY/XFD6lbtgiKRSPQ0AdedUmkhC/KR6E81UE7iTkHntnNYVvrcUUgYwFgPXBq4/ieEtlbXb+AoA245ZJCU8oA9iOtPjnljYrI0iD0HNYKeKIw4LQPx6YqC48QRTSFtkwz2yKAOztpQV/dPEx/wBrOauR6tLboR9oSMjpjmuAi8QpGeIm/IU2TXopD80Un6UAekJ4lv3QxPIHQ9wBWPealchn3qzqf7xrlY/EFvH9xLgH2xUq+I7M/wCthuXz6kf40ATXd/O7sqReWfVaZaWt9fOAFbce5q7pvibw9A265sL12/2dp/ma7PRPin4S0yAK2gXksg/iZUP/ALNQBS8PfDDVdUIeRFKns3Ga6+P4caXooWXUikW3krjqaqXP7QFmkAj07R5YSOjELn9DXFa38VJtWkZ7iKZ89A2MD9aAOr13UNIiBgslaMDgsMc1wmvXttFGTDLnB/iNYOqeJpLwny4xGPTFYE0jSuWckk0ATXt210+SAo9BVWiigAooooAUdeelauniJSDEQT3JrJq7aXMMH3oyxoA6mFv3D49O1c/4bcpeylepiI/UVM2tL5JSNGXI7VR0e8SxumlkUspQrgfUf4UAdLcwM8W/HNQwzbkML/Sm/wDCS2uwg28v6f41nNqsBlLiJ+fpQA250r77pn1ArIIwcHrXRDXLbyyphlz+H+NYNy6STM8YKqTnBoAipyqWOFGTTantJlhkLMCeO1ACIxiDKRyan0+DdcoX6A0ySaF5AxRqmF5CHUhHAH0oA9Q8MSg3MEeNyHAIr2tfhtZato4uIlCysufxr598I+N9E0iRXvbG9mZemzb/AFNep2X7Rej2lqIU0rUeBgfKmP8A0KgDi9e+EeqjUJXjgZlB6iuVvfC1/p8hjnt2Bz3FewwftHaKFYT6PqDE+ip/8VXMeKPjNoer5MOj3aN6sqf0agDgptBzGu9MH3FVNS06OEJHxirGp+NIbpv3VvIg98f41i3uui5I/dsKANeMWltCvAzUN1cs0X7kHHtWN/aMDEeYkhx6YrTt9e06KIKbWYn8P8aAKc93chQq7uavWOkm5USTd/Wq8mt2TvkW0n6f406TxIBFsgiZT70AdLa6VbRRAnGRVqNoxhBjAriD4gmKYwc1Hb67MkpaQZHtQB6bBq0VrtQsAK0L7xZZrYmEEbiMV45fatLcSblyoqo11I3Vjn60Ad7qWuLbQtJG3zHpVKx8bTRqVdjiuMlmeXAdiQOgqKgDrNR1SO/m3lutUrnVDb4WHt6VggkdDQST1oA0rrV57gruPA7Vp2N2sqKuea5oHB55qxbXHkzB8HA7UATa4nl6pMvsp/8AHRRUeqXAur55lBAYLwf90CigCun3X/3f6imU9Puv/u/1FMoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqa1RZJNrAn6VDV7S9okYt2AoA2bXQ4JIt7A/maiuLCwhOCjE/7xr6M8Gw6DpnwS8EXY8J+HNU1/XdXfTI59R0+OXl7qYB3bAZgoUDGfQV6B4v+H2mad8N/Gs2q+G/BjXMGlXMtneaZo62rqwgc5KMXKsrAEMHOfQY5APjrTdFtbyQDy2C/wC8a3z4V0lEy8bE/wC+f8a0V00WEG6PqKzpdUDZSTjHFAHP6tolrG+LXK/Uk0WOgQumZQSfrV17Wa6lzCSa1rGzuIkHmqcUAYZ8Nwl+Adv1Na9h4T0x0zMjMf8AfI/rWiVAHNMW62NtVqAKl54X0eJCVifI/wCmh/xrBn0eyWQiOJsf7xro7tJpkJQkis9EKP8AvRQBjjQonb5UbH1NWP7FsIlzMrH/AIEa1nuVjX5ADVUQT3snyqcGgDIurfS41Ijt3Leu81Wh0xbnmKFgPqa7ix8MRyENOefSt+10q3twFjQGgDzODw8Sf3kbAfU025sdPtQfORsj/aNeszabJJFiOE8+grnr/wAC3t/lliYZ9qAPNy+mb+IpMf7xrufA/h/QNXuY1u7OWRSecSsP5Gtbw/8AB29vrhRKrKvvXuPgv4Y2egRo7je4HegDDsvg94CuLZG/subeRz/pUv8A8VVyL4C+CpvmFtIoPb7RJ/8AFV6J9mjhwFXAHpUyqSnynmgDzkfAPwSDzayN7faZP/iqli+BfgPcA+lSn/t7m/8Aiq9Ahdkb560olVwGU80AeeyfAHwD9lZ00aXdjIP2yb/4uvlf4uaBY+GvGM2n6ZEYrZY1YKXLYOSOpJPavvuGYiF0PTFfEv7SkflfEpxjG61Rv/HnoA8qooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigB8n3h/uj+VFEn3h/uj+VFAAn3X/3f6imU9Puv/u/1FMoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqzZRtLLtT8arVr+HE3XEh9AKAPpf4eeKPh9P8FdD8LeMNSvrS/sbiW5VrazuTJbSi4leORJEjZc7WHr1wa6TxJ8SvBn/CA+LtPh8Xa5rep6lptxbw/brCZfnMLqiKqQRxpktycDOeTwMfP2m6hb2+BLirOqXltPDmMrmgBNR1dBbnke9co8i3cpK8ZNJehpCQhyKk0q1YPlhQBsaZm1jz1NWm1Qs4Qjiq3OcGmtFvYbRQBZmlMifKOTUFnpU88u9iQtaEEIgQNL+tR3GuxwgpCNxoAS8m/s8BTg1lTXBvjtjXk+lPMc2rTjINdRpGiQ2SB3wz0AZGmaBIU8y44X0rYghjt+EUVZup2UYB+Wsm61KOIEA5agDUWTzG2ggGtnTbWNCHmcYHqa8+TUJDKShIzTrq+vynyO2PY0Aeur4k0yxQI5TI44pyeNtO3YjxXhbyzyOTM7fiaa10Y8fOfzoA+gV+JlvZriJFJp1t8WXaX94g2V4CLwbNzNmqza/HHlc0AfVNj8UtCl2rdusbd811mjeI/D+rMotr2Lce26vhK91JrlyY2YfSp9H1TULS5VoLh1I5GDQB+g8ujCaISW7h17Y5qGGAw/Kwwa8I+EvxavrGaK01dzJCcDc3avooSQavZJeWZDBhnigCJICY93WvjH9qhdvxOTjGbGM/+PyV9r2n+rKOeRXxf+1muz4pRj/qHx/+hyUAeLUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA+T7w/3R/KiiT7w/wB0fyooAE+6/wDu/wBRTKen3X/3f6imUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVq6DJsmkH94Csqtnw3bmeWYqMlQP60AaUo3EEmmTu6p8pOKvyWUhGdpqs0Z3BCKAIbFmZsnNdDasuzgc1XtbACPdjFX7WNI+HwKAFiTzJOelTzT2tj80jDPasjUNRW3kIi55rKlWXUmBLGgDS1DWDfHy4eF9qs6PorzkNKPlqDSNK8t13fMa9M8N6FPdqu1cJ3OKAMuy0+OGMLEgz9KS7t7iJdzH5R712Oq2lro9sXmYBgPzrzrV9ZmvnMcA2x57d6AKuoagzKY0GT61kR2zSOWk71oJAYhulFZuparHC22PH4UATSiOBeOoqGLUNx2AA1nTXwkTLdarQThJNwoA17+GQxl1GARXNTs+8hia3LjVcwbTXNXN0WlJAoAmMrBMFuKz5VJckc1btx9ob5q0U04MO1AFXTbUOOalmhNvMGXgCtC1tvJNJf4aMg0AdHo00EtsjhwJFr6S+BXiXz0XTppc9hk18cWU8lvP8r/AC+lenfDLxPJpeu28ofA3AHmgD7W1C0aM+ZEfl7+1fFn7Wmf+Fn22ev9mxf+jJK+2NIvE1fRYp0P+tTn618U/tcRtF8UoEfqNNi/9GSUAeJ0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA+T7w/3R/KiiT7w/3R/KigAT7r/wC7/UUynp91/wDd/qKZQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXo/wb0pdUu9TU4+RIyM+5b/AArzivVvgLIYrzWGH/POP+bUAd5e+GoLa2JkwK4nULC1hkYqy57V1XjbXCsTKrYx715Vc6k9xMR5h/OgC9cX7xOUT7tVbu6eZMIeahY7lx1NNQmLlxQAyGIv/reTWrpdmZJQIhmqEStPIAmevavUfh54aku5ULJ8vckUAXfCfhGS62yyjCjnmuu1TUofDNntXbuAwFrZ1W4t/DulZJUMF4HvXiOv6rca1fPK5OzPAoAl1jUrnXrktKxEeenaqE5g01CzEbqpXt+bGIqv3q4/VdRmnLFnJFAGtrOuNKpEfArmld5pCzHNVmklkOASfpWjpFnLK/zKQKAHpEzrjmpoEEf3hmtyHT9oA4pt9YeVHuoAxXj859qL1rZsvDQ8nzJFzms62l8mbO3JzXX6XqiSRBJOMUAcjeWiWsp2jGKh+1lTXQ68tvJlkIzXLug3cHNAFn7Vn1qteSkrxUE0vl9eKge5BHNAEaqznPStjR7hrW5jcngEViNMf4elSw3DNj2oA+8/gLr66p4cSAtlkWvnP9sgEfFqDP8A0DIcf9/JK7D9mLXPs+oi3kf5WGMZrk/2zefixZkd9Jh/9GS0AeDUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA+T7w/3R/KiiT7w/3R/KigAT7r/wC7/UUynp91/wDd/qKZQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXpfwZmEH9tuTjEcf82rzSut8C3ZtYNUwcb0QfqaAL3i7VHnuZEU8ZrlrbcZjk96n1WctIzA8k1XsEaRs+9AG9GvlqGPNRPOJn2AUu5vL2k1Y0DT3udRRVUnJA6UAdr4B8P/AG64jUp1PNfQNnZWXhvRjJJtQquSazPAfh2DSNJW5mVVfbnJ7V578VvGQupTYWsv7teDg0AY/jTxJJrepOqMfIU4AFYFzeQWtqTxvx0rDF35Kkk5NY99qHnOdx4oAr6tqTTyt6VlhHmbParDqsrYFXrSxmwDtOKAILKBY2G5a37SeKJflUA1DBZMTypFTPbeUM4oAZNfyJLntTri7kuIgKhkXPBHNPjjYJwvFAFEyLEfnHNI13tGUyKku7VpD0qpLbuseApoAjuLl5V+8TVeNmUElqYLadCSVIqpKXDkHigCWdnkPTikCoU+brRFNgYIzmpAgYZ5oAijK5K4pVKh8cVKIVxnvVT/AJbfjQB6z8F9TNn4jtjuwCwFan7X0on+JWlyDkNo0B/8iS1wPgi6+zaxbsD0cV0/7Stz9r8Y6LJnP/EnhH/kSWgDySiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAHyfeH+6P5UUSfeH+6P5UUACfdf/AHf6imU9Puv/ALv9RTKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK1dDl8pLkZxuA/rWVUsUpjDY70ATXz5fitHR4m8rJrF5d/Umuo0iF/KUYNAD4rSeecKikivaPhN4TDyx3FzHwvPIrkvB2mPc3kaiPdk+le8wKmhaKZCAu1cn60AYnxW8RjRdDa2t22uy44NfMU9xPc3DzOxJY55rrfiJ4mm1jVJFY5QH1rjJrgRqQKAIZriQEgk1Xjiknk4BpYw8svI4zXUaVaoEVgBmgCjpektvVpBXUw24jQDaCPpToYguMCtK1lhTHmkCgBkUMZTJQflVZrSJ5OQK0J7yzQfeFUpbuGVh5JyaAGvpETgFAKl/shRH0q3bN5EW+Q8e9SpexTHEbA0AZyaVGfvDFLJpNvt+6CauyE9B1NRxyYk2nqeKAOb1KwWNSAtcvc6cHckAV67L4dury28xImKkZrnL/AEC4ttzyRED6UAeV3cJglwRUkLZTNbOtwIXII5FY6R7TgHigBqz7jjFRSxZfIqyERWqIkb8UAavhtjHqUP8AvCum+OUvm+IdHb00qIf+PyVy+icalDz3FdJ8bFC6/o+O+lxH/wAfkoA88ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigB8n3h/uj+VFEn3h/uj+VFAAn3X/3f6imU9Puv/u/1FMoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAfECZF29a7nwwTK6Iy5zxXE26OzgqOlejeAoGuL2JdvJIoA92+HWhJbwLdSJzjisX4v+KFtoGsoGx2Nd5byHSvD+4gAKmf0r5n+IGsi81iUs2csaAOVvJy8zOepqtgyvT5XViMCtHTrYSEcUAMtLY7Rgc1t2KNGvNXbSyVUGavLZqME9KAKnmuBntVR1ubuYRwKzE+lbM6RFAo616/8ABrwhaXcX2meNWb3FAHlOn+B9WvkU+UwB9RXW6D8MpVkX7SSK+hjY2tkwRYlAHtUN0kGzcqgEc8UAeZ33wwSbTNsbYbFedX3w+1LSmkeMFlFe/JqjC4EX8PTNaE9ik8OZADkd6APl7SreZ7/ybhCvbmuusfBUst5HKDmMnNdX4q8Jkzm4s1AbqcVN4cubi2KQzKSRxzQB2Wi6RbW2npG8YPHpWJ4m0O2ubaRI4xkj0rr7IebbqT3qU2cbD5hmgD4q+I2gzaXfSNsIXOelcKkma+uPjF4bt7nTJZFQbwCelfJ97am1vJEI4BNAFNny2KFTcc1IqqW5oLBOlAFrRVb+1YQP71dR8alZde0gN1/suL/0OSuc8LZm12Bf9oV2H7QEXk+KdIT/AKhMP/oclAHmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAPk+8P90fyook+8P90fyooAE+6/8Au/1FMp6fdf8A3f6imUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUtJV/SLf7RMwIzigBNNhlkmUIDg17p8KdGPnxzOvSuK8PaH5ssYVO9e/8AhHTILDTFzgNjmgDO+JWrPaaK0SNgsOa+Y9SL3N47nJ5r174waxud4o24HFeORGQsS3egCWziww3iup0tYto6Vi6daPM/Tit1LY26e9AFySfawC09rtim0dawLm7MclW7OfzVzQBs2kTSMCxr2v4O67HazrayuADwK8H8+Xohq1p2q3lhcrJGzbhQB9tX9vHPCJYiGBrFmtwAd/ArxPwr8X7izRYtQBZR3rt9P+Idnr8ywW/ylu9AGhqzR2kgkTkjmtXTNYjvbXaOGAxVW80o3MAYnPGak0TTIrYHB+agChqN1JC7AjIqjYCO6vBkANXW3VhBIpLgH61wurzf2fqANv0BoA9Ft4jFCoHTFWY8MpHes7w9qcV/ZorEeZit1LZY13bhigDhfH1gZtMlBHVTXyB4y04wahKdvGTX2v4rkWaykRRk4xXyl8TbR4rmUtGRknHFAHlTrwQvWqW8q/zVd5VjnpTBGkrUAdR8MrMXniS2AHVxXU/tPwG38eaZGR00mH/0ZJT/AIGaYsviaAjnBzU/7WXHxLsl/u6XCP8AyJJQB4rRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAD5PvD/AHR/KiiT7w/3R/KigAT7r/7v9RTKen3X/wB3+oplABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFdb8PrT7Vd3IxnaF/rXJV6f8D4Y5rvVhKOQkePzagD0/wvpccIV2AzXZ3DiOxc5wAtZVhH5eFUcdqTxXeraaJKTwSKAPBfiBfibVJFDbvmrCsoy+KTV/9L1OSQknmpbJtsiqvY0AdTpNq0cYO3tU12rE8A4rU0GMSW4DipNQWGAncRtoA5SS0V2y4NWIbdQAqda2WNk8eS6g1DE9lGc+YMCgBItPkWPeOagBlWXDpwK0V1yzT5PMU496il1qxQ/Ng0AVJ4xKMbSPpV7w9qK6TfRyKxGDTV1TTnT5WAzTbYadcTZaZQfrQB9H+GPFltf6Wqlxv24q7ZXEouQ2CUzXjfhJIY7lBHcDZnpmvoHw3YwXdmhDKWxQBXu9Qi2bOjHiudvtIF2fM65rqtV0MRtvY8U2yt49u0EcUAYWlaRNAu6JiMVcnu9QjHl7jjpWw13FaHa/Sqd9fQuQyEUAVbGKZ/muB19a4H4ueHba50ySZUAYDNejw3BdemBXn3xX1qG30mSEMC5BFAHyRrEYhu3jTsaorC68881q6kPMv5HbuaFQMFA70Aew/s4WLSa4kjdBzWP+1uVPxSgCnIGmxD/x+SvU/wBnXSFjs2uMAEjrXjn7T0hk+J8mTnbaRqP++noA8kooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigB8n3h/uj+VFEn3h/uj+VFAAn3X/AN3+oplPT7r/AO7/AFFMoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr1T4DIH1DVdxxhI/wCbV5XXqfwJieW/1XZ2SPP5tQB7pEo3L5fNcz8T5DFoZByDius0i2YMC5yRXm/xo1Yg/Z1xgCgDxWKU/aGLetb2j28ckwY4rBzySetaFjdeQuc80AdLf6yNOTZD972rnrzXLm4OWyKp3dz50hZjkVDLPHs4FAEst1Oy/KTRHM4Q72Oahs7jL/d4q9Ksci8cGgDIZXefKuR+NW/s8jJyxxTBakSZXNTuxjXBNAFdldFIDkfjUETXEcuRI2PrUxjZjuHSneSzLkUAWYtY1G1O+CduOnNdd4W+MfiHQ5VJlZ4x2bmuMht2cEUrWqovzAZ+lAH0BD+0OL63WO7iw+OTmr1l8V7eRd0cmGPbNfM0tqpyQKjtjPBKCrsAKAPqtPHZveX5qeDxXEJAHJC1896J4pe1dUm5HvXd6brFnqKAI21z2oA9km8bWSWJSJwZCOMda8s8SyTalNJNM52tkgZp1taKsm9qXVFV4iqnFAHkOvQBLs7fWq9nGXmjXrk1u+JbLy3LZ5rK0Jd+pRL/ALQoA+t/g1YtaeFVlPGVzXzD+0FdfaviRdPnO2JV/ItX1d4RlFl4KjJ4xF/Svjj4r3P2vxpeSjof8TQBx9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAPk+8P8AdH8qKJPvD/dH8qKABPuv/u/1FMp6fdf/AHf6imUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV6x8AZfKvtX90i/m1eT16l8CGxqOqD1SP+bUAe7yXLWtlJPnAArwHx5rIvdRk3ndzXqXj+/kttGKxnAIr5/upWubl2fnmgCs8waTC0SM4XilMQD5HWpGX5aAEgG9fmqUpGRjvTYUycU5oQr5zQA+BVjPTinTsMZWo3kVB1FKPnSgCS1lLHB6027BZhSQqYjk0SShn5oAlt1G3DGpDEwHy81XYg428Cr9u2YwOtAFVZREeetPJ84cGmX0IIznFQRuyLgUATvDtX3qsY+oqN5ZWfHarEOcfNQBXW2dmyOlWra5m0+VXQnI7UomIJCiq8rEt81AHpfhLxhDOyQ33T1rvbyC2ubEzWzA8ZGK+eoSYyGXg12/hvxLJBF5UjEqeMGgCl4nkP2h42PQ1W8IWPn61DjpuFS+JJY7mUyx96tfDoM2uQgAn5hQB9L6pKbLwSUTjEX9K+N/Gz+Zr8zeo/qa+uPHV8tr4S25+YpivkDxSS2ryMe4z+poAyKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAfJ94f7o/lRRJ94f7o/lRQAJ91/93+oplPT7r/7v9RTKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK9a/Z+jEl/q+R0SL+bV5LXsH7OzBb/WiRn5Iv5vQB0fxUmKWmwHjHSvElkKOSe5r2X4tyiRcJ2rxwJ1zQBKrowyaekAkBKmqm9eV71ZhR0jypoAaEkSTA5FS+Q0p460QeYzHjNSKZIZdxHFAEb6bIeTUQfyW2mr0mpDbg4zVRQLiTNADbi4+XgZqCE+a3IIq8bX5hkcVZhtotwAHJoAZHbHZkZNSxOsfDDFbEdsqRDdjFXodHt7m1aRWG8e9AHF30hkfCnGalghwgzzmquq280N8UQHAPWpI/NAAOaAL62XmD5BzVa6tZ41OFNX7G5aIjeOK0HvIZQBtBoA5KLzY3+dTSyCSRsgGuokktNvzKKrPLabcJgGgDDWJyuMGrlsGhXJqXK5O3FV52cZHagCcXSycGu8+FkCnV0kxwDmvM8HcMHHNev8AwtMVuhkfGcUAdH8VNXH2WO2U4BFfPXivnUxj/nmP5mvVPHt015qRVfujpXlnixGj1RQwwfLB/U0AYtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAPk+8P8AdH8qKJPvD/dH8qKABPuv/u/1FMp6fdf/AHf6imUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV7H+zmm6+1snoEi/m9eOV7b+zK0Bv9ehmYK0kcOwHvgvQBr/Fq2WOPeteMM2QTivof4u6PLBpxmKlk9a+fGMZdlx3oAhjhjclj1qSJiDtXkUpg6lTUtpb/Nk0AW7cqo6DNQXUockYqSTaOAeaqSNtfmgClPEzPwOK0rCMKgz1pwjDR7gM0QKXY5OBQBJI7JzjioorkLMDVrYp+Wqk9qY33AUAbVzMZrPEZwcVm6fc30LspY7alWcJb+4FVIL1mmK4oAtXNyC+ZBk1AZQxztp7xlnDMOK1LW2gki5xmgDJkukC4I7VXScBvlqXU4EikOOlQ2qo5oAmb98vNQNanGVNX2VFXjFEQU9TQBkNI0bYpplc/Sth7WItubFV7gwgFQBmgCnCDIwHfNel+Fw9tYbjxkV51Zr/AKQuB3r0OCcRaUBnHFAGfdXaz6iVJyS1cj8Q0Eeuxgd4FP6tXQ6bCJ9Q3Z75rA+JAx4gQekCj9WoA5WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAHyfeH+6P5UUSfeH+6P5UUACfdf/d/qKZT0+6/+7/UUygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuu+HN7NY6lNLbuUYBTwfrXI1p6HO8FySnfGaAPpYeLINY0JrTU8FtuMmvCPElnHZ6pKYf9WTkVu21y89uMHBrH1OJmfEmT70AZLNkfLVmCQBcGoHQwjOOKZksPlzQBakCM2c1HNGrjINVwJD60kZcS/NnFAF2KdYY/3nas97mW6uBHZqST6Vce3+2ssUfUnFe9fBX4XWrCO8v4w/fBoA8hsfDOqyQCUwv+VRXttNaKVukKH3r7H8SafpWj6W7eVGoVfSvk/wCImrQ6hqbxwABQT0oA5FnBJHao4mCzAham8namTRboGfgUAaCyhoxkULJ2Wh0Ih6Vlido5SpBoAt3Ufmjk1TaIxjAqcOzMDzU7IQucZoArwKSPmJqx9kY8qaWBfMbAHNbVnYs46ZoAyYrWSQ7c1Uv9OktxuPSuqaxe3bcelZGvTgwbO9AGZoybrkZ5xXT3MreUF/hrntAjfzdxHFb88g6EUAavh6xif5yQCa4r4pRrF4kRV6fZ1P6tXceH7eWb5l4WuD+Jm4eJMMckQqP1NAHJ0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA+T7w/wB0fyook+8P90fyooAE+6/0/qKZTlZlztYjPHBpfMf++350AMop/mP/AH2/OjzH/vt+dADKKf5j/wB9vzo8x/77fnQAyin+Y/8Afb86PMf++350AMop/mP/AH2/OjzH/vt+dADKKf5j/wB9vzo8x/77fnQAyin+Y/8Afb86PMf++350AMop/mP/AH2/OjzH/vt+dADKKf5j/wB9vzo8x/77fnQAyrFm7JIdozUXmP8A32/OjzZP77fnQB1Ok6jJEwDDitS7D3K+Yo4rhBPL/wA9ZP8Avo1Kt/eKMLd3AHoJD/jQB0kqsRtIzUDYiGAOa583lyTk3E2f98003E7femkP1Y0AdRCVKEkYqAoJJCFrn/tM+P8AXS/99mhbmdTlZpQfZzQB3/h7TWW5SRsdc19AeFvGtroumLHKwBUYxXyKmpXyfcvblfpKw/rSvqmoP9++um+szH+tAHvHxH+JU2qu8Fux8s8cGvI3dp5yzcsTmueN1cHrPKfq5pBczjpNKP8AgZoA6t4iUpIo/KG4Vyxu7k9biY/8DNJ9quMf6+X/AL7NAHaRaijfu2Wqt3CrPvUVygnmByJZM/7xp32u5/5+Jv8Avs0AdTGucAVs2NspQeaK89F3cg8XE3/fZp41C9HS8uP+/rf40Aelw2kCOCMVv6dHFt4FeLf2lff8/lz/AN/W/wAakTWNTQfJqN4v0nYf1oA9g1Ub0IWuF1aMiUhq5g6xqR66jeH6zt/jUEl5cynMlxM5/wBpyaAO70orHB796m8xXlwTXn63lyv3biYfRzR9tus5+0z5/wCuhoA9q0i68m3Aj9K8x8fStN4gd367B/M1kJquooMJf3aj0EzD+tQS3VxM++aeWR/7zuSaAIaKf5j/AN9vzo8x/wC+350AMop/mP8A32/OjzH/AL7fnQAyin+Y/wDfb86PMf8Avt+dADKKf5j/AN9vzo8x/wC+350AMop/mP8A32/OjzH/AL7fnQAyin+Y/wDfb86PMf8Avt+dADKKf5j/AN9vzo8x/wC+350AMop/mP8A32/OjzH/AL7fnQAyin+Y/wDfb86PMf8Avt+dABJ94fQfyoprMWOWJJ9TRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial ultrasound (A) demonstrates multiple hypoechoic cysts within the chest. Axial (B) and sagittal (C) T2w MR images demonstrate multiple high signal cysts in the right mid lung. There is no mediastinal shift. The normal lung surround the mass and easily delineated from the cystic mass. No feeding vessel and no hydrops were identified.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy I Bulas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15795=[""].join("\n");
var outline_f15_27_15795=null;
var title_f15_27_15796="Isosorbide mononitrate: Patient drug information";
var content_f15_27_15796=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Isosorbide mononitrate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"     see \"Isosorbide mononitrate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F185079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Imdur&reg;;",
"     </li>",
"     <li>",
"      Monoket&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F185080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-ISMN&reg;;",
"     </li>",
"     <li>",
"      Imdur&reg;;",
"     </li>",
"     <li>",
"      PMS-ISMN;",
"     </li>",
"     <li>",
"      PRO-ISMN",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691499",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat chest pain or pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to isosorbide mononitrate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache. Most of the time it gets better after taking this drug for a week.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698621",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure lasting more than 15 minutes.",
"       <b>",
"        Get emergency medical care right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695321",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10776 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15796=[""].join("\n");
var outline_f15_27_15796=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185079\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185080\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020153\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020155\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020154\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020159\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020160\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020162\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020157\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020158\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020163\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020164\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=related_link\">",
"      Isosorbide mononitrate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_27_15797="Diphtheria cutaneous lesion 1";
var content_f15_27_15797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diphtheria skin lesion on the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention Public Health Image Library. Available at: file://phil.cdc.gov/phil/home.asp.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15797=[""].join("\n");
var outline_f15_27_15797=null;
var title_f15_27_15798="Rilpivirine: Drug information";
var content_f15_27_15798=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rilpivirine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/14/32996?source=see_link\">",
"    see \"Rilpivirine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12891404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Edurant&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13265550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Edurant&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12841056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Non-nucleoside)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F12891440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of HIV-1 infection:",
"     </b>",
"     Oral: 25 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12891439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate renal impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe or end-stage renal impairment: Use with caution; no dosage adjustment necessary (DHHS, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis/peritoneal dialysis: Due to extensive protein binding, significant removal by hemodialysis or peritoneal dialysis is unlikely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12891438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Child-Pugh class C): No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied); DHHS HIV guidelines also have no dosage recommendation (DHHS, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12891454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edurant&reg;: 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12891405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12891445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with a normal- to high-calorie meal. Taking with a protein supplement drink alone does not increase absorption.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12841144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infections in treatment-naive patients with HIV-1 RNA &le;100,000 copies/mL in combination with at least 2 other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12891415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Cholesterol increased (7% to 17%; grade 3: &lt;1%), LDL increased (5% to 14%; grade 3: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (5% to 18%; grade 3/4: 1%), AST increased (4% to 16%; grade 3/4: 1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Depressive disorders (depression, depressed mood, dysphoria, mood changes, negative thoughts, suicide attempts, suicidal ideation) (4% to 9%; grades 3/4: 1%), headache (3%), insomnia (3%), abnormal dreams (2%), fatigue (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (2%; grade 3/4: &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal:  Abdominal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Total bilirubin increased (3% to 5%; grade 3/4: &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (1% to 6%; grade 3/4: &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): Abdominal discomfort, anxiety, appetite decreased, cholecystitis, cholelithiasis, diarrhea, dizziness, glomerulonephritis (membranous and mesangioproliferative), nausea, nephrolithiasis, nephrotic syndrome, sleep disorders, somnolence, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12891411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concurrent use of carbamazepine, dexamethasone (&gt;1 dose), oxcarbazepine, phenobarbital, phenytoin, proton pump inhibitors (PPIs), rifabutin, rifampin, rifapentine, or St John&rsquo;s wort",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12891412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Depressive disorders: May cause depression, depressed mood, dysphoria, mood changes, negative thoughts, suicide attempts, or suicidal ideation; if changes are noted, seek professional intervention immediately; reevaluate risk versus benefit of continued rilpivirine therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity:  Has been reported during use. Patients with significant transaminase elevations or hepatitis B or C prior to treatment may be at greater risk for hepatic adverse events. Hepatotoxicity has occurred in a few patients with no prior hepatic disease or risk factors.  Baseline and periodic laboratory LFT evaluation during therapy is recommended for patients with pre-existing risk factors;  also consider LFT monitoring in patients without identifiable hepatic disease risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Use in treatment-naive patients with HIV-1 RNA &le;100,000 copies/mL; not for use in treatment-experienced patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12931828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Rilpivirine. Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Rilpivirine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexamethasone (Systemic): May decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the absorption of Rilpivirine. More specifically, simultaneous coadministration of these drugs creates a conflict between recommendations to administer with (rilpivirine) and without (didanosine) food. Rilpivirine may decrease the absorption of Didanosine. More specifically, simultaneous coadministration of these drugs creates a conflict between recommendations to administer with (rilpivirine) and without (didanosine) food. Management: Administer didanosine on an empty stomach at least 2 hours before or 4 hours after rilpivirine, due to the requirement that rilpivirine be administered with food.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Rilpivirine. Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Rilpivirine. Rilpivirine may decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May increase the serum concentration of Rilpivirine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the metabolism of Methadone.  Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the metabolism of PACLitaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Non-Nucleoside): May increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, St. Johns Wort may increase the metabolism of Reverse Transcriptase Inhibitors (Non-Nucleoside).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F12891421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Absorption increased by ~40% when taken with a normal- to high-calorie meal. Management: Administer with a normal- to high-calorie meal. Administration with a protein supplement drink alone does not increase absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease the levels/effects of rilpivirine. Management: Avoid St John's wort; concurrent use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12891407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12891408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No evidence of fetal toxicity has been noted in animal reproduction studies. Available data in pregnant women are insufficient and the DHHS Perinatal HIV Guidelines do not recommend use unless other alternatives are not available. Hypersensitivity reactions (including hepatic toxicity and rash) are more common in women on NNRTI therapy; it is not known if pregnancy increases this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12891409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12891410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F12891444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with a normal- to high-calorie meal. Taking with a protein supplement drink alone does not increase absorption.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Edurant Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $855.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12891447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol, triglycerides, hepatic transaminases; signs of skin rash, signs and symptoms of infection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14190115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Edurant (AU, CZ, DK, EE, GB, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12891424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a non-nucleoside reverse transcriptase inhibitor, rilpivirine has activity against HIV-1 by binding to reverse transcriptase. It consequently blocks the RNA-dependent and DNA-dependent DNA polymerase activities, including HIV-1 replication. It does not require intracellular phosphorylation for antiviral activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12891426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Increased 40% with a meal (normal-to-high calorie)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 99.7% (primarily albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic, primarily by CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (85%, ~25% as unchanged drug); urine (~6%; &lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Azijn H, Tirry I, Vingerhoets J, et al, &ldquo;TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active Against Wild-Type and NNRTI-Resistant HIV-1,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2010, 54(2):718-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15798/abstract-text/19933797/pubmed\" id=\"19933797\" target=\"_blank\">",
"        19933797",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen CJ, Molina JM, Cahn P, et al, &ldquo;Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1-Infected Patients: Pooled Results from the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials,&rdquo;",
"      <i>",
"       J Acquir Immune Defic Syndr",
"      </i>",
"      , 2012, 60(1):33-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15798/abstract-text/22343174/pubmed\" id=\"22343174\" target=\"_blank\">",
"        22343174",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen CJ, Molina JM, Cassetti I, et al, &ldquo;Week 96 Efficacy and Safety of Rilpivirine in Treatment-Naive HIV-1 Infected Patients in Two Phase II Randomized Trials,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 2012 [epub ahead of print].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15798/abstract-text/23211772/pubmed\" id=\"23211772\" target=\"_blank\">",
"        23211772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fulco PP and McNicholl IR, &ldquo;Etravirine and Rilpivirine: Nonnucleoside Reverse Transcriptase Inhibitors With Activity Against Human Immunodeficiency Virus Type 1 Strains Resistant to Previous Nonnucleoside Agents,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(3):281-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15798/abstract-text/19249947/pubmed\" id=\"19249947\" target=\"_blank\">",
"        19249947",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacArthur RD, &ldquo;Clinical Trial Report: TMC278 (Rilpivirine) Versus Efavirenz as Initial Therapy in Treatment-Na&iuml;ve, HIV-1-Infected Patients,&rdquo;",
"      <i>",
"       Curr Infect Dis Rep",
"      </i>",
"      , 2011, 13(1):1-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15798/abstract-text/21308448/pubmed\" id=\"21308448\" target=\"_blank\">",
"        21308448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina JM, Clumeck N, Orkin C, et al, &ldquo;Rilpivirine Efficacy, Virology and Safety in ARV Treatment-Na&iuml;ve Patients With Viral Load &le;100,000 HIV-1 RNA c/mL: ECHO and THRIVE 96 Week Results,&rdquo;",
"      <i>",
"       J Int AIDS Soc",
"      </i>",
"      , 2012, 15(6):18250.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15798/abstract-text/23234922/pubmed\" id=\"23234922\" target=\"_blank\">",
"        23234922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson M, Amaya G, Clumeck N, et al, &ldquo;Efficacy and Safety of Rilpivirine in Treatment-Naive HIV-1-Infected Patients With Hepatitis B Virus/Hepatitis C Virus Coinfection Enrolled in the Phase III Randomized, Double-Blind ECHO and THRIVE Trials,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(8):2020-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15798/abstract-text/22532465/pubmed\" id=\"22532465\" target=\"_blank\">",
"        22532465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pozniak AL, Morales-Ramirez J, Katabira E, et al, &ldquo;Efficacy and Safety of TMC278 in Antiretroviral-Na&iuml;ve HIV-1 Patients: Week 96 Results of a Phase IIb Randomized Trial,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 2010, 24(1):55-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15798/abstract-text/19926964/pubmed\" id=\"19926964\" target=\"_blank\">",
"        19926964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16494 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-41.78.124.10-C85CA16B23-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15798=[""].join("\n");
var outline_f15_27_15798=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891404\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265550\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12841056\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891440\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891439\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891438\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891454\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891405\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891445\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12841144\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891415\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891411\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891412\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300000\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12931828\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891421\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891407\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891408\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891409\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891410\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891444\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322901\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891447\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190115\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891424\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891426\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16494\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16494|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/14/32996?source=related_link\">",
"      Rilpivirine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_27_15799="Calcium chloride: Drug information";
var content_f15_27_15799=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium chloride: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/59/13235?source=see_link\">",
"    see \"Calcium chloride: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=see_link\">",
"    see \"Calcium chloride: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Salt;",
"     </li>",
"     <li>",
"      Electrolyte Supplement, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     One gram of calcium chloride salt is equal to 270 mg of elemental calcium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosages are expressed in terms of the",
"      <span style=\"text-decoration: underline\">",
"       calcium chloride salt",
"      </span>",
"      based on a solution concentration of 100 mg/mL (10%) containing 1.4 mEq (27 mg)/mL elemental calcium.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Acute, symptomatic: Manufacturer&rsquo;s recommendations:",
"     </i>",
"     200-1000 mg every 1-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Severe, symptomatic (eg, seizure, tetany):",
"     </i>",
"     1000 mg over 10 minutes; repeat every 60 minutes until symptoms resolve (French, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In general, I.V. calcium gluconate is preferred over I.V. calcium chloride in nonemergency settings due to the potential for extravasation with calcium chloride.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Cardiac arrest or cardiotoxicity in the presence of hyperkalemia, hypocalcemia, or hypermagnesemia:",
"     </b>",
"     I.V.: 500-1000 mg over 2-5 minutes; may repeat as necessary (Vanden Hoek, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Routine use in cardiac arrest is not recommended due to the lack of improved survival (Neumar, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Beta-blocker overdose, refractory to glucagon and high-dose vasopressors (unlabeled use):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Optimal dose has not been established (DeWitt, 2004):  I.V.: 20 mg/kg over 5-10 minutes followed by an infusion of 20 mg/kg/hour titrated to adequate hemodynamic response (Vanden Hoek, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Calcium channel blocker overdose (unlabeled use):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Optimal dose has not been established (DeWitt, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Initial: 1000-2000 mg over 5 minutes; may repeat every 10-20 minutes with 3-4 additional doses",
"     <b>",
"      or",
"     </b>",
"     1000 mg every 2-3 minutes until clinical effect is achieved (DeWitt, 2004); if favorable response obtained, consider I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. infusion: 20-40 mg/kg/hour (DeWitt, 2004; Salhanick, 2003)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F144506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=see_link\">",
"      see \"Calcium chloride: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     One gram of calcium chloride salt is equal to 270 mg of elemental calcium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosages are expressed in terms of the",
"      <span style=\"text-decoration: underline\">",
"       calcium chloride salt",
"      </span>",
"      based on a solution concentration of 100 mg/mL (10%) containing 1.4 mEq (27 mg)/mL elemental calcium.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     <i>",
"      Acute, symptomatic: Manufacturer&rsquo;s recommendations:",
"     </i>",
"     Children: I.V.: 2.7-5 mg/kg/dose every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In general, I.V. calcium gluconate is preferred over I.V. calcium chloride in nonemergency settings due to the potential for extravasation with calcium chloride.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Cardiac arrest or cardiotoxicity in the presence of hyperkalemia, hypocalcemia, or hypermagnesemia:",
"     </b>",
"     Infants and Children: I.V., I.O.: 20 mg/kg (maximum: 2000 mg/dose); may repeat as necessary (Hegenbarth, 2008; Kleinman, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Routine use in cardiac arrest is not recommended due to the lack of improved survival (Kleinman, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Calcium channel blocker overdose (unlabeled use):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Optimal dose has not been established (DeWitt, 2004): Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V., I.O.: Initial: 10-20 mg/kg (maximum: 2000 mg/dose) over 10-15 minutes; may repeat every 10-15 minutes (Arroyo, 2009; Kleinman, 2010); if favorable response obtained, consider I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. infusion: 20-50 mg/kg/hour  (Arroyo, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F144501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No initial dosage adjustment necessary; however, accumulation may occur with renal impairment and subsequent doses may require adjustment based on serum calcium concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14790981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No initial dosage adjustment necessary; subsequent doses should be guided by serum calcium concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10% (10 mL) [equivalent to elemental calcium 27 mg (1.4 mEq)/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 10% (10 mL) [equivalent to elemental calcium 27 mg (1.4 mEq)/mL]; 10% (10 mL) [equivalent to elemental calcium 27.2 mg (1.36 mEq)/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F144487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. administration only; avoid extravasation. Avoid rapid administration (do not exceed 100 mg/minute except in emergency situations). For intermittent I.V. infusion, infuse diluted solution over 1 hour or no greater than 45-90 mg/kg/hour (0.6-1.2 mEq/kg/hour); administration via a central or deep vein is preferred; do not use scalp, small hand or foot veins for I.V. administration since severe necrosis and sloughing may occur. Monitor ECG if calcium is infused faster than 2.5 mEq/minute;",
"     <b>",
"      stop the infusion if the patient complains of pain or discomfort.",
"     </b>",
"     Warm solution to body temperature prior to administration.",
"     <b>",
"      Do not infuse calcium chloride in the same I.V. line as phosphate-containing solutions.",
"     </b>",
"     Not for I.M. or SubQ administration (severe necrosis and sloughing may occur).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F144514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in  D",
"     <sub>",
"      5",
"     </sub>",
"     LR,  D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS;",
"     <b>",
"      variable (consult detailed reference)",
"     </b>",
"     in fat emulsion 10%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, ceftaroline, dobutamine, epinephrine, esmolol, inamrinone, micafungin, milrinone, morphine, nitroprusside, paclitaxel.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, propofol, sodium bicarbonate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Doxapram, pantoprazole",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypocalcemia and conditions secondary to hypocalcemia (eg, tetany, seizures, arrhythmias); emergent treatment of severe hypermagnesemia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F2869595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium channel blocker overdose; beta-blocker overdose (refractory to glucagon and high-dose vasopressors); severe hyperkalemia (K+ &gt;6.5 mEq/L with toxic ECG changes) [ACLS guidelines]; malignant arrhythmias (including cardiac arrest) associated with hypermagnesemia [ACLS guidelines]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5360788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Calcium chloride may be confused with calcium gluconate",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Calcium chloride may be confused with calcium gluconate.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"       Confusion with the different intravenous salt forms of calcium has occurred. There is a threefold difference in the primary cation concentration between calcium chloride (in which 1 g = 14 mEq [270 mg] of elemental Ca++) and calcium gluconate (in which 1 g = 4.65 mEq [90 mg] of elemental Ca++).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"       Prescribers should specify which salt form is desired. Dosages should be expressed either as mEq, mg, or grams of the salt form.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular (following rapid I.V. injection): Arrhythmia, bradycardia, cardiac arrest, hypotension, syncope, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Sense of oppression (with rapid I.V. injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Hypercalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Irritation, chalky taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Serum amylase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local (following extravasation): Tissue necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Tingling sensation (with rapid I.V. injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Renal calculi",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Hot flashes (with rapid I.V. injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Calcinosis cutis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F144490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Known or suspected digoxin toxicity; not recommended as routine treatment in cardiac arrest (includes asystole, ventricular fibrillation, pulseless ventricular tachycardia, or pulseless electrical activity)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acidosis: Use with caution in patients with respiratory acidosis, renal impairment, or respiratory failure; acidifying effect of calcium chloride may potentiate acidosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperphosphatemia: Use with caution in patients with severe hyperphosphatemia as elevated levels of phosphorus and calcium may result in soft tissue and pulmonary arterial calcium-phosphate precipitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with severe hypokalemia as acute rises in serum calcium levels may result in life-threatening cardiac arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypomagnesemia: Hypomagnesemia is a common cause of hypocalcemia; therefore, correction of hypocalcemia may be difficult in patients with concomitant hypomagnesemia. Evaluate serum magnesium and correct hypomagnesemia (if necessary), particularly if initial treatment of hypocalcemia is refractory.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with chronic renal failure to avoid hypercalcemia; frequent monitoring of serum calcium and phosphorus is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ceftriaxone: Ceftriaxone may complex with calcium causing precipitation. Fatal lung and kidney damage associated with calcium-ceftriaxone precipitates has been observed in premature and term neonates. Due to reports of precipitation reaction in neonates, do not coadminister ceftriaxone with calcium-containing solutions, even via separate infusion lines/sites or at different times in any neonate. Ceftriaxone should not be administered simultaneously with any calcium-containing solution via a Y-site in any patient. However, ceftriaxone and calcium-containing solutions may be administered sequentially of one another for use in patients",
"     <b>",
"      other than neonates",
"     </b>",
"     if infusion lines are thoroughly flushed (with a compatible fluid) between infusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digoxin: Use with caution in digitalized patients; hypercalcemia may precipitate cardiac arrhythmias; use is contraindicated with known or suspected digoxin toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Solutions may contain aluminum; toxic levels may occur following prolonged administration in premature neonates or patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of use: Avoid metabolic acidosis (ie, administer only up to 2-3 days then change to another calcium salt).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: For I.V. use only; do not inject SubQ or I.M. Avoid too rapid I.V. administration (do not exceed 100 mg/minute except in emergency situations). Avoid extravasation; adverse events from extravasation can be devastating (eg, profound tissue necrosis). Monitor the I.V. site closely.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CefTRIAXone: Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.  Management: Use of ceftriaxone with calcium-containing solutions within 48 hours of one another is contraindicated in neonates (28 days of age or younger).  In older patients, flush lines with compatible fluid between administration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13333807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Calcium crosses the placenta. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM, 2011). Information related to use as an antidote in pregnancy is limited. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13333808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Calcium Chloride Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (10 mL): $5.54",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2364862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Monitor infusion site, ECG when appropriate; serum calcium and ionized calcium (normal: 8.5-10.2 mg/dL [total]; 4.5-5.0 mg/dL [ionized]), albumin, serum phosphate; magnesium (to facilitate calcium repletion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Calcium channel blocker overdose, beta-blocker overdose:  Hemodynamic response, serum ionized calcium concentration",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F144485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum total calcium: 8.4-10.2 mg/dL (2.1-2.55 mmol/L).",
"     <b>",
"      Note:",
"     </b>",
"     Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     In low albumin states, the corrected",
"     <b>",
"      total",
"     </b>",
"     serum calcium may be estimated by the following equation (assuming a normal albumin of 4 g/dL [40 g/L]).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Corrected total calcium (mg/dL) = measured total calcium (mg/mL) + 0.8 [4 - measured serum albumin(g/dL)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Corrected total calcium (mmol/L) = measured total calcium (mmol/L) + 0.02 [40-measured serum albumin (g/L)]",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F3429680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium chloratum (PL);",
"     </li>",
"     <li>",
"      Solural (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F144472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderates nerve and muscle performance via action potential excitation threshold regulation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F144489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~40%, primarily to albumin (Wills, 1971)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces (80% as insoluble calcium salts); urine (20%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ariyan CE and Sosa JA, &ldquo;Assessment and Management of Patients With Abnormal Calcium,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2004, 32(4 Suppl):146-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/15064673/pubmed\" id=\"15064673\" target=\"_blank\">",
"        15064673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arroyo AM and Kao LW, &ldquo;Calcium Channel Blocker Toxicity,&rdquo;",
"      <i>",
"       Pediatr Emer Care",
"      </i>",
"      , 2009, 25(8):532-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/19687715/pubmed\" id=\"19687715\" target=\"_blank\">",
"        19687715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bilezikian JP, &ldquo;Management of Acute Hypercalcemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 326(18):1196-215.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/1532633/pubmed\" id=\"1532633\" target=\"_blank\">",
"        1532633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Binder LS, &ldquo;Acute Arthropod Envenomation: Incidence, Clinical Features, and Management,&rdquo;",
"      <i>",
"       Med Toxicol Adverse Drug Exp",
"      </i>",
"      , 1989, 4(3):163-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/2664428/pubmed\" id=\"2664428\" target=\"_blank\">",
"        2664428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chin RL, Garmel GM, and Harter PM, &ldquo;Development of Ventricular Fibrillation After Intravenous Calcium Chloride Administration in a Patient With Supraventricular Tachycardia,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1995, 25(3):416-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/7864486/pubmed\" id=\"7864486\" target=\"_blank\">",
"        7864486",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeRoos F, &ldquo;Calcium Channel Blockers,&rdquo; Goldfrank LG, et al, ed,",
"      <i>",
"       Goldfrank&rsquo;s Toxicologic Emergencies",
"      </i>",
"      , 7th ed, New York, (NY):McGraw-Hill Medical Publishing, 2002, 762-74.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeWitt CR and Walsman JC, &ldquo;Pharmacology, Pathophysiology and Management of Calcium Channel Blocker and Beta-Blocker Toxicity,&rdquo;",
"      <i>",
"       Toxicol Rev",
"      </i>",
"      , 2004, 23(4):223-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/15898828/pubmed\" id=\"15898828\" target=\"_blank\">",
"        15898828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickerson RN, &ldquo;Treatment of Hypocalcemia in Critical Illness - Part 1,&rdquo;",
"      <i>",
"       Nutrition",
"      </i>",
"      , 2007, 23(4):358-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/ 17400132/pubmed\" id=\" 17400132\" target=\"_blank\">",
"        17400132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickerson RN, &ldquo;Treatment of Hypocalcemia in Critical Illness - Part 2,&rdquo;",
"      <i>",
"       Nutrition",
"      </i>",
"      , 2007, 23(5):436-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/17360159/pubmed\" id=\"17360159\" target=\"_blank\">",
"        17360159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      French S, Subauste J, and Geraci S, &ldquo;Calcium Abnormalities in Hospitalized Patients,&rdquo;",
"      <i>",
"       Southern Med J",
"      </i>",
"      , 2012, 105(4):231-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/22475676/pubmed\" id=\"22475676\" target=\"_blank\">",
"        22475676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howarth DM, Dawson AH, Smith AJ, et al, &ldquo;Calcium Channel Blocking Drug Overdose: An Australian Series,&rdquo;",
"      <i>",
"       Hum Exp Toxicol",
"      </i>",
"      , 1994, 13(3):161-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/7909677/pubmed\" id=\"7909677\" target=\"_blank\">",
"        7909677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Washington, DC: The National Academies Press, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Isbister GK, &ldquo;Continuous Calcium Chloride Infusion for Massive Nifedipine Overdose,&rdquo;",
"      <i>",
"       Emerg Med J",
"      </i>",
"      , 2002, 19(4):355-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/12101159/pubmed\" id=\"12101159\" target=\"_blank\">",
"        12101159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam YM, Tse HF, and Lau CP, &ldquo;Delayed Asystolic Cardiac Arrest After Diltiazem Overdose: Resuscitation With High Dose Intravenous Calcium,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2001, 119(4):1280-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/11296202/pubmed\" id=\"11296202\" target=\"_blank\">",
"        11296202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luscher TF, Noll G, and Sturmer T, &ldquo;Calcium Gluconate in Severe Verapamil Intoxication,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 330(10):718-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/8107735/pubmed\" id=\"8107735\" target=\"_blank\">",
"        8107735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin TJ, Kang Y, Robertson KM, et al, &ldquo;Ionization and Hemodynamic Effects of Calcium Chloride and Calcium Gluconate in the Absence of Hepatic Function,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1990, 73(1):62-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/2360741/pubmed\" id=\"2360741\" target=\"_blank\">",
"        2360741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McIvor ME, &ldquo;Acute Fluoride Toxicity. Pathophysiology and Management,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1990, 5(2):79-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/2182050/pubmed\" id=\"2182050\" target=\"_blank\">",
"        2182050",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearigen PD and Benowitz NL, &ldquo;Poisoning Due to Calcium Antagonists. Experience With Verapamil, Diltiazem, and Nifedipine,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1991, 6(6):408-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/1793522/pubmed\" id=\"1793522\" target=\"_blank\">",
"        1793522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salhanick SD and Shannon MW, &ldquo;Management of Calcium Channel Antagonist Overdose,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2003, 26(2):65-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/12534324/pubmed\" id=\"12534324\" target=\"_blank\">",
"        12534324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shepherd G, &ldquo;Treatment of Poisoning Caused by &beta;-adrenergic and Calcium-Channel Blockers,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2006, 63(19):1828-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/16990629/pubmed\" id=\"16990629\" target=\"_blank\">",
"        16990629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Slattery A, King WD, Nichols M, et al, &ldquo;Hypercalcemia Following Damp-Rid&trade; Ingestion,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):487.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):829-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/20956228/pubmed\" id=\"20956228\" target=\"_blank\">",
"        20956228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wills MR and Lewin MR, &ldquo;Plasma Calcium Fractions and the Protein-Binding of Calcium in Normal Subjects and in Patients With Hypercalcemia and Hypocalcemia,&rdquo;",
"      <i>",
"       J Clin Pathol",
"      </i>",
"      , 1971, 24(9):856-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15799/abstract-text/5139991/pubmed\" id=\"5139991\" target=\"_blank\">",
"        5139991",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Worthley LI and Phillips PJ, &ldquo;Intravenous Calcium Salts,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1980, 2(8186):149.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9186 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-3ADB073D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15799=[""].join("\n");
var outline_f15_27_15799=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144509\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144499\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144506\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144500\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144501\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14790981\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144484\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144469\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144487\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144514\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144486\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869595\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5360788\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144508\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144490\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144473\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298938\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144478\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144481\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333807\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333808\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323032\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2364862\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144485\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429680\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144472\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144489\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9186\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9186|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/59/13235?source=related_link\">",
"      Calcium chloride: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=related_link\">",
"      Calcium chloride: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_27_15800="Rigid bronchoscope";
var content_f15_27_15800=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53603%7EPULM%2F68017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53603%7EPULM%2F68017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rigid bronchoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Efer-Dumon rigid bronchoscope with external port for ventilation, free moving telescope with attached C-mount for video, and external side port for suction catheter and laser fiber.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henri G Colt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Severe tracheal stenosis before and after dilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left panel shows the bronchoscopic view of a severe tracheal stenosis in a patient with respiratory failure. The right panel depicts the same patient after dilation of the stenosis with the rigid bronchoscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Heinrich Becker, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15800=[""].join("\n");
var outline_f15_27_15800=null;
var title_f15_27_15801="Morbilliform drug eruption histo";
var content_f15_27_15801=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Histopathologic features of exanthematous (morbilliform) drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The histologic features of morbilliform drug eruptions are typically those of an interface dermatitis with scattered dyskeratotic keratinocytes along the dermoepidermal junction. There is also a superficial perivascular lymphocytic infiltrate with scattered eosinophils and mild papillary edema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Justiniano H, Berlingeri-Ramos AC, Sanchez JL. Pattern analysis of drug-induced skin diseases. Am J Dermatopathol 2008; 30:352. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15801=[""].join("\n");
var outline_f15_27_15801=null;
var title_f15_27_15802="Acetaminophen (paracetamol): Drug information";
var content_f15_27_15802=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen (paracetamol): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"    see \"Acetaminophen (paracetamol): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"    see \"Acetaminophen (paracetamol): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F11391964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Acetaminophen: Transition of Pediatric Liquid Products to Standard Concentration",
"     </span>",
"     <span class=\"collapsible-date\">",
"      June 2011",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Based on recommendations provided by the Food and Drug Administration (FDA), all over-the-counter (OTC) pediatric single-ingredient acetaminophen liquid products will transition to a single concentration of 160 mg/5 mL; the transition has already begun and will continue into 2012.  The concentration of acetaminophen infant drops (previously 80 mg/0.8 mL) will now be the same as children&rsquo;s acetaminophen products (160 mg/5 mL) and as a result, new dosing on a volume-per-weight (or volume-per-age) basis will apply. The recommended mg/kg dose is unaffected and continues to be 10-15 mg/kg/dose.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare professionals should be aware that during this transition, acetaminophen infant drop products with both the new and old concentrations may be available on pharmacy shelves. Parents may continue to use either product, but should verify concentration and use according to labeled dosing directions. Healthcare professionals should verify product concentration prior to providing dosing information.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Additional information can be found at  file://www.tylenolprofessional.com/index.html",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acephen&trade; [OTC];",
"     </li>",
"     <li>",
"      APAP 500 [OTC];",
"     </li>",
"     <li>",
"      Aspirin Free Anacin&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Cetafen&reg; Extra [OTC];",
"     </li>",
"     <li>",
"      Cetafen&reg; [OTC];",
"     </li>",
"     <li>",
"      Excedrin&reg; Tension Headache [OTC];",
"     </li>",
"     <li>",
"      Feverall&reg; [OTC];",
"     </li>",
"     <li>",
"      Infantaire [OTC];",
"     </li>",
"     <li>",
"      Little Fevers&trade; [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Arthritis Pain [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Infant's [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Junior Rapid Tabs [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; [OTC];",
"     </li>",
"     <li>",
"      Non-Aspirin Pain Reliever [OTC];",
"     </li>",
"     <li>",
"      Nortemp Children's [OTC];",
"     </li>",
"     <li>",
"      Ofirmev&trade;;",
"     </li>",
"     <li>",
"      Pain &amp; Fever Children's [OTC];",
"     </li>",
"     <li>",
"      Pain Eze [OTC];",
"     </li>",
"     <li>",
"      Q-Pap Children's [OTC];",
"     </li>",
"     <li>",
"      Q-Pap Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Q-Pap Infant's [OTC];",
"     </li>",
"     <li>",
"      Q-Pap [OTC];",
"     </li>",
"     <li>",
"      RapiMed&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      RapiMed&reg; Junior [OTC];",
"     </li>",
"     <li>",
"      Silapap Children's [OTC];",
"     </li>",
"     <li>",
"      Silapap Infant's [OTC];",
"     </li>",
"     <li>",
"      Triaminic&trade; Children's Fever Reducer Pain Reliever [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; 8 Hour [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Arthritis Pain Extended Relief [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Children's Meltaways [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Infant's Concentrated [OTC] [DSC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Jr. Meltaways [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; [OTC];",
"     </li>",
"     <li>",
"      Valorin Extra [OTC];",
"     </li>",
"     <li>",
"      Valorin [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Abenol&reg;;",
"     </li>",
"     <li>",
"      Apo-Acetaminophen&reg;;",
"     </li>",
"     <li>",
"      Atasol&reg;;",
"     </li>",
"     <li>",
"      Novo-Gesic;",
"     </li>",
"     <li>",
"      Pediatrix;",
"     </li>",
"     <li>",
"      Tempra&reg;;",
"     </li>",
"     <li>",
"      Tylenol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     No dose adjustment required if converting between different acetaminophen formulations. Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pain or fever:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Oral:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     OTC dosing recommendations may vary by product and/or manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Regular release: 325-650 mg every 4-6 hours or 1000 mg 3-4 times daily  (maximum: 4 g daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended release: 1300 mg every 8 hours (maximum: 3.9 g daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Rectal:",
"     </i>",
"     325-650 mg every 4-6 hours or 1000 mg 3-4 times daily (maximum: 4 g daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;50 kg: 15 mg/kg every 6 hours or 12.5 mg/kg every 4 hours; maximum single dose: 750 mg/dose; maximum daily dose: 75 mg/kg/day (&le;3.75 g daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;50 kg: 650 mg every 4 hours or 1000 mg every 6 hours; maximum single dose: 1000 mg/dose; maximum daily dose: 4 g daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F129345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"      see \"Acetaminophen (paracetamol): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     No dose adjustment required if converting between different acetaminophen formulations. Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pain or fever:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Oral:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     OTC dosing recommendations may vary by product and/or manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children &lt;12 years: 10-15 mg/kg/dose every 4-6 hours as needed; do",
"     <b>",
"      not",
"     </b>",
"     exceed 5 doses (2.6 g) in 24 hours; alternatively, the following age-based doses may be used; see table.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adolescents: Refer to adult dosing.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Acetaminophen Pediatric Dosing (Oral)",
"      <sup>",
"       1",
"      </sup>",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weight (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (lbs)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Manufacturer's recommendations; use of weight to select dose is preferred; if weight is not available, then use age. Manufacturer&rsquo;s recommendations are based on weight in pounds (OTC labeling); weight in kg listed here is derived from pounds and rounded; kg weight listed also is adjusted to allow for continuous weight ranges in kg. OTC labeling instructs consumer to consult with physician for dosing instructions in children under 2 years of age.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.7-5.3",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         6-11",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0-3 mo",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.4-8.1",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         12-17",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         4-11 mo",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         80",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8.2-10.8",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         18-23",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1-2 y",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         120",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10.9-16.3",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         24-35",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2-3 y",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         160",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16.4-21.7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         36-47",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-5 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         240",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         21.8-27.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         48-59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6-8 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         320",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         27.3-32.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9-10 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         32.7-43.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         72-95",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         480",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Rectal:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Infants and Children &lt;12 years: 10-20 mg/kg/dose every 4-6 hours as needed; do",
"     <b>",
"      not",
"     </b>",
"     exceed 5 doses (2.6 g) in 24 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Although the perioperative use of high-dose rectal acetaminophen (eg, 25-45 mg/kg/dose) has been investigated in several studies, its routine use remains controversial; optimal doses and dosing frequency to ensure efficacy and safety have not yet been established (Buck, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2-12 years: 15 mg/kg every 6 hours",
"     <b>",
"      or",
"     </b>",
"     12.5 mg/kg every 4 hours; maximum single dose: 15 mg/kg/dose; maximum daily dose: 75 mg/kg/day (&le;3.75 g daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F129325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent hemodialysis or peritoneal dialysis: Administer every 8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CRRT: No adjustments necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 6 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent hemodialysis or peritoneal dialysis: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CRRT: Administer every 8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Use with caution; consider decreasing daily dose and extending dosing interval.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F129326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Oral: Use with caution. Limited, low-dose therapy is usually well tolerated in hepatic disease/cirrhosis. However, cases of hepatotoxicity at daily acetaminophen dosages &lt;4 g daily have been reported. Avoid chronic use in hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: Use with caution in hepatic impairment or active liver disease; manufacturer&rsquo;s labeling suggests a reduced total daily dosage may be warranted, although no specific dosage adjustments are provided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cetafen&reg; Extra: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Extra Strength: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pain Eze: 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg;: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Arthritis Pain: 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; 8 Hour: 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Arthritis Pain Extended Relief: 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Captab, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Children's: 160 mg/5 mL (118 mL, 480 mL) [ethanol free; contains benzoic acid, propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gelcap, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg;: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gelcap, rapid release, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Geltab, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excedrin&reg; Tension Headache: 500 mg [contains caffeine 65 mg/geltab]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ofirmev&trade;: 10 mg/mL (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: 160 mg/5 mL (120 mL, 473 mL); 500 mg/5 mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     APAP 500: 500 mg/5 mL (237 mL) [ethanol free, sugar free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Extra Strength: 500 mg/5 mL (237 mL) [contains propylene glycol, sodium 9 mg/15 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Children's: 160 mg/5 mL (118 mL, 473 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Children's: 160 mg/5 mL (118 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silapap Children's: 160 mg/5 mL (118 mL, 237 mL, 473 mL) [ethanol free, sugar free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Extra Strength: 500 mg/15 mL (240 mL) [ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 160 mg/5 mL (5 mL, 10 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pain &amp; Fever Children's: 160 mg/5 mL (118 mL, 473 mL) [ethanol free, sugar free; contains propylene glycol, sodium 1 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [drops]: 80 mg/0.8 mL (15 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infantaire: 80 mg/0.8 mL (15 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Fevers&trade;: 80 mg/mL (30 mL) [dye free, ethanol free, gluten free; contains propylene glycol, sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg;: 80 mg/0.8 mL (15 mL) [fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Infant's: 80 mg/0.8 mL (15 mL) [ethanol free; contains propylene glycol; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silapap Infant's: 80 mg/0.8 mL (15 mL, 30 mL) [ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal: 120 mg (12s); 325 mg (12s); 650 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acephen&trade;: 120 mg (12s, 50s, 100s); 325 mg (6s, 12s, 50s, 100s); 650 mg (12s, 50s, 100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Feverall&reg;: 80 mg (6s, 50s); 120 mg (6s, 50s); 325 mg (6s, 50s); 650 mg (50s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 160 mg/5 mL (5 mL, 10.15 mL, 20.3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Children's: 160 mg/5 mL (118 mL) [ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Infant's: 160 mg/5 mL (59 mL) [dye free, ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nortemp Children's: 160 mg/5 mL (118 mL) [ethanol free; contains propylene glycol, sodium benzoate; cotton candy flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pain &amp; Fever Children's: 160 mg/5 mL (60 mL) [ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Children's: 160 mg/5 mL (118 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Children's: 160 mg/5 mL (118 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Children's: 160 mg/5 mL (118 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's: 160 mg/5 mL (120 mL) [dye free, ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's: 160 mg/5 mL (120 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's: 160 mg/5 mL (60 mL, 120 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's: 160 mg/5 mL (120 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's: 160 mg/5 mL (120 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Infant's: 80 mg/0.8 mL (15 mL, 30 mL) [ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Infant's Concentrated: 80 mg/0.8 mL (30 mL [DSC]) [dye free; contains propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Infant's Concentrated: 80 mg/0.8 mL (15 mL [DSC], 30 mL [DSC]) [ethanol free; contains sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Infant's Concentrated: 80 mg/0.8 mL (15 mL [DSC], 30 mL [DSC]) [ethanol free; contains sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triaminic&trade; Children's Fever Reducer Pain Reliever: 160 mg/5 mL (118 mL) [contains benzoic acid, sodium 6 mg/5 mL; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triaminic&trade; Children's Fever Reducer Pain Reliever: 160 mg/5 mL (118 mL) [contains sodium 5 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 325 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aspirin Free Anacin&reg; Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cetafen&reg;: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg;: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Non-Aspirin Pain Reliever: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap: 325 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Extra Strength: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg;: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Valorin: 325 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Valorin Extra: 500 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Children's: 80 mg [fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 80 mg, 160 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Children's: 80 mg [bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Children's: 80 mg [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Junior Rapid Tabs: 160 mg [bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RapiMed&reg; Children's: 80 mg [gluten free, sugar free; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RapiMed&reg; Children's: 80 mg [gluten free, sugar free; wild grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RapiMed&reg; Junior: 160 mg [gluten free, sugar free; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RapiMed&reg; Junior: 160 mg [gluten free, sugar free; wild grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's Meltaways: 80 mg [scored; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's Meltaways: 80 mg [scored; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Jr. Meltaways: 160 mg [bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Jr. Meltaways: 160 mg [grape flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release products; injectable formulation",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F129297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: Shake well before pouring a dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: For I.V. infusion only. May administer undiluted over 15 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F11385126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Buprenorphine, butorphanol, cimetidine, dexamethasone sodium phosphate, diphenhydramine, dolasetron, droperidol, fentanyl, granisetron, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, ketorolac, lidocaine, lorazepam, mannitol, meperidine, methylprednisolone sodium succinate, metoclopramide, midazolam, morphine, nalbuphine, ondansetron, potassium chloride, prochlorperazine, sufentanil.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild-to-moderate pain and fever (analgesic/antipyretic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Additional indication: Management of moderate-to-severe pain when combined with opioid analgesia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acephen&reg; may be confused with AcipHex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       FeverALL&reg; may be confused with Fiberall&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Triaminic&trade; Children's Fever Reducer Pain Reliever may be confused with Triaminic&reg; cough and cold products",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tylenol&reg; may be confused with atenolol, timolol, Tylenol&reg; PM, Tylox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Infant concentration change: The new infant acetaminophen concentration (160 mg/5 mL) is available. All children&rsquo;s liquid acetaminophen products will now be the same 160 mg/5 mL concentration. However, the former infant acetaminophen concentration (80 mg/0.8 mL) may still be available in some pharmacies until supplies run out. Check concentrations closely prior to administering or dispensing (November 2011).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Injection: Reports of 10-fold overdose errors using the parenteral product have occurred in the U.S. and Europe; calculation of doses in \"mg\" and subsequent administration of the dose in \"mL\" using the commercially available concentration of 10 mg/mL contributed to these errors. Expressing doses as mg",
"       <b>",
"        and",
"       </b>",
"       mL, as well as pharmacy preparation of doses,  may decrease error potential (Dart, 2012; ISMP, 2012).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depon [Greece] may be confused with Depen brand name for penicillamine [U.S.]; Depin brand name for  nifedipine [India]; Dipen brand name for diltiazem [Greece]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Duorol [Spain] may be confused with Diuril brand name for chlorothiazide [U.S., Canada]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Paralen [Czech Republic] may be confused with Aralen brand name for chloroquine [U.S., Mexico]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Oral, Rectal:",
"     </b>",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: May increase chloride, uric acid, glucose; may decrease sodium, bicarbonate, calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, blood dyscrasias (neutropenia, pancytopenia, leukopenia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, alkaline phosphatase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Ammonia increased, nephrotoxicity with chronic overdose, analgesic nephropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      I.V.:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Nausea (adults 34%; children &ge;5%), vomiting (adults 15%; children &ge;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Edema (peripheral), hypervolemia, hypo/hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache (adults 10%; children &ge;1%), insomnia (adults 7%; children &ge;1%), agitation (children &ge;5%), anxiety, fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Pruritus (children &ge;5%), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoalbuminemia, hypokalemia, hypomagnesemia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Constipation (children &ge;5%), abdominal pain, diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Local: Infusion site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasms, pain in extremity, trismus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ocular: Periorbital edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Renal: Oliguria (children &ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Atelectasis (children &ge;5%), breath sounds abnormal, dyspnea, hypoxia, pleural effusion, pulmonary edema, stridor, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      All formulations:",
"     </b>",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis (rare), hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F129300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or severe active liver disease (Ofirmev&trade;)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F129282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: May cause severe hepatotoxicity on acute overdose; in addition, chronic daily dosing in adults has resulted in liver damage in some patients; hepatotoxicity is usually associated with excessive acetaminophen intake (&gt;4 g/day). Use with caution in patients with chronic malnutrition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency; rare reports of hemolysis have occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment or active liver disease; use of the intravenous formulation is contraindicated in patients with severe hepatic impairment or severe active liver disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypovolemia: Use the intravenous formulation with caution in patients with severe hypovolemia (eg, due to dehydration or blood loss).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; consider dosing adjustments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage limit: Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication, patients should be instructed to contact healthcare provider if used for fever lasting &gt;3 days or for pain lasting &gt;10 days in adults or &gt;5 days in children. OTC labeling limits the maximum daily dose to &le;3250 mg (dosage form specific).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2A6 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F129314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Excessive intake of ethanol may increase the risk of acetaminophen-induced hepatotoxicity. Avoid ethanol or limit to &lt;3 drinks/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Rate of absorption may be decreased when given with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease acetaminophen levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11385104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (intravenous) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5630924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with intravenous acetaminophen, therefore, acetaminophen I.V. is classified as pregnancy category C.   Acetaminophen crosses the placenta and can be detected in cord blood, newborn serum, and urine immediately after delivery. An increased risk of teratogenic effects has not been observed following maternal use of acetaminophen during pregnancy. Prenatal constriction of the ductus arteriosus has been noted in case reports following maternal use during the third trimester. The use of acetaminophen in normal doses during pregnancy is not associated with an increased risk of miscarriage or still birth; however, an increase in fetal death or spontaneous abortion may be seen following maternal overdose if treatment is delayed. Frequent maternal use of acetaminophen during pregnancy may be associated with wheezing and asthma in early childhood. The absorption may be delayed and the bioavailability of acetaminophen may be decreased in some women during pregnancy due to delayed gastric emptying.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F129330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11384044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low concentrations of acetaminophen are excreted into breast milk and can be detected in the urine of nursing infants. Adverse reactions have generally not been observed; however, a rash caused by acetaminophen exposure was reported in one breast-feeding infant.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F129303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F129302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Acetaminophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (50): $3.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Acetaminophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (30): $2.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Childrens Medi-Tabs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (30): $2.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Medi-Tabs Junior Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg (24): $3.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Tylenol Go Tabs Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (12): $3.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (Medi-Tabs Childrens Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/2.5 mL (118 mL): $4.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (ElixSure Fever/Pain Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg/5 mL (120 mL): $4.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tylenol Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg/30 mL (240 mL): $5.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tylenol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg/15 mL (240 mL): $5.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Bromo-Seltzer Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     650-2.67-3.5 mg-gm-gm (10): $3.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Stanback Aspirin Free Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     950 mg (2): $0.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acetaminophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (15 mL): $3.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg/5 mL (10.15 mL): $0.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Little Fevers Fever-Pain Rel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/mL (30 mL): $4.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg/5 mL (118 mL): $5.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ofirmev Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (100 mL): $14.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Acephen Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (50): $30.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (50): $32.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     650 mg (12): $8.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Acetaminophen Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (12): $6.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     650 mg (50): $29.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Feverall Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (6): $4.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (6): $4.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (6): $4.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     650 mg (50): $33.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Infants Medi-Tabs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/0.8 mL (30 mL): $5.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Nortemp Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg/5 mL (118 mL): $5.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Tylenol Childrens Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg/5 mL (120 mL): $5.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Tylenol Childrens/Flav Creator Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg/5 mL (120 mL): $8.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Tylenol Infants Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/0.8 mL (30 mL): $8.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Triaminic Fever Reducer Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg/5 mL (118 mL): $4.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Tylenol 8 Hour Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     650 mg (100): $10.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Tylenol Arthritis Pain Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     650 mg (24): $3.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Tylenol Childrens Meltaways Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (30): $3.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Tylenol Jr Meltaways Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg (24): $4.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Acetaminophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (100): $4.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $3.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Excedrin Tension Headache Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-65 mg (50): $5.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mapap Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (50): $3.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Medi-Tabs Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $4.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Medi-Tabs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (100): $3.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pharbetol Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $2.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pharbetol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (100): $2.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tylenol Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $9.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tylenol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (100): $7.54",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F129291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum APAP levels: Where acute overdose suspected and with long-term use in patients with hepatic disease; relief of pain or fever",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F129304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A-Mol (TH);",
"     </li>",
"     <li>",
"      Acamol (CN, IL);",
"     </li>",
"     <li>",
"      Acamol To-Go (IL);",
"     </li>",
"     <li>",
"      Acamoli Baby (IL);",
"     </li>",
"     <li>",
"      Acamoli Forte suppositories for Kids (IL);",
"     </li>",
"     <li>",
"      ACET suppositories (SG);",
"     </li>",
"     <li>",
"      Acetalgin (CH);",
"     </li>",
"     <li>",
"      Acetamol (IT);",
"     </li>",
"     <li>",
"      Adinol (MX);",
"     </li>",
"     <li>",
"      Adorem (CO);",
"     </li>",
"     <li>",
"      Afebrin (HK);",
"     </li>",
"     <li>",
"      Afebryl (LU);",
"     </li>",
"     <li>",
"      Alcocin (IN);",
"     </li>",
"     <li>",
"      Alginox (EC);",
"     </li>",
"     <li>",
"      Alvedon (SE);",
"     </li>",
"     <li>",
"      Ametrex (CO);",
"     </li>",
"     <li>",
"      Amol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Analgiser (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Analphen (MX);",
"     </li>",
"     <li>",
"      Angela (TH);",
"     </li>",
"     <li>",
"      Aptamol (IN);",
"     </li>",
"     <li>",
"      Arfen (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Atamel (PE);",
"     </li>",
"     <li>",
"      Avadol (MY);",
"     </li>",
"     <li>",
"      Ben-U-Ron (CH, PT);",
"     </li>",
"     <li>",
"      ben-u-ron (HU);",
"     </li>",
"     <li>",
"      Benuron (JP);",
"     </li>",
"     <li>",
"      Biogesic (PH, SG);",
"     </li>",
"     <li>",
"      Biogesic Suspension (HK);",
"     </li>",
"     <li>",
"      Biopain (PH);",
"     </li>",
"     <li>",
"      Calapol (ID);",
"     </li>",
"     <li>",
"      Calpol (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IE, IQ, IR, JO, JP, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PR, QA, SA, SC, SD, SL, SN, SY, TH, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Causalon (AR);",
"     </li>",
"     <li>",
"      Cemol (TH);",
"     </li>",
"     <li>",
"      Cetta (TH);",
"     </li>",
"     <li>",
"      Children's Bufferin (CL);",
"     </li>",
"     <li>",
"      Children's S Tylenol (KP);",
"     </li>",
"     <li>",
"      Christamol (HK);",
"     </li>",
"     <li>",
"      Claradol (MA);",
"     </li>",
"     <li>",
"      Cotemp (TH);",
"     </li>",
"     <li>",
"      Croix Blanche (LU);",
"     </li>",
"     <li>",
"      Curpol (LU);",
"     </li>",
"     <li>",
"      Dafalgan (BE, LU);",
"     </li>",
"     <li>",
"      Dafalgan odis (LU);",
"     </li>",
"     <li>",
"      Daga (TH);",
"     </li>",
"     <li>",
"      Denamol (TH);",
"     </li>",
"     <li>",
"      Dirox (AR);",
"     </li>",
"     <li>",
"      Dismifen (MX);",
"     </li>",
"     <li>",
"      Dol-Stop (LU);",
"     </li>",
"     <li>",
"      Dolan Infantil (GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Dolex (UY);",
"     </li>",
"     <li>",
"      Dolgesic (ES);",
"     </li>",
"     <li>",
"      Doliprane (FR, IN, MA);",
"     </li>",
"     <li>",
"      Dolitabs (FR);",
"     </li>",
"     <li>",
"      Dolomol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Dolorol (ZA);",
"     </li>",
"     <li>",
"      Dolprone (LU);",
"     </li>",
"     <li>",
"      Doluvital (MX);",
"     </li>",
"     <li>",
"      Dolviran (MX);",
"     </li>",
"     <li>",
"      Dymadon (AU);",
"     </li>",
"     <li>",
"      Efferalgan (HU, LU);",
"     </li>",
"     <li>",
"      Efferalgan 500 (CR, DO, EE, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Efferalganodis (FR);",
"     </li>",
"     <li>",
"      Enelfa (LU);",
"     </li>",
"     <li>",
"      Europain (HK);",
"     </li>",
"     <li>",
"      Febridol (AU);",
"     </li>",
"     <li>",
"      Febrile Free (PH);",
"     </li>",
"     <li>",
"      Fervex (BR);",
"     </li>",
"     <li>",
"      Filanc (MX);",
"     </li>",
"     <li>",
"      Fortolin (HK);",
"     </li>",
"     <li>",
"      Gelocatil (ES);",
"     </li>",
"     <li>",
"      Geluprane 500 (FR);",
"     </li>",
"     <li>",
"      Hedex (IE);",
"     </li>",
"     <li>",
"      Hoemal (MY, SG);",
"     </li>",
"     <li>",
"      Lekadol (HR);",
"     </li>",
"     <li>",
"      Lemgrip (BE, LU);",
"     </li>",
"     <li>",
"      Lonarid mono (LU);",
"     </li>",
"     <li>",
"      Lotemp (TH);",
"     </li>",
"     <li>",
"      Lupocet (HR);",
"     </li>",
"     <li>",
"      Mafidol (PE);",
"     </li>",
"     <li>",
"      Mejoralito Junior (MX);",
"     </li>",
"     <li>",
"      Mejoralito Pedi&aacute;trico (MX);",
"     </li>",
"     <li>",
"      Metagesic (PH);",
"     </li>",
"     <li>",
"      Mexalen (AT, CZ, HU);",
"     </li>",
"     <li>",
"      Minopan (KP);",
"     </li>",
"     <li>",
"      Momentum (LU);",
"     </li>",
"     <li>",
"      Mypara (TH);",
"     </li>",
"     <li>",
"      Nalgesik (ID);",
"     </li>",
"     <li>",
"      Napafen (EC);",
"     </li>",
"     <li>",
"      Napamol (ZA);",
"     </li>",
"     <li>",
"      Napran (PH);",
"     </li>",
"     <li>",
"      Naprex (ID);",
"     </li>",
"     <li>",
"      NEBS (JP);",
"     </li>",
"     <li>",
"      Neuridon (LU);",
"     </li>",
"     <li>",
"      Nordinet Infantil (MX);",
"     </li>",
"     <li>",
"      Pacimol (IN);",
"     </li>",
"     <li>",
"      Pamol (DK, NZ);",
"     </li>",
"     <li>",
"      Panadol (AE, AU, BE, BF, BG, BH, BJ, CH, CI, CN, CY, CZ, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, HK, HU, ID, IE, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, NZ, OM, PE, PK, PL, PT, QA, RU, SA, SC, SD, SG, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Panadol Actifast (MY, SG);",
"     </li>",
"     <li>",
"      Panadol Extend (SG);",
"     </li>",
"     <li>",
"      Panadol for Children (SG);",
"     </li>",
"     <li>",
"      Panadon (HR);",
"     </li>",
"     <li>",
"      Panamax (AU);",
"     </li>",
"     <li>",
"      Panodil (DK, NO, SE);",
"     </li>",
"     <li>",
"      Para-IV (PH);",
"     </li>",
"     <li>",
"      Paracet (NO);",
"     </li>",
"     <li>",
"      Paracetamol (HR);",
"     </li>",
"     <li>",
"      Paracetamol Pharmavit (HU);",
"     </li>",
"     <li>",
"      Paracetamol-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Parageniol (PY);",
"     </li>",
"     <li>",
"      Paragin (TH);",
"     </li>",
"     <li>",
"      Paralgin (AU);",
"     </li>",
"     <li>",
"      Paramol (IL, TW);",
"     </li>",
"     <li>",
"      Paramol Kat Drops (IL);",
"     </li>",
"     <li>",
"      Parapaed (DE);",
"     </li>",
"     <li>",
"      Parapaed Junior (NZ);",
"     </li>",
"     <li>",
"      Parapaed Six Plus (NZ);",
"     </li>",
"     <li>",
"      Parcemol (HK);",
"     </li>",
"     <li>",
"      Parcemol Forte (HK);",
"     </li>",
"     <li>",
"      Parvid (PH);",
"     </li>",
"     <li>",
"      Paximol (SG);",
"     </li>",
"     <li>",
"      Pe-Tam (LU);",
"     </li>",
"     <li>",
"      Pedipan (KP);",
"     </li>",
"     <li>",
"      Penral-Night (KP);",
"     </li>",
"     <li>",
"      Perdolan Mono (LU);",
"     </li>",
"     <li>",
"      Perfalgan (AT, AU, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, IE, IN, IT, MT, NL, NO, NZ, PL, PT, RU, SE, SK, TR, ZA);",
"     </li>",
"     <li>",
"      Perfusalgan (BE);",
"     </li>",
"     <li>",
"      Pharmacen-M (MX);",
"     </li>",
"     <li>",
"      Pinex (NO);",
"     </li>",
"     <li>",
"      Plicet (HR);",
"     </li>",
"     <li>",
"      Poro (MY, PH, SG, TH);",
"     </li>",
"     <li>",
"      Raperon (KP);",
"     </li>",
"     <li>",
"      Rapidol (CN);",
"     </li>",
"     <li>",
"      Reliv (SE);",
"     </li>",
"     <li>",
"      Remedol (PR);",
"     </li>",
"     <li>",
"      Revanin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Rhinapen elixir (KP);",
"     </li>",
"     <li>",
"      Rubophen (HU);",
"     </li>",
"     <li>",
"      Salzone (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Sanmol Infusion (ID);",
"     </li>",
"     <li>",
"      Saridon (CO);",
"     </li>",
"     <li>",
"      Sedalito (MX);",
"     </li>",
"     <li>",
"      Selegesic (PH);",
"     </li>",
"     <li>",
"      Sensamol (IL);",
"     </li>",
"     <li>",
"      Setopain (KP);",
"     </li>",
"     <li>",
"      Setopain ER (KP);",
"     </li>",
"     <li>",
"      Sinedol (DO, MX);",
"     </li>",
"     <li>",
"      Supadol mono (LU);",
"     </li>",
"     <li>",
"      Suspen ER (KP);",
"     </li>",
"     <li>",
"      Tafirol (PE);",
"     </li>",
"     <li>",
"      Tamoliv (ID);",
"     </li>",
"     <li>",
"      Tasmen (KP);",
"     </li>",
"     <li>",
"      Tempol (MY);",
"     </li>",
"     <li>",
"      Tempra (EC, ID, JP, LU, MX);",
"     </li>",
"     <li>",
"      Tempte (TW);",
"     </li>",
"     <li>",
"      Teramol (PH);",
"     </li>",
"     <li>",
"      Teramol Forte (PH);",
"     </li>",
"     <li>",
"      Toniker (TW);",
"     </li>",
"     <li>",
"      Turpan (ID);",
"     </li>",
"     <li>",
"      Tylenol (BR, CH, DE, JP, KP, MX, PH, PT, TH, VE);",
"     </li>",
"     <li>",
"      Tylenol 8-hour (TH);",
"     </li>",
"     <li>",
"      Tylenol Acetaminophen Extended Relief (CL);",
"     </li>",
"     <li>",
"      Tylenol ER (KP);",
"     </li>",
"     <li>",
"      Tylenol Extra Fuerte (PY);",
"     </li>",
"     <li>",
"      Tylenol Forte (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Tylex (BB, BM, BS, BZ, GY, JM, MX, SR, TT);",
"     </li>",
"     <li>",
"      Winadol (CO, VE);",
"     </li>",
"     <li>",
"      Winasorb (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Xebramol (TH);",
"     </li>",
"     <li>",
"      XL-Dol Infantil (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F129281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although not fully elucidated, believed to inhibit the synthesis of prostaglandins in the central nervous system and work peripherally to block pain impulse generation; produces antipyresis from inhibition of hypothalamic heat-regulating center",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F129299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: &lt;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Analgesia: 5-10 minutes; Antipyretic: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak effect: I.V.: Analgesic: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V., Oral: Analgesia: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Antipyretic: &ge;6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Primarily absorbed in small intestine (rate of absorption dependent upon gastric emptying); minimal absorption from stomach; varies by dosage form",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: ~1 L/kg at therapeutic doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 10% to 25% at therapeutic concentrations; 8% to 43% at toxic concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: At normal therapeutic dosages, primarily hepatic metabolism to sulfate and glucuronide conjugates, while a small amount is metabolized by CYP2E1 to a highly reactive intermediate, N-acetyl-p-benzoquinone imine (NAPQI), which is conjugated rapidly with glutathione and inactivated to nontoxic cysteine and mercapturic acid conjugates. At toxic doses (as little as 4 g daily) glutathione conjugation becomes insufficient to meet the metabolic demand causing an increase in NAPQI concentrations, which may cause hepatic cell necrosis. Oral administration is subject to first pass metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Prolonged following toxic doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 7 hours (range: 4-10 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: ~4 hours (range: 1-7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 3 hours (range: 2-5 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: ~3 hours (range: 2-4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: ~2 hours (range: 2-3 hours); may be slightly prolonged in severe renal insufficiency (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): 2-5.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: Immediate release: 10-60 minutes (may be delayed in acute overdoses); I.V.: 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;5% unchanged; 60% to 80% as glucuronide metabolites; 20% to 30% as sulphate metabolites; ~8% cysteine and mercapturic acid metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Acetaminophen Toxicity in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(4):1020-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/11581462/pubmed\" id=\"11581462\" target=\"_blank\">",
"        11581462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson PO, Sauberan JB, Lane JR, et al, &ldquo;Hydrocodone Excretion Into Breast Milk: The First Two Reported Cases,&rdquo;",
"      <i>",
"       Breastfeed Med",
"      </i>",
"      , 2007, 2(1):10-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/17661614/pubmed\" id=\"17661614\" target=\"_blank\">",
"        17661614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barker JD Jr, de Carle DJ, and Anuras S, &ldquo;Chronic Excessive Acetaminophen Use in Liver Damage,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1977, 87(3):299-301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/900673/pubmed\" id=\"900673\" target=\"_blank\">",
"        900673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Birmingham PK, Tobin MJ, Fisher DM, et al, &ldquo;Initial and Subsequent Dosing of Rectal Acetaminophen in Children: A 24-Hour Pharmacokinetic Study of New Dose Recommendations,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2001, 94(3):385-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/11374595/pubmed\" id=\"11374595\" target=\"_blank\">",
"        11374595",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brackett CC and Bloch JD, &ldquo;Phenytoin as a Possible Cause of Acetaminophen Hepatotoxicity: Case Report and Review of the Literature,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2000, 20(2):229-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/10678302/pubmed\" id=\"10678302\" target=\"_blank\">",
"        10678302",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JD, Brandt KD, Katz BP, et al, &ldquo;Comparison of an Antiinflammatory Dose of Ibuprofen, an Analgesic Dose of Ibuprofen, and Acetaminophen in the Treatment of Patients With Osteoarthritis of the Knee,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 325(2):87-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/2052056/pubmed\" id=\"2052056\" target=\"_blank\">",
"        2052056",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buck ML, &ldquo;Perioperative Use of High-Dose Rectal Acetaminophen,&rdquo;",
"      <i>",
"       Pediatr Pharmacol (New York)",
"      </i>",
"      , 2001, 7(9). Available at  file://www.medscape.com/viewarticle/415082_2",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burkhart KK, Janco N, Kulig KW, et al, &ldquo;Cimetidine as Adjunctive Treatment for Acetaminophen Overdose,&rdquo;",
"      <i>",
"       Hum Exp Toxicol",
"      </i>",
"      , 1995, 14(3):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/7779462/pubmed\" id=\"7779462\" target=\"_blank\">",
"        7779462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clissold SP, &ldquo;Paracetamol and Phenacetin,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1986, 32(Suppl 4):46-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/3552585/pubmed\" id=\"3552585\" target=\"_blank\">",
"        3552585",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dart RC and Rumack BH, &ldquo;Intravenous Acetaminophen in the United States: Iatrogenic Dosing Errors,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2012, 129(2):349-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/22271694/pubmed\" id=\"22271694\" target=\"_blank\">",
"        22271694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, Campbell RA, Cooper SA, et al, &ldquo;Suppression of Postoperative Pain by Preoperative Administration of Ibuprofen in Comparison to Placebo, Acetaminophen, and Acetaminophen Plus Codeine,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1983, 23(1):37-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/6341415/pubmed\" id=\"6341415\" target=\"_blank\">",
"        6341415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2000, 42(1085):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/10951654/pubmed\" id=\"10951654\" target=\"_blank\">",
"        10951654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Duggan ST and Scott LJ, &ldquo;Intravenous Paracetamol (Acetaminophen),&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2009, 69(1):101-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/19192939/pubmed\" id=\"19192939\" target=\"_blank\">",
"        19192939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harrison PM, Keays R, Bray GP, et al, &ldquo;Improved Outcome of Paracetamol-Induced Fulminant Hepatic Failure by Late Administration of Acetylcysteine,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1990, 335(8705):1572-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/1972496/pubmed\" id=\"1972496\" target=\"_blank\">",
"        1972496",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practices (ISMP), &ldquo;IV Acetaminophen and Overdoses in Kids,&rdquo;",
"      <i>",
"       ISMP Medication Safety Alert",
"      </i>",
"      , April 19, 2012. Available at file://ismp.org/Newsletters/acutecare/issue.asp?dt=20120419",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katzir Z, Baruch O, Hochman B, et al, &ldquo;Spontaneous Remission of Paracetamol Induced Acute Renal Failure,&rdquo;",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1995, 43(5):346.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/7634553/pubmed\" id=\"7634553\" target=\"_blank\">",
"        7634553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knoop KJ, Snook CP, Stephan M, et al, &ldquo;Failure of N-Acetylcysteine (NAC) to Prevent Acetaminophen-Induced Renal Failure,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1993, 35:336.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee WM, &ldquo;Drug-Induced Hepatotoxicity,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(17):1118-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/7565951/pubmed\" id=\"7565951\" target=\"_blank\">",
"        7565951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Licht H, Seeff LB, and Zimmerman HJ, &ldquo;Apparent Potentiation of Acetaminophen Hepatotoxicity by Alcohol,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1980, 92(4):511.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayoral CE, Marino RV, Rosenfeld W, et al, &ldquo;Alternating Antipyretics: Is This an Alternative?&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 105(5):1009-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/10790455/pubmed\" id=\"10790455\" target=\"_blank\">",
"        10790455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McClain CJ, Kromhout JP, Peterson FJ, et al, &ldquo;Potentiation of Acetaminophen Hepatotoxicity by Alcohol,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1980, 244(3):251-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/7382090/pubmed\" id=\"7382090\" target=\"_blank\">",
"        7382090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathmell JP, Viscomi CM, and Ashburn MA, &ldquo;Management of Nonobstetric Pain During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997, 85(5):1074-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/9356103/pubmed\" id=\"9356103\" target=\"_blank\">",
"        9356103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rose SR, &ldquo;Subtleties of Managing Acetaminophen Poisoning,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1994, 51(24):3065-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/7856628/pubmed\" id=\"7856628\" target=\"_blank\">",
"        7856628",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, &ldquo;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&rdquo;",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singer AJ, Carracio TR, and Mofenson HC, &ldquo;The Temporal Profile of Increased Transaminase Levels in Patients With Acetaminophen-Induced Liver Dysfunction,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1995, 26(1):49-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/7793720/pubmed\" id=\"7793720\" target=\"_blank\">",
"        7793720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smilkstein MJ, Knapp GL, Kulig KW, et al, &ldquo;Efficacy of Oral N-Acetylcysteine in the Treatment of Acetaminophen Overdose. Analysis of the National Multicenter Study (1976 to 1985),&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 319(24):1557-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/3059186/pubmed\" id=\"3059186\" target=\"_blank\">",
"        3059186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stork CM, Rees S, Howland MA, et al, &ldquo;Pharmacokinetics of Extended Relief vs Regular Release Tylenol&reg; in a Simulated Human Overdose,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1996, 34(2):157-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/8618248/pubmed\" id=\"8618248\" target=\"_blank\">",
"        8618248",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, &ldquo;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van der Steeg J, Akhtar J, Burkhart K, et al, &ldquo;Initial Prothrombin Time as a Predictor of Acetaminophen-Induced Hepatotoxicity,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):508-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watkins PB, Kaplowitz N, Slattery JT, et al,  &ldquo;Aminotransferase Elevations in Healthy Adults Receiving 4 Grams of Acetaminophen Daily: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2006, 296(1):87-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/16820551/pubmed\" id=\"16820551\" target=\"_blank\">",
"        16820551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whitcomb DC and Block GD, &ldquo;Association of Acetaminophen Hepatotoxicity With Fasting and Ethanol Use,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1994, 272(23):1845-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/7990219/pubmed\" id=\"7990219\" target=\"_blank\">",
"        7990219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams HJ, Ward JR, Egger MJ, et al, &ldquo;Comparison of Naproxen and Acetaminophen in a Two-Year Study of Treatment of Osteoarthritis of the Knee,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1993, 36(9):1196-206.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/8216413/pubmed\" id=\"8216413\" target=\"_blank\">",
"        8216413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woo OF, Anderson IB, Kim SY, et al, &ldquo;Shorter Duration of N-Acetylcysteine (NAC) for Acute Acetaminophen Poisoning,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):508.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yerman B, Tseng J, and Caravati EM, &ldquo;Pediatric Acetaminophen Ingestion: A Prospective Study of Referral Criteria,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):530.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zenger F, Russmann S, Junker E, et al, &ldquo;Decreased Glutathione in Patients With Anorexia Nervosa. Risk Factor for Toxic Liver Injury?&rdquo;",
"      <i>",
"       Eur J Clin Nutr",
"      </i>",
"      , 2004, 58(2):238-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/14749742/pubmed\" id=\"14749742\" target=\"_blank\">",
"        14749742",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zimmerman HJ and Maddrey WC, &ldquo;Acetaminophen (Paracetamol) Hepatotoxicity With Regular Intake of Alcohol: Analysis of Instances of Therapeutic Misadventure,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 1995, 22(3):767-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/27/15802/abstract-text/7657281/pubmed\" id=\"7657281\" target=\"_blank\">",
"        7657281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9242 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15802=[""].join("\n");
var outline_f15_27_15802=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391964\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129318\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129319\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129370\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129323\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129345\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129324\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129325\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129326\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129293\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129278\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129297\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11385126\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129296\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129376\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129368\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129300\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129282\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129365\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129287\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129314\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11385104\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5630924\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129330\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11384044\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129303\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129302\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129291\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129304\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129281\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129299\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9242\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9242|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=related_link\">",
"      Acetaminophen (paracetamol): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=related_link\">",
"      Acetaminophen (paracetamol): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_27_15803="Recommended nutritional supplementation after bariatric surgery";
var content_f15_27_15803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended nutritional supplementation after bariatric surgery in adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastric bypass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Standard multivitamin with folate and iron, or prenatal vitamin if female*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B12 500 micrograms orally daily, or 1000 micrograms intramuscularly monthly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium 1200 mg to 1500 mg daily with 800 units vitamin D",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supplemental iron if iron deficient*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Adjustable banding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Standard multivitamin with folate and iron* or prenatal vitamin if female*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B12, iron, calcium with vitamin D as indicated clinically",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Additional iron and folate may be necessary in pregnant females.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Calcium citrate may be better absorbed.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15803=[""].join("\n");
var outline_f15_27_15803=null;
var title_f15_27_15804="Clinical features PNFA";
var content_f15_27_15804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The clinical diagnostic features of progressive nonfluent aphasia: Clinical profile",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorder of expressive language is the dominant feature initially and throughout the disease course. Other aspects of cognition are intact or relatively well preserved.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        I. Core diagnostic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Insidious onset and gradual progression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. Nonfluent spontaneous speech with at least one of the following: agrammatism, phonemic paraphasias, anomia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        II. Supportive diagnostic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Speech and language",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Stuttering or oral apraxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Impaired repetition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3. Alexia, agraphia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        4. Early preservation of word meaning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        5. Late mutism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. Behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Early preservation of social skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Late behavioral changes similar to FTD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C. Physical signs: late contralateral primitive reflexes, akinesia, rigidity, and tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D. Investigations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Neuropsychology: nonfluent aphasia in the absence of severe amnesia or perceptuospatial disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Electroencephalography: normal or minor asymmetric slowing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3. Brain imaging (structural and/or functional): asymmetric abnormality predominantly affecting dominant (usually left) hemisphere",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998; 51:1546. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15804=[""].join("\n");
var outline_f15_27_15804=null;
var title_f15_27_15805="IL formulas preterm infant";
var content_f15_27_15805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of different intravenous lipid emulsion formulations used in premature infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intralipid&reg; (Baxter Healthcare/Fresenius Kabi)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Liposyn&reg; II (Hospira)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Liposyn&reg; III (Hospira)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Omegaven&reg; (Fresenius AG)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Concentrations (percent)",
"       </td>",
"       <td>",
"        10, 20, 30",
"       </td>",
"       <td>",
"        10, 20",
"       </td>",
"       <td>",
"        10, 20, 30",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oil source (percent)",
"       </td>",
"       <td>",
"        Soybean 100",
"       </td>",
"       <td>",
"        <p>",
"         Soybean 50",
"        </p>",
"        <p>",
"         Safflower 50",
"        </p>",
"       </td>",
"       <td>",
"        Soybean 100",
"       </td>",
"       <td>",
"        Fish 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\">",
"        Fatty acids (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Linoleic",
"       </td>",
"       <td class=\"sublist_other\">",
"        44 to 62",
"       </td>",
"       <td class=\"sublist_other\">",
"        66",
"       </td>",
"       <td class=\"sublist_other\">",
"        55",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.1 to 0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Linolenic",
"       </td>",
"       <td class=\"sublist_other\">",
"        4 to 11",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\">",
"        8",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Palmitic",
"       </td>",
"       <td class=\"sublist_other\">",
"        7 to 14",
"       </td>",
"       <td class=\"sublist_other\">",
"        9",
"       </td>",
"       <td class=\"sublist_other\">",
"        11",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.25 to 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Oleic",
"       </td>",
"       <td class=\"sublist_other\">",
"        19 to 30",
"       </td>",
"       <td class=\"sublist_other\">",
"        18",
"       </td>",
"       <td class=\"sublist_other\">",
"        22",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.6 to 1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Stearic",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.4 to 5.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.4",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.05 to 0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        EPA",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.25 to 2.82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        DHA",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.44 to 3.09",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Egg yolk phospholipids (percent)",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"       <td>",
"        1.2, 1.2, 1.8",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glycerin (percent)",
"       </td>",
"       <td>",
"        2.25, 2.25, 1.7",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Energy density (kcal/mL)",
"       </td>",
"       <td>",
"        1.1, 2.0, 3.0",
"       </td>",
"       <td>",
"        1.1, 2.0",
"       </td>",
"       <td>",
"        1.1, 2.0, 2.9",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osmolarity (mosm/L)",
"       </td>",
"       <td>",
"        260, 260, 200",
"       </td>",
"       <td>",
"        276, 258",
"       </td>",
"       <td>",
"        284, 292, 293",
"       </td>",
"       <td>",
"        308 to 376&bull;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Omegaven&reg; (Fresenius AG) is not FDA approved.",
"    <div class=\"footnotes\">",
"     * Not available in US.",
"     <br>",
"      &bull; mosm/kg.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      1. Gura KM, Duggan CP, Collier SB, et al. Reversal of parenteral nutrition - associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics 2006; 118:197.",
"      <br>",
"       2. Nordenstrom J, Thorne A. Comparative studies on a new concentrated fat emulsion: intralipid 30 percent vs. 20 percent. Clin Nutr 1993; 12:160.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15805=[""].join("\n");
var outline_f15_27_15805=null;
var title_f15_27_15806="Aortic dissection PA";
var content_f15_27_15806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 224px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PA chest film in a patient with the sudden onset of excruciating interscapular pain and hypotension. The ascending aortic arch is dilated, displacing the trachea to the right (black arrow). A left lower lobe density is suggestive of a pleural effusion. Surgery revealed a dilated ascending aorta with a dissection approximately 3 cm distal to the aortic valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert A Novelline, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15806=[""].join("\n");
var outline_f15_27_15806=null;
var title_f15_27_15807="Dissection of the descending aorta on TEE";
var content_f15_27_15807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/73639/teedeaod_conv.mp4?title=Dissection+of+the+descending+aorta+on+TEE\" style=\"width:431px;height:322px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dissection of the descending aorta on transesophageal echocardiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram shows a large dissection of the descending aorta. Spontaneous echo contrast is seen in the false lumen, resulting from turbulent blood flow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_27_15807=[""].join("\n");
var outline_f15_27_15807=null;
      